

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 01/45717

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K39/39 A61P31/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 99 29728 A (GALLO ROBERT C.; DEVI ANTHONY L (US); GARZINO DEMO ALFREDO (US);) 17 June 1999 (1999-06-17)</p> <p>the whole document</p> <p>---</p> <p>-/---</p>	<p>1-6, 8-14, 17, 18, 20-26, 29, 32-39, 42-45, 47-50, 67, 68</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

30 October 2002

Date of mailing of the international search report

12/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Noë, V

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 01/45717

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EP 0 974 357 A (SCHERING PLOUGH CORP) 26 January 2000 (2000-01-26)</p> <p>the whole document</p>	<p>1-11, 13, 14, 17-24, 29, 32-40, 42-49, 67, 68</p>
X	<p>WO 98 04282 A (GRAF MARTIN R ; GRANGER GALE A (US); HISERODT JOHN C (US); UNIV CAL) 5 February 1998 (1998-02-05) abstract page 7, line 3 - line 26 page 8, line 32 - page 10, line 28 page 11, line 33 - line 37 page 12, line 34 - line 38 page 14, line 39 - page 15, line 27 page 16, line 6 - line 16 page 26, line 15 - last line examples 5-7</p>	<p>50-66</p>
X	<p>DE GIOVANNI CARLA ET AL: "The prospects for cancer gene therapy." INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. 22, no. 12, December 2000 (2000-12), pages 1025-1032, XP002218907 ISSN: 0192-0561 the whole document</p>	<p>1, 37, 50, 54</p>
A	<p>GREAVES DAVID R ET AL: "Chemokines and myeloid cell recruitment." MICROBES AND INFECTION, vol. 2, no. 3, March 2000 (2000-03), pages 331-336, XP002218908 ISSN: 1286-4579 the whole document</p>	
P, X	<p>WO 01 80887 A (TALBOT DALE ; SCHALL THOMAS J (US); CHEMOCENTRYX INC (US)) 1 November 2001 (2001-11-01) the whole document</p>	<p>1-49</p>



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/52, C12N 15/12, 15/19, 15/63, A61K 38/16, 38/19, 48/00	A1	(11) International Publication Number: WO 99/29728 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/26291 (22) International Filing Date: 11 December 1998 (11.12.98) (30) Priority Data: 60/069,281 11 December 1997 (11.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/069,281 (CON) Filed on 11 December 1997 (11.12.97) (71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE [US/US]: 4321 Hartwick Road, College Park, MD 20740 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GALLO, Robert, C. [US/US]: 8513 Thornden Terrace, Bethesda, MD 02817 (US). DEVICO, Anthony, L. [US/US]: 4533 Peacock Avenue, Alexandria, VA 22304 (US). GARZINO-DEMO, Alfredo [IT/US], 601 North Eutaw Street, Baltimore, MD 21201 (US).	(74) Agent: BARRETT, William, A.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES (57) Abstract The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/069,281 filed December 11, 1997.

2. BACKGROUND OF THE INVENTION

The present invention relates to a method to enhance the efficacy of a vaccine by administration of a chemokine, such as macrophage derived chemokine (MDC), in conjunction with the vaccine. The present invention also relates to compositions useful in the method.

2.1. GENERATION OF AN IMMUNE RESPONSE

The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively (see generally Coutinho, 1991, *Immune System, Encyclopedia of Human Biology*, Vol. 4, Ed. Dulbecco, Academic Press, Inc.). A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system.

Another T cell subset is capable of developing into antigen-specific cytotoxic effector cells, which can directly kill antigen-positive target cells. On the other hand, the B cell response is primarily carried out by secretory proteins, antibodies, which directly bind and neutralize antigens.

Helper T cells (TH) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of the glycoprotein marker CD4. Although the mechanism by which CD4⁺ TH function has not been fully elucidated, the existence of functionally distinct subsets within the CD4⁺ T cell compartment has been reported (Mosmann and Coffman, 1989, *Ann. Rev. Immunol.*

7:145-173). In the mouse, type 1 helper T cells (TH1) produce interleukin-2 (IL-2) and τ -interferon (τ -IFN) upon activation, while type 2 helper T cells (TH2) produce IL-4 and IL-5. Based on the profile of lymphokine production, TH1 appear to be involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas TH2 specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most TH, these cells display cytolytic activity upon direct contact with target cells, rather than through the production of lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. Significant experimental evidence indicates that CTL rather than B cells and their antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. Class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, *Nature* 329:506-512).

Another level of complexity in the interaction between a T cell and an antigenic fragment is that it occurs only if the MHC molecules involved are the same on the APC and the responding T cells. In other words, a T cell specific for a particular antigenic epitope expresses a receptor having low affinity for self MHC

proteins, which when such MHC proteins on APC are occupied by the epitope, engage the T cell in a stronger interaction leading to antigen-specific T cell activation. The phenomenon of a T cell reacting with a processed antigen only when presented by cells expressing a matching MHC is known as MHC-restriction.

The specificity of T cell immune responses for antigens is a function of the unique receptors expressed by these cells. The T cell receptor (TCR) is structurally homologous to an antibody; it is a heterodimer composed of disulfide-linked glycoproteins. Four TCR polypeptide chains known as α , β , τ , and δ have been identified, although the vast majority of functional T cells express the $\alpha\beta$ heterodimeric TCR. Transfer of α and β genes alone into recipient cells was shown to be both necessary and sufficient to confer antigen specificity and MHC-restriction (Dembic et al., 1986, *Nature* 320:232-238). Thus, the $\alpha\beta$ TCR appears to be responsible for recognizing a combination of antigenic fragment and MHC determinants.

The apparent basis of MHC restriction is that $CD4^+$ T cells express $\alpha\beta$ TCR which recognize antigenic fragments physically associated with MHC class II proteins, while the TCR on $CD8^+$ CTL recognize MHC class I-associated fragments. Thus, $CD4^+$ T cells can recognize only a restricted class of APC that are class II⁺, whereas $CD8^+$ CTL can interact with virtually any antigen-positive cells, since all cells express class I molecules. $CD4^+$ CTL have been identified, and they are MHC class II restricted, and lyse target cells only if the latter express self-MHC class II determinants associated with specific antigenic fragments. Both CD4 and CD8 molecules also contribute to this interaction by binding to monotypic determinants on the MHC class II and I molecules, respectively.

A second type of TCR composed of $\tau\delta$ heterodimers is expressed by a small percentage of T cells, but the involvement of $\tau\delta$ T cells in antigen-specific recognition is still poorly understood. Some studies have shown that functionally active $\tau\delta$ T cells can be cytolytic in a MHC non-restricted manner.

In summary, the generation of an immune response begins with the sensitization of $CD4^+$ and $CD8^+$ T cell subsets through their interaction with APC that express MHC-class I or class II molecules associated with antigenic fragments. The sensitized or primed $CD4^+$ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized $CD8^+$ T cells increase in numbers in response to lymphokines and are capable of destroying any

cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. For example, in the course of a viral infection, CTL eradicate virally-infected cells, thereby limiting the progression of virus spread and disease development.

2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as antigen presenting cells (APC). Typically, APC include macrophages/monocytes, B cells, and bone marrow derived dendritic cells (DC). APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded products for expression on the cell surface (Goldberg and Rock, 1992, *Nature* 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both CD4⁺ and CD8⁺ T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbitt et al., 1985, *Nature* 317:359; Townsend et al., 1986, *Cell* 44:959). However, it is believed that, normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the MHC-encoded proteins intracellularly prior to

trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, *Immunol. Rev.* 98:95-114). It was thought that exogenous antigens were taken up by APC, processed and presented by the exogenous pathway to class II restricted CD4⁺ T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC class I proteins and presentation to CD8⁺ CTL. However, although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, *Cell* 54:777).

The term "dendritic cells" (DC) refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues (Steinman, 1991, *Ann. Rev. Immunol.* 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their morphology, high levels of surface MHC-class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all function as APC in the same manner. Further, since the vast majority of published reports have utilized DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types. (Inaba et al., 1997, *J. Exp. Med.* 166:182-194; Hengel et al., 1987, *J. Immunol.*, 139:4196-4202; Kaut et al., 1988, *J. Immunol.*, 140:3186-3193; Romani et al., 1989, *J. Exp. Med.* 169:1169-1178; Macatonia et al., 1989, *J. Exp. Med.* 169:1255-1264; Inaba et al., 1990, *J. Exp. Med.* 172:631-6640). For example, despite high levels of MHC-class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) (Witmer-Pock et al., 1987, *J. Exp. Med.* 166:1484-1498; Heufler et al., 1988, *J. Exp. Med.* 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while blood DC do not. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; in part, due to inherent differences between the

human and murine immune systems.

Recently, a few studies have described the isolation of human DC from the peripheral blood, which involves the use of sheep red blood cells and/or fetal calf serum (Young and Steinman, 1990, *J. Exp. Med.* 171:1315-1332; Freudenthal and Steinman, 1990, *Proc. Natl. Acad. Sci. USA* 87:7698-7702; Macatonia et al., 1989 *Immunol.* 67:285-289; Markowicz and Engleman, 1990, *J. Clin. Invest.* 85:955-961). Engleman et al. described a partial purification procedure of DC from human blood, which does not involve the use of sheep red blood cells and/or fetal calf serum, and showed that the partially purified human DC can, in fact, present exogenous antigens to naive T cells (PCT Publication WO 94/02156 dated February 3, 1994 at page 9, lines 5-32).

Recent studies have indicated that DCs are superior APCs as compared to other APCs such as macrophages and monocytes. First, the potent accessory cell function of DCs provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. For example, Engleman et al. demonstrate that human DCs can present both complex protein antigens and small peptides to CD4⁺ T cells as well as to CD8⁺ CTL (PCT Publication WO 94/02156 dated February 3, 1994, Example 7, from page 29, line 10 to page 34, line 16). Engleman et al. also show that the *in vitro* priming effect of DCs does not require the addition of exogenous lymphokines, indicating that DCs produce all of the necessary signals in antigen presentation leading to the activation of T cells (PCT Publication WO 94/02156 dated February 3, 1994, from page 32, line 36 to page 33, line 2). More importantly, DCs can induce a primary CD4⁺ T cell-mediated proliferative response when similarly prepared monocytes can not induce such a response (PCT Publication WO 94/02156 dated February 3, 1994 at page 31, lines 23-30). Similarly, when DCs and monocytes were compared for their ability to present antigens for re-activating secondary T cell response, it was observed that DCs were capable of stimulating a stronger response than monocytes (PCT Publication WO 94/02156 dated February 3, 1994 at page 32, lines 12-16).

2.3. CHEMOKINES

Chemokines, or chemoattractant cytokines, are a subgroup of immune factors

that have been shown to mediate chemotactic and other pro-inflammatory phenomena (see, Schall, 1991, *Cytokine* 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, α which have two N-terminal cysteines separated by a single amino acid (CxC) and β which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1 α and MIP-1 β are members of the β subgroup (reviewed by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633; Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

MCP-1 has been shown to attract monocytes but not neutrophils. MCP-1, MCP-2, and MCP-3 share a pyroglutamate proline NH₂-terminal motif and are structurally closely related to each other and to eotaxin (56% to 71% amino acid sequence identity). MCP-1, MCP-2, and MCP-3 attract monocytes, CD4⁺ and CD8⁺ T lymphocytes (Loetscher et al. *FAESB J.* 1994, 8:1055-60), as well as basophil leukocytes. MCP-2, MCP-3, and MCP-4 (but not MCP-1) attracts eosinophil leukocytes. All four MCPs attract activated T lymphocytes, natural killer (NK) cells, and dendritic cells (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

Eotaxin acts on eosinophils and is inactive on neutrophils and monocytes, but has weak-to-moderate chemotactic activity toward IL-2-conditioned T lymphocytes (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705). Due to its preferential, powerful action on eosinophils and its occurrence in different species, eotaxin is considered to be an important chemokine in the pathophysiology of allergic conditions and asthma (See Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

IP10 is a CXC chemokine attracts human monocytes, T lymphocytes, and NK cells, and Mig attracts tumor-infiltrating T lymphocytes. It has been suggested that IP10 and Mig may also be involved in the regulation of lymphocyte recruitment and the formation of the lymphoid infiltrates observed in autoimmune inflammatory lesions, delayed-type hypersensitivity, some viral infections, and certain tumors (Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

SDF-1 (stromal cell-derived factor 1), including SDF-1 and SDF-1 β stimulates the proliferation of B cell progenitors, and attracts mature dendritic cells (Finkel et al. *Immunobiology* 1998, 198:490-500). Synthetic human SDF-1 stimulates monocytes, neutrophils, and peripheral blood lymphocytes, as is indicated by [Ca²⁺]_i changes and chemotaxis. SDF-1 is also a powerful HIV-suppressive factor (See Baggiolini et al.

Annu. Rev. Immunol. 1997, 15:675-705).

The amino terminus of the β chemokines RANTES, MCP-1, and MCP-3 has been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996, *J. Biol. Chem.* 271:10521-10527; Proudfoot et al., 1996 *J. Biol. Chem.* 271:2599-2603). Additionally, α chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, *J. Biol. Chem.* 267:3455-3459).

The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of α and β groups are distinct. While the monomeric structures of the β and α chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (γ) of chemokines (Yoshida et al., 1995, *FEBS Lett.* 360:155-159; and Kelner et al., 1994, *Science* 266:1395-1399).

Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; and Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among β chemokine receptors include: CCR-1, which binds RANTES and MIP-1 α (Neote et al., 1993, *Cell* 72:415-425), CCR-4, which binds RANTES, MIP-1 α , and MCP-1 (Power et al., 1995, *J. Biol. Chem.* 270:19495-19500), and CCR-5, which binds RANTES, MIP-1 α , and MIP-1 β (Alkhatib et al., 1996, *Science* 272:1955-1958 and Dragic et al., 1996, *Nature* 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both α and β chemokines (Horuk et al., 1994, *J. Biol. Chem.* 269:17730-17733; Neote et al., 1994, *Blood* 84:44-52; and Neote et al., 1993, *J. Biol. Chem.* 268:12247-12249). Thus the sequence and

structural homologies evident among chemokines and their receptors allow some overlap in receptor-ligand interactions.

Godiska et al. identified and described the nucleic acid and amino acid sequences of an additional β chemokine designated macrophage derived chemokine (MDC) (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). PCT publication WO 96/40923 further provides materials and methods for the recombinant production of the chemokine, the purified and isolated chemokine protein, and polypeptide analogues thereof. The PCT publication WO 96/40923 does not disclose that the human MDC has chemotactic activity upon DC. While Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604) showed that, in a microchamber migration assay, monocyte-derived DC migrated toward the human MDC, the reference fails to teach that MDC can enhance an immune response to an antigen *in vivo*.

Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237), isolated a stimulated T cell chemotactic protein (STCP-1) from an activated macrophage cDNA library. The nucleotide sequence of the STCP-1 is identical to that of the MDC isolated by Godiska et al. (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). However, unlike the results observed by Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604), Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237) showed that although the STCP-1 acted as a mild chemoattractant for primary activated T lymphocytes and a potent chemoattractant for chronically activated T lymphocytes, the STCP-1 has no chemoattractant activity for monocytes, neutrophils, eosinophils and resting T lymphocytes. Chang et al. further showed that the STCP-1 does not induce Ca^{2+} mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes.

2.4. HIV VACCINES

Human immunodeficiency virus (HIV) induces a persistent and progressive infection leading, in the vast majority of cases, to the development of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983, *Science* 220:868-870; Gallo et al., 1984, *Science* 224:500-503). The HIV envelope surface glycoproteins are

synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane glycoprotein and gp120 is an extracellular glycoprotein which remains non-covalently associated with gp41, possibly in a trimeric or multimeric form (Hammerskjold, M. and Rekosh, D., 1989, *Biochem. Biophys. Acta* 989:269-280). The V3 loop of gp120 is the major determinant of sensitivity to chemokine inhibition of infection or replication (Cocchi et al., 1996, *Nature Medicine* 2:1244-1247; and Oravec et al., 1996, *J. Immunol.* 157:1329-1332).

Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for neutralizing anti-HIV antibodies present in AIDS patients (Barin et al., 1985, *Science* 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. Several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system (see, for example, Ivanoff et al., U.S. Pat. No. 5,141,867; Saith et al., PCT publication WO 92/22654; Shafferman, A., PCT publication WO 91/09872; Formoso et al., PCT publication WO 90/07119). Therefore, methods to increase the efficacy of vaccines against HIV, especially vaccines using gp120 as the antigen, are needed.

Additionally a novel vaccine technology, designated genetic vaccination, nucleic acid vaccination or DNA vaccination, has been explored to induce immune responses *in vivo*. Injection of cDNA expression cassettes results in *in vivo* expression of the encoded proteins (Dubensky et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:7529-7533; Raz et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4523; Wolff et al., 1990, *Science* 247:1465-1468), with the concomitant development of specific cellular and humoral immune responses directed against the encoded antigen(s) (Wang et al., 1995, *Hum. Gene Ther.* 6:407-418; Ulmer et al., 1993, *Science* 259:1745-1749; Tang et al., 1992, *Nature* 356:152-154; Michel et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; and Lowrie et al., 1994, *Vaccine* 12:1537-1540). Humoral and cellular responses have been induced to HIV-1 and SIV antigens through various applications of this technology in macaques (Wang et al., 1995, *Virology* 221:102-112; Wang et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; and Boyer et al., 1996, *J. Med.*

Primatol. 25:242-250) as well as mice (Wang et al., 1995, *Virology* 221:102-112; Lu et al., 1995, *Virology* 209:147-154; Haynes et al., 1994, *AIDS Res. Hum. Retroviruses* 10 (Suppl. 2):S43-S45; Okuda et al., 1995, *AIDS Res. Hum. Retroviruses* 11:933-943).

Recently, Lekutis et al. (1997, *J. Immunol.* 158:4471-4477), assessed the TH cell response elicited by an HIV-1 gp120 DNA vaccine in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted CD4⁺ T cell lines from the vaccinated animals. Lekutis et al. showed that the isolated cell lines proliferated in response to APC in the presence of recombinant gp120, as well as to APC expressing HIV encoded env protein. Lekutis et al. further showed that these cell lines responded to env by secreting IFN- γ and IFN- α without appreciable IL-4 production. These results demonstrate that the animals exhibited a cellular immune response to the DNA vaccine.

Boyer et al. (1997, *Nature Medicine* 3:625-532), inoculated chimpanzees with an HIV-1 DNA vaccine encoding env, rev, and gag/pol, and found that the immunized animals developed specific cellular and humoral immune responses to these proteins. After challenging the immunized animals with a heterologous chimpanzee titrated stock of HIV-1 SF2, Boyer et al. further found, using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay, that those animals vaccinated with the DNA vaccine were protected against infection whereas the control animals were not so protected.

Kim et al., (1997 *J. Immunol.* 158:816-826), investigated the role of co-delivery of genes for IL-12 and GM-CSF along with DNA vaccine formulation for HIV-1 antigens env and gag/pol in mice. Kim et al. observed a dramatic increase in specific CTL response from the mice immunized with the HIV-1 DNA vaccine and IL-12. Kim et al. also observed that the co-delivery of IL-12 genes resulted in the reduction of specific antibody response, whereas the codelivery of GM-CSF genes resulted in the enhancement of specific antibody response. Kim et al. further observed that co-delivery of IL-12 gene with a HIV DNA vaccine results in splenomegaly (Kim et al. 1997, *J. Immunol.*, 158:816-826), which has been shown in mice to have toxic effects such as weight reduction or even death (Eng et al., 1995, *J. Exp. Med.* 181:1893; Stevensen et al., 1995, *J. Immunol.* 155:2545; and Orange et al., 1995, *J. Exp. Med.* 181:901).

Notwithstanding the recent developments of the HIV DNA vaccine, there still

exists a need for a method to enhance the efficacy of a vaccine, especially an HIV DNA vaccine. For instance, for efficacious vaccine against HIV-1 one preferably induces both cellular and humoral immune responses to control the infection (Boyer et al., 1997, *Nature Medicine* 3:625-532). The induction of both cellular and humoral immune response by the Berjer et al. method is still quite low because only one of the three immunized chimpanzees developed both cellular and humoral responses. Similarly, although co-delivery of an IL-12 encoding gene with a HIV DNA vaccine, as described in Kim et al. (1997, *J. Immun.* 158:816-826), may have enhanced the cellular immune response, this co-delivery also decreased the humoral response.

Citation of a reference hereinabove shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION. SUMMARY OF THE INVENTION.. SUMMARY OF THE INVENTION

The present invention is based upon the ability of chemokines, such as MDC, Rantes, MIP-1d, MIP-1B, and I-309, to enhance the immune response to an antigen, particularly a vaccine. Accordingly, in a first aspect, the present invention provides a method for enhancing the efficacy of a vaccine, which method comprises administration to a subject of one or more purified chemokines, or biologically active fragments, analogues or derivatives thereof, either concurrently with one or more purified antigens against which an immune response is desired or within a time period either before or after administration of the antigens such that the immune response against the antigens is enhanced.

In a second aspect, the present invention provides a method to enhance the efficacy of a vaccine, which method comprises administration to a subject of a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments, derivatives, analogues, and/or truncation isoforms thereof, and a second purified nucleic acid comprising a nucleotide sequence encoding one or more antigens against which an immune response is desired, such that, the one or more chemokine(s) and the antigen(s) are expressed in a coordinated manner upon introduction into a suitable cell. Alternatively, the nucleotide sequences encoding one or more chemokines, or

fragments, derivatives, and/or analogues thereof, and the antigens against which an immune response is desired are present on the same nucleic acid.

In a preferred embodiment, the invention provides a method to enhance the efficacy of an HIV vaccine.

In yet another aspect, the present invention provides a composition comprising an immunogenic amount of one or more purified antigens, an amount of one or more purified chemokines, or a fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response to the antigen. In another aspect, the present invention provides a composition comprising a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, fragments, derivatives analogues and or truncation isoforms thereof, and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens against which an immune response is desired, such that, the chemokine(s) and the antigen are expressed in a coordinated manner upon introduction into a suitable cell. In a preferred embodiment, the antigen is an HIV antigen. In another preferred embodiment, the chemokine is selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha

chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. DESCRIPTION OF FIGURES

Figures 1A and 1B. The nucleotide and amino acid sequences of MDC. 1A depicts the nucleotide sequence of MDC (SEQ ID NO:1), with the coding region indicated by the appearance of the amino acid sequence in the line below; and 1B depicts the amino acid of MDC (SEQ ID NO:2) from GenBank accession no. U83171 (Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing the efficacy of a vaccine in a subject comprising administering to the subject one or more purified antigens in conjunction with one or more purified chemokines, or more purified fragments, derivatives or analogues and/or truncation isoforms thereof.

While any chemokine may be employed according to the present invention, the chemokine is preferably selected from the following table:

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines	Macrophage-derived chemokine	MDC/STCP-1	u83171; u83239
	Monocyte chemotactic protein 1	MCP-1	x14768
	Monocyte chemotactic protein 2	MCP-2	X99886
	Monocyte chemotactic protein 3	MCP-3	x72308; s57464
	Monocyte chemotactic protein 4	MCP-4	u46767
	activated macrophage specific chemokine 1	AMAC-1	Y13710
	Macrophage inflammatory protein 1 alpha	MIP-1 α	AF043339; X03754; D90144

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Macrophage inflammatory protein 1 beta	MIP-1 β	j04130; d90145
	Macrophage inflammatory protein 1 gamma	MIP-1 γ	
	Macrophage inflammatory protein 1 delta	MIP-1 δ	AF031587
	Macrophage inflammatory protein 2 alpha	MIP-2 α	AF043340
	Macrophage inflammatory protein 3 alpha	MIP-3 α	u77035
	Macrophage inflammatory protein 3 beta	MIP-3 β	u77180
	Regulated upon activation, normal T cell expressed and secreted (and its variants)	RANTES	M21211
	I-309		M57502
	EBI1-ligand chemokine	ELC	AB000887
	Pulmonary and activation regulated chemokine	PARC/DC-CK-1/MIP4	AB000221
	Liver and activation-regulated chemokine	LARC	D86955
	Thymus and activation regulated chemokine	TARC	D43767
	Eotaxin (and variants)		D49372; Z69291; Z75669; Z75668
	Human chemokine 1	HCC1; NCC2	Z49270; z49269
	Human chemokine 2	HCC2; NCC3, MIP-5, MIP-1 δ	Z70292
	Human chemokine 3	HCC3	Z70293
	IL-10-inducible chemokine	HCC4	U91746
	liver-expressed chemokine.	LEC; HCC4;NCC4	AB007454
	6Ckine		AF001979
	Exodus 1		u64197
	Exodus 2		U88320
	Exodus 3		U88321
	thymus-expressed chemokine	TECK	U86358
	Secondary Lymphoid tissue chemokine	SLC	AB002409

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Lymphocyte and Monocyte chemoattractant; Monotactin	LMC	AF055467
	Activation-induced, chemokine-related molecule	ATAC	x86474
	Myeloid progenitor inhibitory factor-1	MPIF-1; MIP-3 or ckbeta8	u85767
	Myeloid progenitor inhibitory factor-2	MPIF-2	u85768
	Stromal cell-derived factor 1 alpha	SDF-1 α ; PBSF	L36034
CXC chemokines	Stromal cell-derived factor 1 beta	SDF-1 β ; PBSF	L36033
	B-cell-attracting chemokine 1	BLC	AJ002211
	HuMIG		x72755 s60728
	H174		AF002985
	Interferon-stimulated T-cell alpha chemoattractant	I-TAC	AF030514
	Interleukin-8	IL-8	m17017; y00787
	IP-10		X02530
	platelet factor 4	PF4	M20901
	growth-regulated gene-alpha	GRO- α	J03561
	growth-regulated gene-beta	GRO- β	M36820
	growth-regulated gene-gamma	GRO- γ	M36821
	Neutrophil-activating protein 2	NAP-2; CTAP-3	M54995; M38441
	ENA-78		L37036
	granulocyte chemotactic protein 2	GCP-2	Y08770
C-CHEMOKINES	LYMPHOTACTIN	SCM-1	D63789 D63790
CX3C-CHEMOKINES	Fractalkine/neurotactin		U91835 U84487

The present invention also relates to the use of fragments, analogues and derivatives of the foregoing chemokines, as well as truncation isoforms of such chemokines which are known in the art.

The present invention also relates to therapeutic compositions comprising one or more chemokines, nucleic acids encoding one or more chemokines, derivatives, analogues, and/or truncation isoforms thereof, and nucleic acids encoding the same, that are effective to enhance the immune response of a subject to a vaccine.

In another preferred embodiment of the invention, nucleic acids comprising

nucleotide sequences encoding one or more chemokines or fragments or derivatives, including truncation isoforms, thereof, and encoding one or more antigens against which an immune response is desired, which coding sequences are operatively linked to gene regulatory sequences capable of directing the expression of the one or more chemokines and the one or more antigens upon introduction into a suitable cell, for example, but not limited to, the cell (of a subject), are administered to a subject such that the one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, and one or more antigens, are expressed in the subject.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE

The present invention provides methods for enhancing the efficacy of a vaccine in a subject, which methods comprise administering to a subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject in conjunction with an amount of one or more purified chemokines, or fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response against the antigen. In one aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered to the subject concurrently with (e.g., in the same composition with) the purified antigen or antigens against which an immune response is desired. In another, aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered either before or after the administration of one or more purified antigens against which immunity is desired in the subject, but is administered within such time that the chemokine(s) enhance the immune response to the one or more antigens. For example, but not by way of limitation, the purified chemokine(s) are administered during the time that the subject mounts an immune response against the administered one or more antigens, or, the purified MDC is administered within, for example, but not limited to, 30 minutes, 1 hour, 5 hours, 10 hours, 1 day, 2 days of (preferably, after) administration of the one or more purified antigens against which immunity is desired.

In a preferred embodiment, the present invention provides compositions comprising an immunogenic amount of one or more purified antigens and an amount of purified MDC, or one or more fragments, derivatives or analogues thereof, effective to enhance the immune response to said antigen and, preferably, the composition further comprises a pharmaceutically acceptable carrier.

A preferred chemokine for use in the methods and compositions of the present invention is any MDC protein, fragment or derivative thereof, that is capable of enhancing the efficacy of a vaccine (for example, but not limited to, as determined by the assays described in Section 5.4, *infra*). In one specific embodiment, the MDC is purified full length MDC, preferably full length MDC having the amino acid sequence of SEQ ID NO: 2 (Figure 1B). In another embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 2-69 of SEQ ID NO: 2 (Figure 1B). In another specific embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 3-69 of SEQ ID NO: 2 (Figure 1B). In still another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine. In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine.

In yet another specific embodiment, the chemokine is a purified derivative of the protein, which derivative has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. In yet another specific

embodiment, the chemokine is a purified derivative of the protein that has only one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. The chemokines useful in the present invention may be derived from any suitable source and obtained by any method known in the art, for example but not limited to the methods described in Section 5.2 *infra*.

Preferably, the chemokine(s) are of the same species as the subject to which the vaccine is administered. In a preferred embodiment, one or more human chemokines are administered to a human subject, e.g., human MDC is administered to a human subject, alone or in combination with another chemokine.

The present invention also provides a method to enhance the efficacy of a vaccine in a subject, which method comprises administering to a subject a purified first nucleic acid comprising a nucleotide sequence encoding an antigen against which an immune response is desired in a subject and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragment(s), derivative(s) or analogue(s) thereof, where the expression of the encoded antigen(s) and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are under control of one or more appropriate gene regulatory elements (which regulatory elements can be any regulatory element known in the art, for example, but not limited to, those regulatory elements described in Section 5.2 *supra*), such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are coordinately expressed, *i.e.*, are expressed either at the same time or within an appropriate time period (*i.e.*, sufficient for the chemokine(s) to enhance the immune response against the antigen relative to a corresponding immune response in the absence of the chemokine) and the antigen(s) are expressed in an immunogenic amount and the chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are expressed in an amount sufficient to enhance the immune response against the antigen(s). In a specific embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen are present on separate nucleic acids. In another embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen(s) are present on the same nucleic acid.

The present invention also provides compositions to enhance the

efficacy of a vaccine in a subject, which compositions comprise a purified first nucleic acid comprising a nucleotide sequence encoding one or more antigen(s) and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, wherein the nucleotide sequences encoding the antigens and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens and a purified second set of one or more purified nucleic acids comprising a nucleotide sequence encoding one or more chemokines, or fragments, analogues, derivatives, (including truncation isoforms) thereof, wherein the nucleotide sequence(s) encoding the antigen(s) and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second sets of nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified nucleic acid comprising a first set of one or more nucleotide sequences encoding one or more antigens and a second set of one or more nucleotide sequence encoding one or more chemokines, or fragments, derivatives, or analogues thereof (including truncation isoforms), wherein the first and second sets of nucleotide sequences are operably linked to one or more gene regulatory elements such that, upon introduction into a suitable cell, the antigen(s) and the chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are

expressed in an amount effective to enhance the immune response against the antigen(s).

Any nucleic acid comprising a nucleotide sequence encoding one or more chemokine proteins, or fragments or derivatives, thereof (including truncation isoforms), that are capable of enhancing the immune response to the antigen (for example, but not limited to, as determined by any of the assays described in Section 5.2., *infra*) can be used in the methods and compositions of the present invention.

In a preferred embodiment, the nucleotide sequence encodes MDC. In another embodiment, the MDC-encoding nucleotide consists of the nucleotide sequence of SEQ ID NO:1 (Figure 1A). In another specific embodiment, the method or composition of the invention uses a nucleic acid encoding an MDC derivative having deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the immune response against an antigen in a subject.

Such compositions of nucleic acids encoding an antigen are often referred to as DNA vaccines.

Such DNA vaccines are produced by any method known in the art for constructing an expression plasmid vector containing the nucleotide sequences of the antigen(s) and/or chemokine(s) to be expressed which vector is suitable for expression of the encoded proteins in the subject or in cells recombinant for the expression vector, which cells are to be provided to the subject. Such expression vectors may contain various promoters, terminators and polyadenylation coding regions to control the expression of the encoded protein.

The DNA vaccine can be administered by any method known in the art for administration of DNA. The DNA vaccine may be delivered either directly, in which case the subject is directly exposed to the DNA vaccine such that the DNA enters and is expressed in cells of the subject, or indirectly, in which case, the DNA vaccine is first introduced into suitable cells by any method known in the art *in vitro*, then the cells containing the DNA vaccine are transplanted into the subject.

In a specific embodiment, the DNA vaccine is directly administered *in vivo*, where it is expressed to produce the encoded antigens and chemokine(s). This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or

other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In a preferred embodiment, the nucleic acid of a DNA vaccine is injected into the muscle of the subject to be immunized.

Another approach is to introduce the nucleic acid of the DNA vaccine into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign nucleic acid into cells (see e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Cells into which a DNA vaccine can be introduced for purposes of immunization encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

The resulting recombinant cells can be delivered to a subject by various

methods known in the art. In a preferred embodiment, the recombinant cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The cells can also be encapsulated in a suitable vehicle and then implanted in the subject (see, e.g., Dionne et al. PCT Publication WO 92/19195, dated November 12, 1992). The amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.

By way of example, and not by way of limitation a DNA vaccine may be generated as described by Lekutis et al. for an HIV DNA vaccine (1997, *J. Immunol.* 158:4471-4477). Briefly, an expression vector is constructed with the promoter, enhancer and intron A of human cytomegalovirus (CMV) and the termination and polyadenylation sequences of bovine growth hormone in a plasmid backbone. Additionally, the nucleotide sequence for signal sequence of tissue plasminogen activator is either substituted for the signal sequence of the antigen, if the antigen has a signal sequence or is added onto the amino-terminus of the antigen, thereby eliminating the dependence on viral proteins for expression (e.g., in the case of gp120 expression, rev and env proteins are required unless the HIV-1 signal sequence is so substituted). The resulting formulation is then injected intra-muscularly.

Further examples of DNA vaccines are set forth in Boyer et al. (1996, *J. Med. Primatol.*, 25:242-250), which describes the construction of a plasmid encoding the HIV-1 gp160 envelope glycoprotein as well as the rev-tax region cloned into pMAMneoBlue vector (Clonetech, Inc., Palo Alto, CA), and a vector encoding the envelope glycoprotein and rev from HIV-1 strain MN under the control of the CMV promoter. Another vector which can be used in the present invention is as described in Boyer et al. (1997, *Nature Medicine* 3:526-532) and contains expression cassettes encoding the envelope and Rev proteins of HIV-1 strain MN, and encoding the Gag/Pol proteins of HIV-1 strain IIIB.

For the practice of the present invention, the nucleotide sequence for the one or more chemokines, or fragments, derivatives, or analogues thereof, can either be incorporated into the same expression vector containing the nucleotide sequence encoding the antigen in such a manner that the chemokine(s) are expressed. Alternatively, the nucleotide sequence encoding the chemokine(s), or fragment(s),

derivative(s) or analogue(s) thereof, can be cloned into a separate expression vector (e.g., as described above for the expression vector containing the sequences coding for antigen) and the expression vector that expresses the antigen(s) mixed with the expression vector that expresses the chemokine(s). The mixture of the two expression vectors can then be administered to the subject.

The methods and compositions of the present invention may be used as a vaccine in a subject in which immunity for the antigen(s) is desired. Such antigens can be any antigen known in the art to be useful in a vaccine formulation. The methods and compositions of the present invention can be used to enhance the efficacy of any vaccine known in the art. The vaccine of the present invention may be used to enhance an immune response to infectious agents and diseased or abnormal cells, such as but not limited to bacteria, parasites, fungi, viruses, tumors and cancers. The compositions of the invention may be used to either treat or prevent a disease or disorder amenable to treatment or prevention by generating an immune response to the antigen provided in the composition. In one preferred embodiment, the antigen(s) are proteins, fragments or derivatives, including truncation isoforms, thereof, encoded by any genes of the HIV genome including the *env*, *gag*, *pol*, *nef*, *vif*, *rev*, and *tat* genes. In a more preferred embodiment, the antigen is an HIV-associated gp120 protein.

The methods and compositions of the present invention may be used to elicit a humoral and/or a cell-mediated response against the antigen(s) of the vaccine in a subject. In one specific embodiment, the methods and compositions elicit a humoral response against the administered antigen in a subject. In another specific embodiment, the methods and compositions elicit a cell-mediated response against the administered antigen in a subject. In a preferred embodiment, the methods and compositions elicit both a humoral and a cell-mediated response.

The subjects to which the present invention is applicable may be any mammalian or vertebrate species, which include, but are not limited to, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats, monkeys, rabbits, chimpanzees, and humans. In a preferred embodiment, the subject is a human. The compositions and methods of the invention can be used to either prevent a disease or disorder, or to treat a particular disease or disorder, where an immune response against a particular antigen or antigens is effective to treat or prevent the

disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc, bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by eliciting an immune response against a particular antigen or antigens. In another preferred embodiment, the subject is infected or at risk of being infected with HIV virus.

In another preferred embodiment the invention provides methods and compositions to enhance the efficacy of an HIV vaccine, such a vaccine can be administered to either prevent or treat HIV.

5.2. CHEMOKINE GENES AND PROTEINS

Chemokine proteins and nucleic acids can be obtained by any method known in the art. Chemokine nucleotide and amino acid sequences are available in public databases such as Genbank and are also published in various references known to those of skill in the art. The gene bank accession numbers for the preferred chemokines of the present invention are provided in Table I, in Section 5 above. The ensuing discussion uses MDC by way of example, but applies equally to other chemokines as well.

The MDC nucleotide and amino acid sequences for, *inter alia*, human, are available in the public databases (e.g. Genbank accession No. U83171) also published in Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604. The nucleotide sequence and the amino acid sequence for the human MDC are provided in Figures 1A and B (SEQ ID NOS:1 and 2, respectively).

Chemokines used herein include, but are not limited to, chemokines from mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, and human. In one preferred embodiment, the chemokine is of human origin.

Any vertebrate cell potentially can serve as the nucleic acid source for the isolation of chemokine nucleic acids. The nucleic acid sequences encoding the chemokine(s) can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a

DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from cDNA, cDNA is generated from totally cellular RNA or mRNA by methods that are well known in the art. The gene may also be obtained from genomic DNA, where DNA fragments are generated (e.g. using restriction enzymes or by mechanical shearing), some of which will encode the desired gene. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing all or a portion of the chemokine gene may be accomplished in a number of ways.

A preferred method for isolating a chemokine gene is by the polymerase chain reaction (PCR), which can be used to amplify the desired chemokine sequence in a genomic or cDNA library or from genomic DNA or cDNA that has not been incorporated into a library. Oligonucleotide primers which would hybridize to chemokine sequences can be used as primers in PCR.

Additionally, a portion of the chemokine (of any species) gene or its specific RNA, or a fragment thereof, can be purified (or an oligonucleotide synthesized) and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, *Science* 196:180; Grunstein, M. And Hogness, D., 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. Chemokine nucleic acids can be also identified and isolated by expression cloning using, for example, anti-chemokine antibodies for selection.

Alternatives to obtaining the chemokine DNA by cloning or amplification

include, but are not limited to, chemically synthesizing the gene sequence itself from the known chemokine sequence or making cDNA to the mRNA which encodes the chemokine protein. Other methods are possible and within the scope of the invention. Once a clone has been obtained, its identity can be confirmed by nucleic acid sequencing (by any method well known in the art) and comparison to known chemokine sequences. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, *Meth. Enzymol.* 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, *Proc. Natl. Acad. Sci. U.S.A.* 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699), use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA) or the method described in PCT Publication WO 97/ 15690.

Nucleic acids which are hybridizable to a chemokine nucleic acid, or to a nucleic acid encoding a chemokine derivative can be isolated, by nucleic acid hybridization under conditions of low, high, or moderate stringency (see also Shilo and Weinberg, 1981, *Proc. Natl. Acad. Sci. USA* 78:6789-6792). For example, the nucleic acid of SEQ ID No: 1 is hybridizable to an MDC nucleic acid.

Chemokine proteins and derivatives, analogs and fragments of chemokine proteins can be obtained by any method known in the art, including but not limited to recombinant expression methods, purification from natural sources, and chemical synthesis.

For example, chemokines can be obtained by recombinant protein expression techniques. For recombinant expression, the chemokine gene or portion thereof is inserted into an appropriate cloning vector for expression in a particular host cell. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site

desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and chemokine gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated chemokine gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleotide sequence coding for a chemokine protein or a functionally active analog or fragment or other derivative thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native chemokine gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein

coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a chemokine protein or peptide fragment may be regulated by a second nucleic acid sequence so that the chemokine protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a chemokine protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control chemokine expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region

which is active in myeloid cells (Mogam et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

For example, a vector can be used that comprises a promoter operably linked to an chemokine-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning a chemokine coding sequence into the *EcoRI* restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression of the chemokine protein product from the subclone in the correct reading frame.

Expression vectors containing chemokine gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a chemokine gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted chemokine gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a chemokine gene in the vector. For example, if the chemokine gene is inserted within the marker gene sequence of the vector, recombinants containing the chemokine insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chemokine protein in *in vitro* assay systems, e.g., binding with anti-chemokine antibody or the chemokine's receptor.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host

system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other specific embodiments, the chemokine protein(s), fragment(s), analogue(s), or derivative(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric protein containing all or a portion of the chemokine is joined via a peptide bond to all or a portion of an antigen against which immunity is desired.

Both cDNA and genomic sequences can be cloned and expressed.

The chemokine protein(s) may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column

chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.5). Alternatively, the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M., et al., 1984, *Nature* 310:105-111). The chemokine-encoding nucleic acid sequence(s) can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 253:6551), use of TAB linkers (Pharmacia), mutation-containing PCR primers, etc.

The experimentation involved in mutagenesis consists primarily of site-directed mutagenesis followed by phenotypic testing of the altered gene product. Some of the more commonly employed site-directed mutagenesis protocols take advantage of vectors that can provide single stranded as well as double stranded DNA, as needed. Generally, the mutagenesis protocol with such vectors is as follows. A mutagenic primer, *i.e.*, a primer complementary to the sequence to be changed, but consisting of one or a small number of altered, added, or deleted bases, is synthesized. The primer is extended *in vitro* by a DNA polymerase and, after some additional manipulations, the now double-stranded DNA is transfected into bacterial cells. Next, by a variety of methods, the desired mutated DNA is identified, and the desired protein is purified from clones containing the mutated sequence. For longer sequences, additional cloning steps are often required because long inserts (longer than 2 kilobases) are unstable in those vectors. Protocols are known to those skilled in the art and kits for site-directed mutagenesis are widely available from biotechnology supply companies, for example from Amersham Life Science, Inc. (Arlington Heights, IL) and Stratagene Cloning Systems (La Jolla, CA).

In other specific embodiments, the chemokine derivative(s) or analogue(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analogue, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

In addition, chemokine proteins, derivatives (including fragments and chimeric proteins), and analogues can be chemically synthesized. See, e.g., Clark-Lewis et al., 1991, *Biochem.* 30:3128-3135 and Merrifield, 1963, *J. Amer. Chem. Soc.* 85:2149-2156. For example, chemokines, derivatives and analogues can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 50-60). Chemokines, derivatives and analogues that are proteins can also be synthesized by use of a peptide synthesizer. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 34-49).

The chemokine proteins, derivatives, or analogues of the invention may be synthesized in their entirety by the sequential addition of amino acid residues or alternatively as fragment subcomponents which may be combined using techniques well known in the art, such as, for example, fragment condensation (Shin et al., 1992, *Biosci. Biotech. Biochem.* 56:404-408; Nyfeler et al., 1992, *Peptides*, Proc. 12th Amer. Pep. Soc., Smith and Rivier (eds), Leiden, pp 661-663); and Nokihara et al., 1990, Protein Research Foundation, Yanaihara (ed), Osaka, pp 315-320).

In a less preferred embodiment, chemokine derivatives can be obtained by proteolysis of the protein followed by purification using standard methods such as those described above (e.g., immunoaffinity purification).

In another alternate embodiment, native chemokine proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).

5.3. COMPOSITION FORMULATIONS AND METHODS OF ADMINISTRATION

The composition formulations of the invention comprise an effective immunizing amount of an immunologically active ingredient, i.e., one or more antigens, and an amount of one or more chemokine(s), or fragment(s) or derivative thereof, effective to enhance the immune response against the antigen in a subject, and a pharmaceutically acceptable carrier or excipient. In a specific embodiment, the

chemokines are selected from the group consisting of Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

Pharmaceutically acceptable carriers or excipients are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

In addition, if desired, the vaccine or composition preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine or composition. Suitable adjuvants may include, but are not limited to: mineral gels,

e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine. The effectiveness of an adjuvant may be determined by comparing the induction of antibodies directed against a MDC-containing composition in the presence and in the absence of various adjuvants.

In instances where the recombinant antigen is a hapten, *i.e.*, a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

The chemokine(s), or fragment(s) or derivative(s) thereof, and/or the antigen(s) may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

An effective dose (immunizing amount) is that amount sufficient to produce an immune response to the antigen(s) in the host to which the vaccine preparation is administered. The precise dose of the composition to be employed in the formulation will depend on the route of administration, and the nature of the subject to be

immunized, and should be decided by the practitioner according to standard clinical techniques. Effective doses of the vaccines or compositions of the present invention may also be extrapolated from dose-response curves derived from animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the composition formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized immunologically active ingredient and one or more chemokine polypeptide(s) of the invention are provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Many methods may be used to introduce the composition formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The DNA vaccines of the invention can be administered by any method known in the art for delivery of DNA to subject (for example, as described in Section 5.3 *supra*)

5.4. DETERMINATION OF COMPOSITION EFFICACY

The activity of one or more chemokines, or a fragment, derivative or analogue thereof, to enhance immune response to an antigen can be determined by monitoring the immune response in test animals following immunization with a composition containing the chemokine(s) and an antigen and comparing the response to that following immunization with the antigen in the absence of the chemokine(s). Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Assays for humoral and cell-mediated immunity are well known in the art.

Methods of introducing the composition may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches well known in the art, such as but not limited to: testing the reactivity of the resultant immune serum to the antigen of the chemokine-containing vaccine, as assayed by known techniques, e.g., immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.

As one example of suitable animal testing, a composition of the present invention may be tested in mice for the ability to enhance an antibody response to an antigen (using for example, but not limited to, the method as described in Section 6, *infra*) and the delayed-type hypersensitivity (DTH) response (also described in Section 6 *infra*), measured by an increase in footpad swelling after inoculation in the footpad of the test animal, as compared to the measurements in animals administered the antigen in a composition not containing chemokine. For example, as test animals BALB/c mice may be used. The test group each receives an inoculation with fixed amount of antigen and varying amount of one or more chemokines. The control group receives an inoculation of comparable amount of antigen alone.

Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation), and serum is analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA. DTH responses to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and/or

an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokine(s) as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing the chemokine(s), indicates that the chemokine(s) enhance the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokines as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing chemokine(s), indicates that the chemokine(s) enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen.

6. EXAMPLE: IMMUNIZATION WITH MDC-CONTAINING COMPOSITION

The following experiment illustrates the evaluation of whether MDC will act as an adjuvant for a protein antigen and enhance the efficacy of a vaccine. However, it will be appreciated that the description applies equally to other chemokines and combinations of chemokines.

6.1. MATERIALS AND METHODS

6.1.1. ANIMALS AND REAGENTS

BALB/c mice are purchased from Harlan-Sprague-Dawley (Indianapolis, IN).

Human MDC (hMDC) was obtained from CD8⁺ T cell clones immortalized *in vitro* prepared as previously described (Markham et al., 1983 *Int. J. Cancer* 31:413; Markham et al. 1984, *Int. J. Cancer* 33:13). One such immortalized CD8⁺ T cell clone, F3b Clone 19, was adapted to growth in serum-free medium by the following procedure and used for further studies. F3b Clone 19 cells were grown in complete medium containing rIL-2 (16 ng/ml) at 37°C in a CO₂ incubator. After expanding the culture to 200 ml, the cells were pelleted and resuspended in RPMI medium containing HB101 (Irvine Scientific) supplemented with 16 ng/ml of rIL-2, 1% glutamine and 1% penicillin/streptomycin. The cells were grown to full confluence and the medium harvested by centrifugation at 670 x g for 10 minutes.

Human MDC (hMDC) was purified from F3b Clone 19 as described in Pal et al., 1997, *Science* 278:695-698. Briefly, the cell free culture supernatant from F3b Clone 19 was clarified by high speed centrifugation and fractionated by heparin affinity chromatography, taking advantage of the heparin binding characteristics of chemokines (Witt and Lander, 1994, *Current Biology* 4:394; Proost et al., 1996, *Method: A Companion to Methods in Enzymology* 10:82). Culture supernatant (1200 ml) from F3b Clone 19, grown to high cell density in serum-free medium supplemented with rIL-2 was clarified by high speed centrifugation (100,000 x g for 60 minutes at 4°C) and applied to a 5 ml HiTrap heparin affinity FPLC column (Pharmacia) equilibrated in 10 mM Tris-HCl, pH 7.6 containing 0.1 M NaCl (column buffer). The column was then washed extensively with column buffer and the bound proteins eluted from the column with 10 mM Tris-HCl, pH 7.6 containing 2.0 M NaCl at a flow rate of 0.5 to 1 ml/minute. Virtually all of the HIV suppressive activity effective against primary NSI and SI isolates and HIV-1_{IIIIB} was recovered in the column eluate (data not shown). The heparin affinity column eluate was brought to pH 2.0 by addition of trifluoroacetic acid (TFA) and subjected to reversed phase HPLC on a PEEK C-18 column (Waters Instruments) equilibrated in H₂O containing 0.1 % TFA. Proteins bound to the column were eluted with a 5 minute linear gradient of aqueous acetonitrile (0 to 35 %) containing 0.1% TFA. After 10 minutes at 35% acetonitrile, the column was further developed with a 60 minute linear gradient of 35-70% aqueous acetonitrile in TFA. The flow rate was maintained at 0.5 to 1 ml/minute. The fractions obtained were then tested for suppressor activity in the acute infectivity assay using HIV-1_{IIIIB}. Active fractions were pooled, diluted twofold in H₂O with 0.1 % TFA

and reapplied to the column. The column was then developed with a 30 minute linear aqueous acetonitrile gradient (0-60%) containing 0.1% TFA at a flow rate of 0.5 to 1 ml/minute. The fractions obtained were assayed as above. Active fractions were pooled, diluted with H₂O/0.1 % TFA and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity was cofractionated with the protein.

Suppressive activity against HIV-1_{IIIB} in the absence of cytotoxic effects consistently copurified with a single protein peak that appeared as a homogeneous 8 kDa band when analyzed by SDS-polyacrylamide gel electrophoresis. This protein was not reactive in ELISAs for RANTES, MIP-1 α or MIP-1 β (R&D Systems).

Recombinant gp120 protein derived from HIV-1 IIIB isolate is purchased from Intracel (Foster City, CA).

6.1.2 IMMUNIZATION OF MICE

The hMDC and the gp120 is resuspended in a total volume of 50 μ l of phosphate-buffered saline (PBS). Mice are divided into 5 groups with 3-4 mice in each group. Groups 1-4 are inoculated with 10 μ g gp120 and 0.3 μ g, 0.1 μ g, 0.03 μ g, and 0.01 μ g of hMDC, respectively. As a control, group 5 is inoculated with 10 μ g of gp120 in the absence of hMDC. For primary inoculation, each group of mice is inoculated with 10 μ l of the hMDC and gp120 solution via footpad. Two to three weeks after the primary inoculation, each mouse is given the same dose of hMDC/gp120 that is used in primary inoculation.

6.1.3 ELISA ASSAY

Serum samples are collected one week after the second inoculation via tail vein bleed. gp120 serum responses are measured using standard gp120 antibody ELISA assays.

6.1.4 DTH ASSAY

The delayed-type hypersensitivity (DTH) response is measured from 1-7 days after the second inoculation. A caliper is to be used to measure footpad swelling.

6.2. RESULTS

Mice inoculated with hMDC/gp120 are expected to have greater serum antibody and DTH responses than mice inoculated with gp120 alone. The improved responses will be reflected in either increased titers of serum antibody responses or increased footpad swelling. A dose response effect is expected - increasing the dose of hMDC used is expected to cause a corresponding improvement in the serum and DHT gp120-specific responses.

7. EXAMPLE: OTHER CHEMOKINES AND COMBINATIONS OF CHEMOKINES

The foregoing experiments can be repeated using other chemokines and combinations of chemokines. For example, the experiments are preferably repeated using one or more chemokines selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

THE CLAIMS:

1. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject and an amount of one or more chemokines, or purified fragments or derivatives thereof, effective to enhance the efficacy of said vaccine.
2. The method of claim 1, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
3. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-

regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
5. The method of claim 1 wherein the fragment(s) or derivative(s) are truncation isoforms.
6. The method of claim 1, wherein the one or more chemokines include MDC comprising the amino acid sequence of SEQ ID NO: 2.
7. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
8. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2., which derivative has activity to enhance the efficacy of the vaccine.
9. The method of claim 1, wherein the one or more chemokine derivatives has one or more insertions or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
10. The method of claim 1, including a chemokine derivative having one or more conservative substitutions in sequence relative a wildtype MDC, which derivative has activity to enhance the efficacy of the vaccine.
11. The method of claim 1, wherein the one or more chemokines include a human chemokine.

12. The method of claim 1, wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof is/are administered concurrently with the purified antigen(s).
13. The method of claim 1 wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof, are administered within a time period before or after administration of the purified antigen, which time period permits the purified MDC or purified fragment or derivative thereof MDC to enhance the efficacy of the vaccine.
14. The method of claim 1, wherein the antigen is an HIV antigen.
15. The method of claim 14, wherein the HIV antigen is HIV-associated gp120 protein.
16. The method of claim 1, wherein the subject is a human.
17. The method of claim 1, wherein the subject is infected or at risk of being infected with HIV virus.
18. The method of claim 1, wherein the vaccine elicits a humoral response against the antigen in the subject.
19. The method of claim 1, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
20. The method of claim 1, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
21. The method of claim 1, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

22. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject a first amount of a first set of one or more purified nucleotide sequences encoding one or more antigens against which an immune response is desired in the subject and a second second set of one or more purified nucleic acids, each comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner upon introduction into a suitable cell, said first amount is immunogenic and said second amount is effective in enhancing the efficacy of the vaccine.
23. The method of claim 22, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
24. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine

- 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
25. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
26. The method of claim 22 wherein the fragment(s) or derivative(s) are truncation isoforms.
27. The method of claim 22, wherein the nucleotide sequence encoding one or more chemokines comprises the nucleotide sequence of SEQ ID NO:1.
28. The method of claim 22, wherein one or more of the chemokine derivative(s) have deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the efficacy of the vaccine.
29. The method of claim 22, wherein the vaccine elicits a humoral response against the antigen in the subject.
30. The method of claim 22, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
31. The method of claim 22, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
32. The method of claim 22, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
33. A composition comprising: an immunogenic amount of one or more purified antigens and an amount of one or more purified chemokines, or purified

fragments or derivatives thereof, effective to enhance the immune response to said antigen(s); and a pharmaceutically acceptable carrier.

34. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
35. The composition of claim 33, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
36. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating

protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

37. The composition of claim 33, wherein the fragment(s) or derivative(s) are truncation isoforms.
38. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragmentsselected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
39. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragmentsselected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2, which derivative has activity to enhance the efficacy of the vaccine.
40. The composition of claim 33, wherein the one or more chemokine derivatives has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
41. The composition of claim 33, wherein the one or more chemokine derivatives has one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
42. The composition of claim 33, wherein the chemokine is a human chemokine.
43. The composition of claim 33, wherein the antigen is an HIV antigen.
44. The composition of claim 43, wherein the antigen is HIV associated gp120 protein.
45. A composition comprising an amount of a first set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens

and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s), or fragment(s) or derivative(s) thereof, are expressed from said first set of nucleic acid(s) and second set of nucleic acid(s) in a coordinated manner such that upon introduction into a suitable cell, the amount of said first set of nucleic acid(s) is sufficient to express an immunogenic amount of the antigen and the amount of the said second set of nucleic acid(s) is effective in enhancing the efficacy of the vaccine; and a pharmaceutically acceptable carrier.

46. The composition of claim 45, wherein the chemokine is MDC and the nucleic acid encoding the MDC comprises the nucleotide sequence of SEQ ID NO: 1.
47. The composition of claim 45, wherein the chemokine derivative(s) have deletional, insertional or substitutional mutations and/or combinations thereof, and the derivative(s) have activity to enhance the efficacy of the vaccine.
48. The composition of claim 45, further comprising pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
49. A composition comprising a first set of purified nucleotide sequences encoding one or more antigens and a second set of purified nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner such that upon introduction into a suitable cell, the sets produce an amount of said antigen(s) that is immunogenic and an amount of chemokine(s), or fragment(s) or derivative(s) thereof, that is effective in enhancing the efficacy of the vaccine relative to a corresponding vaccine composition without such chemokine(s), fragment(s) or derivative(s) thereof.
50. The composition of claim 49, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine,

Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

51. The method of claim 49, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
52. The method of claim 49, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
53. The composition of claim 49, wherein the fragment(s) or derivative(s) are truncation isoforms.

54. The composition of claim 49, wherein the nucleic acid is administered directly to the subject.
55. The composition of claim 49, wherein the nucleic acid is introduced into a suitable host cell and said suitable host cell is introduced into the subject.

GAGACATACA	GGACAGAGC	ATG	GCT	CGC	CTA	CAG	ACT	GCA	CTC	CTG	GTT	GTC		52		
Met Ala Arg Leu Gln Thr Ala Leu Val Val													-15			
													-24			
CTC	GTC	CTC	CTT	GCT	GTG	GCG	CTT	CAA	GCA	ACT	GAG	GCA	GGC	CCC	TAC	100
Leu	Val	Leu	Leu	Ala	Val	Ala	Val	Gln	Ala	Thr	Glu	Ala	Gly	Pro	Tyr	
													-10			
													-5			
GGC	GCC	AAC	ATG	GAA	GAC	AGC	GTC	TGC	TGC	CGT	GAT	TAC	GTC	CGT	TAC	148
Gly	Ala	Asn	Met	Glu	Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	
													15			
													10			
CGT	CTG	CCC	CTG	CGC	GTG	GTG	AAA	CAC	TTC	TAC	TGG	ACC	TCA	GAC	TCC	196
Arg	Leu	Pro	Leu	Arg	Val	Val	Lys	His	Phe	Tyr	Trp	Thr	Ser	Asp	Ser	
													25			
													30			
													35			
TGC	CCG	AGG	CCT	GGC	GTG	GTG	TTG	CTA	ACC	TTC	AGG	GAT	AAG	GAG	ATC	244
Cys	Pro	Arg	Pro	Gly	Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	Lys	Glu	Ile	
													40			
													45			
													50			
TGT	GCC	GAT	CCC	AGA	GTG	CCC	TGG	GTG	AAG	ATG	ATT	CTC	AAT	AAG	CTG	292
Cys	Ala	Asp	Pro	Arg	Val	Pro	Trp	Val	Lys	Met	Ile	Leu	Asn	Lys	Leu	
													55			
													60			
													65			

FIG. 1A-1

AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA 348
Ser Gln

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG 408

CATCCCTGA TCTCCATCCC TGTGGCTGC ACCCTTGGTC ACCTCCGTGC TGTCACCTGCC 468

ATCTCCCCC TGACCCCTCT AACCATCCT CTGCCCTCCCT CCGTGCAGTC AGAGGGTCCT 528

GTTCCTCATCA GCGATTCCCC TGCTTAAACC CTTCATGAC TCCCCACTGC CCTAAGCTGA 588 2/6

GGTCAGTCTC CCAAGCCTGG CATGTGGCC TCTGGATCTG GGTCCATCT CTGTCTCCAG 648

CCTGCCCACT TCCCTTCATG AATGTTGGT TCTAGCTCCC TGTTCTCCA ACCCATACTA 708

CACATCCCAC TTCTGGGTCT TTGCCCTGGA TGTGTCTGAC ACTCAGAAAG TCCCACCACC 768

TGCACATGTG TAGCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC 828

CATTTCATGT ATTAGATGTC CCGTGGCCCT CTGTCCCCCTC TTAATAACCC TAGTCACAGT 888

CTCCGCAGAT TCTTGGGATT TGGGGTTTT CTCCCCCACC TCTCCACTAG TTGGACCAAG 948

FIG. 1A-2

GTTCCTAGCT	AAGTTACTCT	AGTCTCCAAG	CCTCTAGCAT	AGAGCACTGC	AGACAGGCC	1008
TGGCTCAGAA	TCAGAGCCCA	GAAAGTGGCT	GCAGACAAA	TCAATAAAC	TAATGTCCCT	1068
CCCCTCTCCC	TGCCAAAGG	CAGTTACATA	TCAATACAGA	GACTCAAGGT	CACTAGAAAT	1128
GGCCAGCTG	GGTCAATGTG	AAGCCCCAA	TTTGCCAGA	TTCACCTTC	TTCCCCACT	1188
CCCTTTTTT	TTTTTTTTT	TTTGAGATGG	AGTTTCGCTC	TTGTCACCCA	CGCTGGAGTG	1248
CAATGGGTG	GTCTTGGCTT	ATTGAAGCCT	CTGCCCTCCTG	GGTTCAAGTG	ATTCTCTTGC	1308
CTCAGCCTCC	TGAGTAGCTG	GGATTACAGG	TTCTCTGCTAC	CACGCCCAGC	TAATTTTGT	1368
ATTTTtagTA	GAGACGAGGC	TTCACCATGT	TGGCCAGGCT	GGTCTCGAAC	TCCTGTCCCTC	1428
AGGTAATCCG	CCCACCTCAG	CCTCCCCAAG	TGCTGGGATT	ACAGGCGTGA	GCCACAGTGC	1488
CTGGCCTCTT	CCCTCTCCCC	ACTGCCCCCC	CCAACCTTTT	TTTTTTTTTT	ATGCGAGGGT	1548
CTCACTCTGT	CGCCAGGCT	GGAGTGCAGT	GGCGTGATCT	CGGCTCACTA	CAACCTCGAC	1608
CTCCCTGGGT	CAAGTGATTC	TCCCACCCCA	GCCTCCCAAG	TAGCTGGGAT	TACAGGTGTG	1668

FIG. 1A-3

3/6

4/6

TGCCACTACG	GCTGGCTAAT	TTTTGTAATT	TTAGTAGAGA	CAGGTTTCAC	CATATTGGCC	1728
AGGCTGGTCT	TGAACTCCTG	ACCTCAAGTG	ATCCACCTTC	CTTGTGCTCC	CAAAGTGCTG	1788
AGATTACAGG	CGTGAGCTAT	CACACCCAGC	CTCCCCCTTT	TTTTCCCTAAT	AGGAGACTCC	1848
TGTACCTTC	TTCGTTTAC	CTATGTGTCG	TGCTGCTTA	CATTTCCTTC	TCCCCCTCAGG	1908
CTTTTTTTGG	GTGGTCCTCC	AACCTCCAAT	ACCCAGGCCT	GGCCTCTTCA	GAGTACCCCC	1968
CATTCCACTT	TCCCTGCCTC	CTTCCTTAAA	TAGCTGACAA	TCAAATTCAT	GCTATGGTGT	2028
GAAAGACTAC	CTTTGACTTG	GTATTATAAG	CTGGAGTTAT	ATATGTATTT	GAAAACAGAG	2088
TAAATACTTA	AGAGGCCAAA	TAGATGAATG	GAAGAATTTT	AGGAACTGTG	AGAGGGGGAC	2148
AAGGTGAAGC	TTTCCTGGCC	CTGGGAGGAA	GCTGGCTGTG	GTAGCGTAGC	GCTCTCTCTC	2208
TCTGTCTGTG	GCAGGAGCCA	AAGAGTAGGG	TGTAATTGAG	TGAAGGAATC	CTGGGTAGAG	2268
ACCATTCTCA	GGTGGTTGGG	CCAGGCTAAA	GACTGGGAGT	TGGGTCTATC	TATGCCCTTC	2328
TGGCTGATTT	TTGTAGAGAC	GGGGTTTTCG	CATGTTACCC	AGGCTGGTCT	CAAACTCCTG	2388

FIG. 1A-4

GGCTCAAGCG	ATCCTCCTGG	CTCAGCCTCC	CAAAGTGCTG	GGATTACAGG	CGTGAATCAC	2448
TGCGCCTGGC	TTCTCTCTCC	TCTTGAGAAA	TATTTCTTTC	ATACAGCAAG	TATGGGACAG	2508
CAGTGTCCCA	GGTAAAGGAC	ATAAATGTTA	CAAGTGTCTG	GTCCTTTTCTG	AGGAGGCTG	2568
GTGCCGCTCT	GCAGGGTATT	TGAACCTGTG	GAAATTGGAGG	AGGCCATTTC	ACTCCCTGAA	2628
CCCAGCCTGA	CAAATCACAG	TGAGAAATGTT	CACCTTATAG	GCTTGCTGTG	GGGCTCAGGT	2688
TGAAAGTGTG	GGGAGTGACA	CTGCCTAGGC	ATCCAGCTCA	GTGTCATCCA	GGGCCCTGTGT	2748 ^{5/6}
CCCTCCCGAA	CCCAGGGTCA	ACCTGCCTGC	CACAGGCACT	AGAAGGACGA	ATCTGCCCTAC	2808
TGCCCATGAA	CGGGGCCCTC	AAGCGTCCTG	GGATCTCCTT	CTCCCTCCTG	TCCTGTCCTT	2868
GCCCCTCAGG	ACTGCTGGAA	AATAAATCCT	TTAAATAAGT	AAAAAATAAGT	AAAAA	2923

FIG. 1A-5

FIG. 1A

FIG. 1A-1
FIG. 1A-2
FIG. 1A-3
FIG. 1A-4
FIG. 1A-5

6/6

Met	Ala	Arg	Leu	Gln	Thr	Ala	Leu	Leu	Val	Val	Leu	Val	Leu	Leu	Ala
-24				-20					-15				-10		
Val	Ala	Leu	Gln	Ala	Thr	Glu	Ala	Gly	Pro	Tyr	Gly	Ala	Asn	Met	Glu
			-5					1				5			
Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	Arg	Leu	Pro	Leu	Arg
						15					20				
Val	Lys	His	Phe	Tyr	Tyr	Trp	Thr	Ser	Asp	Ser	Cys	Pro	Arg	Pro	Gly
25				30					35						40
Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	Lys	Glu	Ile	Cys	Ala	Asp	Pro	Arg
				45					50					55	
Val	Pro	Trp	Val	Lys	Met	Ile	Leu	Asn	Lys	Leu	Ser	Gln			
				60				65							

FIG. 1B

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Gallo, Robert C.
DeVico, Anthony L.
Garzino, Alfredo

(ii) TITLE OF THE INVENTION: METHOD AND COMPOSITION TO ENHANCE
THE EFFICACY OF A VACCINE USING MACROPHAGE DERIVED CHEMOKINE

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pennie & Edmonds LLP
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036/2711

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 8769-029

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2923 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 92..298

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Val	
-24 -20 -15	
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
-10 -5 1	
GGC GCC AAC ATG GAA GAC AGC GTC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr	
5 10 15	
CGT CTG CCC CTG CGC GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
20 25 30 35	
TGC CCG AGG CCT GGC GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Leu Thr Phe Arg Asp Lys Glu Ile	
40 45 50	
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
55 60 65	
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG 408
 CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCACCTGCC 468
 ATCTCCCCCT TGACCCCTCT AACCCTATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCCT 528
 GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCATGAC TCCCCACTGC CCTAAGCTGA 588
 GGTCACTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCATCT CTGTCTCCAG 648
 CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTTCTCCAA ACCCATACTA 708
 CACATCCAC TTTCTGGGTCT TTGCCTGGGA TGTGTCTGAC ACTCAGAAAG TCCCACCACC 768
 TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC 828
 CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCTC TTAATAACCC TAGTCACAGT 888
 CTCCGCAGAT TCTTGGGATT TGGGGGTTTT CTCCCCACC TCTCCACTAG TTGGACCAAG 948
 GTTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCCC 1008
 TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAAA TCAATAAAAC TAATGTCCCT 1068
 CCCCTCTCCC TGCCAAAAGG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT 1128
 GGGCCAGCTG GGTCAATGTG AAGCCCCAAA TTTGCCCAGA TTCACCTTTC TTCCCCCACT 1188
 CCCTTTTTTT TTTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTACCCCA CGCTGGAGTG 1248
 CAATGGTGTG GTCTTGGCTT ATTGAAGCCT CTGCCTCCTG GGTTCAGTG ATTCTCTTGC 1308
 CTCAGCCTCC TGAGTAGCTG GGATTACAGG TCCCTGCTAC CACGCCAGC TAATTTTTGT 1368
 ATTTTATAGTA GAGACGAGGC TTCACCATGT TGGCCAGGCT GGTCTCGAAC TCCTGTCTCT 1428
 AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC 1488
 CTGGCCTCTT CCCTCTCCCC ACTGCCCCC CCAACTTTTT TTTTTTTTTT ATGGCAGGCT 1548
 CTCACCTGTG CGCCAGGCT GGAGTGCAGT GCGCTGATCT CGGCTCACTA CAACCTCGAC 1608
 CTCCTGGGTT CAAGTGATTC TCCCACCCCA GCCTCCCAAG TAGCTGGGAT TACAGGTGTG 1668
 TGCCACTACG GCTGGCTAAT TTTTGTATTT TTAGTAGAGA CAGGTTTCAC CATATTGGCC 1728
 AGGCTGGTCT TGAACCTCTG ACCTCAAGTG ATCCACCTTC CTTGTGCTCC CAAAGTGTG 1788
 AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCTTTT TTTTCTAAT AGGAGACTCC 1848
 TGTACCTTTC TTCGTTTAC CTATGTGTCG TGCTGCTTA CATTTCCTTC TCCCCTCAGG 1908
 CTTTTTTTGG GTGGTCTCC AACCTCCAAT ACCCAGGCT GGCCTCTTCA GAGTACCCCC 1968
 CATTCCACTT TCCCTGCCTC CTCTCTTAAA TAGCTGACAA TCAAATTCAT GCTATGGTGT 2028
 GAAAGACTAC CTTTGACTTG GTATTATAAG CAAGTGTTAT ATATGTATTT GAAAACAGAG 2088
 TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAATTTT AGGAACTGTG AGAGGGGGAC 2148
 AAGGTGAAGC TTTCTGGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC 2208
 TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAATTGAG TGAAGGAATC CTGGGTAGAG 2268
 ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCCTTC 2328
 TGGCTGATTT TTGTAGAGAC GGGGTTTTGC CATGTTACCC AGGCTGGTCT CAAACTCCTG 2388
 GGCTCAAGCG ATCTCTCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC 2448
 TGCGCCTGGC TTCCTCTTCC TCTTGAGAAA TATTCTTTTC ATACAGCAAG TATGGGACAG 2508
 CAGTGTCCCA GGTAAAGGAC ATAAATGTTA CAAGTGTCTG GTCCCTTCTG AGGGAGGCTG 2568
 GTGCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTT ACTCCCTGAA 2628
 CCCAGCCTGA CAAATCACAG TGAGAATGTT CACCTTATAG GCTTGCTGTG GGGCTCAGGT 2688
 TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTCAATCCA GGGCCTGTGT 2748
 CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CAGAGCACT AGAAGGACGA ATCTGCCTAC 2808
 TGCCCATGAA CGGGGCCCTC AAGCGTCTCT GGATCTCCTT CTCCCTCCTG TCCTGTCTCT 2868
 GCCCCTCAGG ACTGCTGGAA AATAAATCCT TTAATAAGT AAAAAAAAAA AAAAA 2923

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Arg Leu Gln Thr Ala Leu Val Leu Val Leu Ala
 -24 -20 -15 -10
 Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
 -5 1 5
 Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
 10 15 20
 Val Lys His Phe Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
 25 30 35 40
 Val Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
 45 50 55
 Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
 60 65

C-CHEMOKINES
LYMPHOTACTIN

(SCM-1)

D63789 D63790

CX3C-chemokines
Fractalkine/neurotactin

U91835 U84487

LOCUS HSU83171 2923 bp mRNA
 DEFINITION Human macrophage-derived chemokine precursor (MDC) mRNA,
 complete cds.
 ACCESSION U83171
 NID g1931580
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2923)
 AUTHORS Godiska,R., Chantry,D., Raport,C.J., Sozzani,S., Allavena,P.,
 Leviten,D., Mantovani,A. and Gray,P.W.
 TITLE Human macrophage-derived chemokine (MDC), a novel
 chemoattractant for monocytes, monocyte-derived dendritic cells, and natural
 killer cells
 JOURNAL J. Exp. Med. 185 (9), 1595-1604 (1997)
 MEDLINE 97296313
 REFERENCE 2 (bases 1 to 2923)
 AUTHORS Godiska,R. and Gray,P.W.
 TITLE Direct Submission
 JOURNAL Submitted (23-DEC-1996) ICOS Corporation, 22021 20th Avenue SE,
 Bothell, WA 98021, USA
 FEATURES
 source Location/Qualifiers
 1..2923
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="16"
 gene 20..301
 /gene="MDC"
 sig_peptide 20..91
 /gene="MDC"
 CDS 20..301
 /gene="MDC"
 /function="chemotactic for dendritic cells and natural
 killer cells"
 /codon_start=1
 /product="macrophage-derived chemokine precursor"
 /db_xref="PID:g1931581"
 /translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR
 LPLRVVKHFWYTSQSCPRPGVLLTFRDKEICADPRVPWVKMILNKLQ"
 mat_peptide 92..298
 /gene="MDC"
 /product="macrophage-derived chemokine"
 repeat_region complement(1194..1805)
 /rpt_family="ALU"
 repeat_region complement(2335..2443)
 /rpt_family="ALU"
 BASE COUNT 605 a 861 c 669 g 788 t
 ORIGIN
 1 gagacataca ggacagagca tggctgcct acagactgca ctcctggttg tctcgtcct
 61 ccttgccttg gcgcttcaag caactgaggc aggcccttac ggcgccaaca tggagacag
 121 cgtctgctgc cgtgattacg tccgttaccg tctgcccctg cgcgtggtga aacacttcta
 181 ctggacctca gactcctgcc cgaggcctgg cgtggtggtg ctaaccttca gggataagga
 241 gatctgtgcc gatcccagag tgccctgggt gaagatgatt ctcaataagc tgagccaatg
 301 aagagcctac tctgatgacc gtggccttgg ctcctccagg aaggctcagg agccctacct
 361 ccctgccatt atagctgtc cccgccagaa gcctgtgtcca actctctgca ttccctgatc
 421 tccatccctg tggctgtcac ccttggtcac ctccgtgctg tcaactgcat tcccccttg
 481 accctcttaa cccatcctct gcctccctcc ctgcagtcag aggtcctgt tccatcagc
 541 gattccccctg cttaaaccct tccatgactc cccactgccc taagctgagg tcagtctccc
 601 aagcctggca tgtggccctc tggatctggg ttccatctct gtctccagcc tgcccacttc
 661 ccttcatgaa tgttgggttc tagctccctg ttctccaaac ccatactaca catcccactt
 721 ctgggtcttt gcctgggatg ttgctgacac tcagaaaagtc ccaccactg cacatgtgta
 781 gccccaccag ccctccaagg cattgctcgc ccaagcagct ggtaattcca tttcatgtat
 841 tagatgtccc ctggccctct gtccctctt aataacccta gtcacagtct ccgcagattc

```

901 ttgggatttg ggggttttct cccccacctc tccactagtt ggaccaaggt ttctagctaa
961 gttactctag tctccaagcc tctagcatag agcactgcag acaggccctg gctcagaatc
1021 agagcccaga aagtggctgc agacaaaatc aataaaacta atgtccctcc cctctccctg
1081 ccaaaaggca gttacatata aatacagaga ctcaagggtca ctagaaatgg gccagctggg
1141 tcaatgtgaa gcccacaaatt tgcccagatt cacttttctt cccccactcc cttttttttt
1201 tttttttttt tgagatggag tttcgtctct gtccccacg ctggagtgca atgggtgtgt
1261 cttggcttat tgaagcctct gcctcctggg ttcaagtgat tctcttgect cagcctcctg
1321 agtagctggg attacaggtt cctgctacca cgccagctca atttttgtat ttttagtaga
1381 gacgaggctt caccatgttg gccaggctgg tctcgaactc ctgtccctcag gtaatccgcc
1441 cactcagacc tcccaaagtg ctgggattac aggcgtgagc cacagtgcct ggccctcttc
1501 ctctccccac tgcccccccc aacttttttt ttttttttat ggcagggtct cactctgtcg
1561 cccaggtggg agtgacgtgg cgtgatctcg gctcactaca acctcgacct cctgggttca
1621 agtgattctc ccaccccagc ctcccaagta gctgggatta cagggtgtgtg ccactacggc
1681 tggctaattt ttgtattttt agtagagaca ggtttcacca tattggccag gctggctctg
1741 aactcctgac ctcaagtgat ccacctctct tgtgtctcca aagtgtctgag attacaggcg
1801 tgagctatca caccagcctt cccctttttt ttcttaatag gagactcctg tacctttctt
1861 cgtttttacct atgtgtcgtg tctgcttaca ttctctctc ccctcaggct ttttttgggt
1921 ggtcctccaa cctccaatac ccaggcctgg cctcttcaga gtacccccca ttccactttc
1981 cctgcctcct tccttaaata gctgacaatc aaattcatgc tatgggtgtg aagactacct
2041 ttgacttggt attataagct ggagttatat atgtatttga aaacagagta aatacttaag
2101 aggccaaata gatgaatgga agaatttttag gaactgtgag agggggacaa ggtgaagctt
2161 tcctggccct gggaggaagc tggctgtggt agcgtagcgc tctctctctc tgtctgtggc
2221 aggagccaaa gagttaggtg taattgagtg aaggaatcct gggtagagac cattctcagg
2281 tggttggggc aggttaaaga ctgggagttg ggtctatcta tgcttttctg gctgattttt
2341 gtagagacgg ggttttgcca tgttaccag gctggtctca aactcctggg ctcaagcgat
2401 cctcctggct cagcctccca aagtgtctgg attacaggcg tgaatcactg cgcttggtt
2461 cctcttcttc ttgagaaata ttcttttcat acagcaagta tgggacagca gtgtcccagg
2521 taaaggacat aaatgtttaca agtgctctgt cctttctgag ggaggctggg gccgctctgc
2581 aggggtattt aacctgtgga attggaggag gccatttcac tccctgaacc cagcctgaca
2641 aatcacagtg agaattgttca ctttataggc ttgctgtggg gctcagggtt aaagtgtggg
2701 gagtgcact gcctagcat ccagctcagt gtcattccagg gcctgtgtcc ctcccgaacc
2761 caggggtcaac ctgcctgcca caggcactag aaggacgaat ctgcctactg ccatgaacg
2821 gggccctcaa gcgtcctggg atctccttct cctcctgtc ctgtccttgc ccctcaggac
2881 tgctggaaaa taaatccttt aaaatagtaa aaaaaaaaaa aaa

```

```

//
LOCUS      HSU83239      932 bp      mRNA      PRI      02-MAY-1997
DEFINITION Human CC chemokine STCP-1 mRNA, complete cds.
ACCESSION  U83239
NID        g2062424
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 932)
AUTHORS    Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
            Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
TITLE      Molecular cloning and functional characterization of a novel CC
            chemokine STCP-1 which specifically acts on activated T
            lymphocytes
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 932)
AUTHORS    Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
            Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
TITLE      Direct Submission
JOURNAL    Submitted (26-DEC-1996) Research Computing, Amgen Institute,
            620
            University Ave, Suite 706, Toronto, ON M5G 2C1, Canada
FEATURES   Location/Qualifiers
            source          1..932
                        /organism="Homo sapiens"
                        /note="Amgen EST program"
                        /db_xref="taxon:9606"
            CDS             15..296
                        /codon_start=1
                        /product="CC chemokine STCP-1"
                        /db_xref="PID:g2062425"

/translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR

```

```

LPLRVVVKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLQSQ"
BASE COUNT      166 a      330 c      201 g      235 t
ORIGIN
1  atacaggaca gagcatggct cgcctacaga ctgcactcct ggttgctctc gtccctcttg
61  ctgtggcgct tcaagcaact gaggcaggcc cctacggcgc caacatggaa gacagcgtct
121 gctgccgtga ttacgtccgt taccgtctgc cctgcgcgt ggtgaaacac ttctactgga
181 cctcagactc ctgcccgagg cctggcgtgg tgttgctaac cttcagggat aaggagatct
241 gtgccgatcc cagagtgcgc tgggtgaaga tgattctcaa taagctgagc caatgaagag
301 cctactctga tgaccgtggc cttggctcct ccaggaaggg tcaggagccc tacctccctg
361 ccattatagc tgctcccccgc cagaagcctg tgccaactct ctgcattccc tgatctccat
421 ccctgtggct gtcacccttg gtcacctccg tgctgtcact gccatctccc ccctgacccc
481 tctaaccatc cctctgcctc cctccctgca gtcagagggt cctgttcccc tcagcgattc
541 cctgtcttaa acccttccat gactccccac tgccctaagc tgaggtcagt ctcccaagcc
601 tggcatgtgg ccctctggat ctgggttcca tctctgtctc cagcctgccc acttcccttc
661 atgaatgttg ggttctagct cctgtttctc caaaccata ctacacatcc cacttctggg
721 tctttgcctg ggatgttgct gacactcaga aagtcccacc acctgcacat gtgtagcccc
781 accagccctc caaggcattg ctgcgccaaag cagctggtaa ttccatttca tgtattagat
841 gtcccttggc cctctgtccc ctcttaataa ccttagtcac agtctccgca gattcttggg
901 atttgggggt tttctcccc acccttccac ta

//
LOCUS      HSMCP1      725 bp      RNA      PRI      03-APR-1995
DEFINITION H.sapiens mRNA for monocyte chemoattractant protein 1 (MCP-1).
ACCESSION  X14768
NID        g34513
KEYWORDS   monocyte chemoattractant protein 1.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 725)
AUTHORS    Yoshimura,T., Yuhki,N., Moore,S.K., Appella,E., Lerman,M.I. and
            Leonard,E.J.
TITLE      Human monocyte chemoattractant protein-1 (MCP-1). Full-length
cDNA
            cloning, expression in mitogen-stimulated blood mononuclear
            leukocytes, and sequence similarity to mouse competence gene JE
JOURNAL    FEBS Lett. 244 (2), 487-493 (1989)
MEDLINE    89153605
COMMENT    ZAPII.
FEATURES   Location/Qualifiers
            source          1..725
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="glioma cells"
                        /cell_line="U105MG"
                        /clone_lib="lambda"
            sig_peptide     54..122
                        /note="signal peptide (AA -23 to -1)"
            CDS              54..353
                        /codon_start=1
                        /product="monocyte chemoattractant preprotein"
                        /db_xref="PID:g34514"
                        /db_xref="SWISS-PROT:P13500"
            /translation="MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKIS
VQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT"
            mat_peptide     123..350
                        /note="MCP-1 (AA 1 - 76)"
            misc_feature     162..170
                        /note="pot. N-linked glycosylation site"
            misc_feature     707..712
                        /note="pot. polyA signal"
            polyA_site       725
                        /note="polyA site"
BASE COUNT      208 a      171 c      126 g      220 t
ORIGIN
1  ctaaccaga aacatccaat tctcaaactg aagctcgcac tctcgctccc agcatgaaag
61  tctctgccgc cctctgtgct ctgctgtctc tagcagccac cttcattccc caagggtcgc
121 ctcagccaga tgcaatcaat gcccagtcac cctgctgtta taacttcacc aataggaaga
181 tctcagtgcg gaggtctcgc agctatagaa gaatcaccag cagcaagtgt cccaaagaag

```

```

241 ctgtgatctt caagaccatt gtggccaagg agatctgtgc tgacccaag cagaagtggg
301 ttcaggattc catggaccac ctggacaagc aaacccaaac tccgaagact tgaacactca
361 ctccacaacc caagaatctg cagctaactt atttcccctt agctttcccc agacaccctg
421 ttttatttta ttataatgaa ttttgtttgt tgatgtgaaa cattatgcct taagtaatgt
481 taattcttat ttaagttatt gatgttttaa gtttatcttt catggtacta gtgtttttta
541 gatacagaga cttggggaaa ttgcttttcc tcttgaacca cagttctacc cctgggatgt
601 tttgagggtc tttgcaagaa tcattaatac aaagaatttt tttaacatt ccaatgcatt
661 gctaaaatat tattgtggaa atgaatatatt tgtaactatt acaccaaata aatatatatt
721 tgtac

```

```

//
LOCUS      HSMCP2      2991 bp      DNA      PRI      20-MAR-1997
DEFINITION H.sapiens MCP-2 gene.
ACCESSION  X99886
NID        g1905800
KEYWORDS   MCP-2 gene; monocyte chemotactic protein 2; SCYA10 gene.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2991)
AUTHORS    Van Coillie,E., Fiten,P., Nomiya,H., Sakaki,Y., Miura,R.,
            Yoshie,O., Van Damme,J. and Opdenakker,G.
TITLE      The human MCP-2 gene (SCYA8): cloning, sequence analysis,
tissue     expression, and assignment to the CC chemokine gene contig on
            chromosome 17q11.2
JOURNAL     Genomics 40 (2), 323-331 (1997)
MEDLINE     97237052
REFERENCE  2 (bases 1 to 2991)
AUTHORS    Opdenakker,G.M.M.
TITLE      Direct Submission
JOURNAL     Submitted (07-AUG-1996) G.M.M. Opdenakker, Rega Institute for
            Medical Research, Minderbroedersstraat 10, B 3000 Leuven,

```

```

BELGIUM
FEATURES
    source          Location/Qualifiers
                    1..2991
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /chromosome="17"
                    /map="q11.2"
    repeat_region   209..219
                    /note="DR-A"
                    /rpt_type=DIRECT
    repeat_region   240..248
                    /note="DR-B"
                    /rpt_type=DIRECT
    CAAT_signal     296..300
    repeat_region   310..318
                    /note="IR-A"
                    /rpt_type=INVERTED
    repeat_region   406..415
                    /note="DR-B"
                    /rpt_type=DIRECT
    repeat_region   407..416
                    /note="IR-B"
                    /rpt_type=INVERTED
    repeat_region   425..435
                    /note="DR-A"
                    /rpt_type=DIRECT
    repeat_region   429..437
                    /note="IR-B"
                    /rpt_type=INVERTED
    repeat_region   455..465
                    /note="IR-C"
                    /rpt_type=INVERTED
    TATA_signal     467..472
    repeat_region   492..502
                    /note="IR-C"
                    /rpt_type=INVERTED
    repeat_region   492..500
                    /note="IR-A"

```

```

    exon                /rpt_type=INVERTED
                        534..639
                        /gene="MCP-2 (SCYA10)"
                        /number=1
    gene                534..1969
                        /gene="MCP-2 (SCYA10)"
    CDS                 join(534..639,1331..1448,1864..1969)
                        /gene="MCP-2 (SCYA10)"
                        /codon_start=1
                        /product="monocyte chemotactic protein-2"
                        /db_xref="PID:e279930"
                        /db_xref="PID:g1905801"

/translation="MLKLTPLP SKMKVSAALLCLLLMAATFSPQGLAQPDVSIPITC
CFNVINRKIPQIRLESYTRITNIQCPKEAVIFKTQRGKEVCADPKERWVRDSMKHLDQ
IFQNLKP"
    intron              640..1330
                        /gene="MCP-2 (SCYA10)"
                        /number=1
    exon                1331..1448
                        /gene="MCP-2 (SCYA10)"
                        /number=2
    intron              1449..1863
                        /gene="MCP-2 (SCYA10)"
                        /number=2
    exon                1864..1969
                        /gene="MCP-2 (SCYA10)"
                        /number=3
BASE COUNT            799 a      709 c      632 g      851 t
ORIGIN

```

```

1 agattctggg gcattaagac ttagttccag gattctgtca ttctgccaac gttctgtggc
61 tgggggttcta aaggagcttg cctggccttag aactgcaagt gactctagtg tgatggagag
121 caccagcaaa gccttagggc ccacccttg cctcctgtta cccacagagg ggtaagcctt
181 ggctctcttc cactatgacg tcagcttcca ttcttcttt cttatagaca attttccatt
241 tcaaggaaat cagagccctt aatagttcag tgaggctact ttgctgagca caatcccata
301 cccttcagcc tctgtctccac agagcctaag caaagatag aaactcaca cttccttggt
361 ttgttatctg gaaattatcc caggatctgg tgcttactca gcatattcaa ggaaggtctt
421 acttcattct tccttgattg tgaccatgcc caggctctct gctccctata aaaggcaggc
481 agagccaccg aggagcagag aggttgagaa caaccagaa acccttacct ctcagtctga
541 agctcacacc cttgccctcc aagatgaagg ttctgcagc gcttctgtgc ctgctgtctc
601 tggcagccac ttccagccct cagggacttg ctcagccagg taagacctct ccctttttaa
661 ggggagacca aaagaggaa taagaagagc cattatgtca cagctcatta ggaacaaaac
721 cagaactaaa ggctcaggtc actgaggctg gttcccttga tcttctctga cccagttttt
781 gggaggagac agtggagccg ctacagcaac aaccctcca ttgtttgggg aaataatcca
841 gaacgaagaa ctgttttcca ctgtgggtgt aaaggacatt tcaggccgta gtggagaggg
901 agaaactatt gcctgaagct tcaaattttg gttatggttc agtgtacctt ccagaacagt
961 ggctgtgtaa agaggatgag gaccagagg aatctcagcg tatggcatag gctaactcta
1021 aagcccatga ggatgaaaga ctgggaagca aggtattgga acttatgttc ccagtgtcag
1081 aagtttttgg ttagtagaca aggactagct tgttactcaa aatgtttcca aaccagtc
1141 acaatgacgg gccgcagagt tcaatagagg aaagagactc acaggcaaca ttttatctct
1201 gggatctgga ctaagacact gaacttggga tgggtgactt ttggtcttct ccttcttctt
1261 cttcttttcc ttacaaatgc acacttacgg tgggtcctaa atgtctcatt ctttgcaaaa
1321 tttctttcag attcagtttc cattccaatc acctgctgct ttaacgtgat caataggaaa
1381 attcctatcc agaggctgga gagctacaca agaatcacca acatccaatg tcccaaggaa
1441 gctgtgatgt gaggtagacg tgccctggcac cccattcaa aagtcttgat ggacaacata
1501 gagaagtcaa gattcatgtc catatgagtc ggatgcatat aacttctatc caaagggg
1561 cttaccacca tagagaaact cagtcctgta gaaggagtc ataactgtct taggattccc
1621 ttctaggggc ttgtgaaac taaccataa tctgtagcca ggaccctgga gggtttacc
1681 tggacagcaa gagcagagct tccttctgga gcttcttct cccacttctt ccttccctcc
1741 tctcccggtt ccgggtcctt cacctaagga ccaagggtct atcagtccta gggaccaatg
1801 gcccacagtc ctgtgcagga tcttcaaagt cttccatcta attgtgcccc ctctccccca
1861 cagcttcaag acccaacggg gcaaggaggt ctgtgctgac cccaaggaga gatgggtcag
1921 ggattccatg aagcatctgg accaaatatt tcaaaaatctg aagccatgag ccttcataca
1981 tggactgaga gtcagagctt gaagaaaagc ttattttatt tccccaacct ccccagggtg
2041 cagtgtgaca ttattttatt ataacatcca caaagagatt atttttaaat aatttaaagc
2101 ataataattt ttaaaaagta ttaattata ttttaagttg tgatgttttt actctatctg
2161 tcatacatcc tagtgaatgt aaaaatgcaa atcctgggtg tgtgtttttt gttttgtgtt
2221 tcctgtgagc tcaactaagt tcacggcaaa atgtcattgt tctccctctt acctgtctgt
2281 agtgtgtgtg ggtcctccca tggatcatca aggtgaaaca ctttggtatt ctttggaat
2341 cagtgtcctt gtaagtcaaa tgtgtgcttt gtactgctgt tgttgaaatt gatgttactg

```

```

2401 tatataacta tggaattttg aaaaaaatt tcaaaaagaa aaaaatatat ataatttaac
2461 actacttagt cttattcttc ttggggtaac atttagctgg gagtgagttt tgggcatcat
2521 ggggtgacagt ttgggcatgg acgggccatt tttcaagaat gtcttctggc tacgctggac
2581 tcaaccaagg ttctcagaga acttgggtggg accaggccag gatgttccag ctctctgact
2641 ctagtcccta acttcagcag ccctgattcg ctagcctctc ttgtttctct tgtttatata
2701 ttatccagcc taaggatatt tgttatagct gcccataaag actaagataa tctccatcac
2761 tctaccccca accccaatcc caagaacttg caagcatcca tttaaaggcg tggaacctct
2821 tctttttgac agccttttaa ggtcaagatt cccctgtact tagtgagctt agctgaatct
2881 tcttacaac atgtgacccg ccatattgag ccatacatc cgagcttatt atttttccag
2941 cttattggga aaacacgtct aaggcaaaaca aatttattgt actgttgaac c

```

//LOCUS HSY16645 1368 bp mRNA PRI 25-SEP-1998

DEFINITION Homo sapiens mRNA for monocyte chemotactic protein-2.

ACCESSION Y16645

NID g2916795

KEYWORDS MCP-2 gene; monocyte chemotactic protein 2.

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1368)

AUTHORS Van Coillie, E.

TITLE Functional comparison of two human monocyte chemotactic
protein-2

isoforms, role of the amino-terminal pyroglutamic acid and
processing by CD26/dipeptidyl peptidase IV

JOURNAL Biochemistry 37, 12672-12680 (1998)

REFERENCE 2 (bases 1 to 1368)

AUTHORS Van Coillie, E.

TITLE Direct Submission

JOURNAL Submitted (23-FEB-1998) E. Van Coillie, Rega Institute for
Medical

Research, Minderbroedersstraat 10, 3000 Leuven, BELGIUM

COMMENT Related sequences: X99886, Y10802.

FEATURES Location/Qualifiers

source

1..1368

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="17"

/tissue_type="testis"

/clone_lib="Clontech"

/clone="HL1142q"

/map="q11.2"

gene

473..772

/gene="MCP-2"

sig_peptide

473..541

/gene="MCP-2"

CDS

473..772

/gene="MCP-2"

/codon_start=1

/product="monocyte chemotactic protein-2"

/db_xref="PID:e1253690"

/db_xref="PID:g2916796"

/translation="MKVSAALLCLLLMAATFSPQGLAQPDVSIPITCCFNVINRKIP

IQRLESYTRITNIQCPKEAVIFKTKRGKEVCADPKERWVRDSMKHLDQIFQNLKP"

mat_peptide 542..769

/gene="MCP-2"

variation

677

/gene="MCP-2"

/note="polymorphism, Lys -> Gln"

/replace="c"

BASE COUNT 457 a 292 c 243 g 376 t

ORIGIN

```

1 atccattgtg ctctaaagt atggagagca ccagcaaagc cttaggggccc atccctggcc
61 tcctgttacc cacagagggg tagggccttg gctctcttc actatgacgt cagcttccat
121 tcttcttttc ttatagacaa ttttcattt caaggaaatc agagccctta atagttcagt
181 gaggtcactt tgctgagcac aatcccatac ctttcagcct ctgctccaca gaggcctaagc
241 aaaagataga aactcacaac ttccttgttt tgttatctgg aaattatccc aggatctggt
301 gcttactcag catattcaag gaaggtctta cttcattctt ccttgattgt gaccatgccc
361 aggctctctg ctccctataa aaggcaggca gagccaccga ggagcagaga gggttgagaac

```

```

421 aaccagaaa ccttcacctc tcatgctgaa gctcacaccc ttgccctcca agatgaaggt
481 ttctgcagcg cttctgtgcc tgctgctcat ggcagccact ttcagccctc agggacttgc
541 tcagccagat tcagtttcca ttccaatcac ctgctgcttt aacgtgatca ataggaaaat
601 tcctatccag aggctggaga gctacacaag aatcaccaac atccaatgct ccaaggaagc
661 tgtgatcttc aagacaaaac ggggcaagga ggtctgtgct gaccccaagg agagatgggt
721 cagggattcc atgaagcatc tggacaaaat atttcaaaat ctgaagccat gagccttcat
781 acatggactg agagtcagag cttgaagaaa agcttattta tttcccccag cctccccag
841 gtgcagtgtg acattatttt attataacat ccacaaagag attattttta aataatttaa
901 agcataatat ttcttaaaaa gtatttaatt atattttaagt tggatgatgtt ttaactctat
961 ctgtcataca tcctagttaa tgtaaaatgc aaaatcctgg tgatgtgttt tttgttttg
1021 ttttctgtg agctcaacta agttcacggc aaaatgtcat tgttctccct cctacctgct
1081 tgtagtgttg tgggtctctc ccattggatca tcaaggtgaa acactttggt attctttggc
1141 aatcagtgct cctgtaagtc aaatgtgtgc tttgtactgc tgttgttgaa attgatgtta
1201 ctgtatataa ctatggaatt ttgaaaaaaa atttcaaaaa gaaaaaataa tatataattt
1261 aaaactaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1321 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

```

//LOCUS HSMCP3A 1085 bp DNA PRI 25-JUL-1994

DEFINITION H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.

ACCESSION X72308 S57464

NID g313707

KEYWORDS monocyte chemotactic protein 3.

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1085)

AUTHORS Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.

TITLE Human monocyte chemotactic protein-3 (MCP-3): molecular cloning

of the cDNA and comparison with other chemokines

JOURNAL Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)

MEDLINE 93213290

REFERENCE 2 (bases 1 to 1085)

AUTHORS Opdenakker,G.M.

TITLE Direct Submission

JOURNAL Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,

University

of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM

REFERENCE 3 (bases 1 to 1085)

AUTHORS Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
Speleman,F., Laureys,G. and Van Damme,J.

TITLE The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
assignment to the C-C chemokine gene cluster on chromosome
17q11.2-q12

JOURNAL Genomics 21 (2), 403-408 (1994)

MEDLINE 94375065

FEATURES Location/Qualifiers

source

1..1085

/organism="Homo sapiens"

/db_xref="taxon:9606"

gene

299..810

/gene="MCP-3"

CDS

299..628

/gene="MCP-3"

/codon_start=1

/product="monocyte chemotactic protein-3"

/db_xref="PID:g313708"

/db_xref="SWISS-PROT:P80098"

/translation="MWKPMPSPSNMKASALLCLLLTAAAFSPQGLAQPVGINTSTTC

CYRFINKKIPKQRLSYRRTTSSHC PREAVIFKTKLDKEICADPTQKWVQDFMKHLDK

sig_peptide

KTQTPKL"

299..397

/gene="MCP-3"

mat_peptide

398..625

/gene="MCP-3"

/product="monocyte chemotactic protein-3"

polyA_signal

806..810

/gene="MCP-3"

BASE COUNT 314 a 214 c 229 g 328 t

ORIGIN

```

1 gggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61 ctgggggttag tatagcttag ttaaactttc gtttattgct aaagggttaat cactgctggt
121 tcccggtggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
181 gtcccttttg atcgtggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccagggt gcttgctcag ccagttggga ttaatacttc
421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481 cagaaggacc accagtagcc actgtccccc ggaagctgta atcttcaaga ccaaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcactgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaa caagccatga
661 cttgagaaac aaataatttg tataccctgt cctttctcag agtggttctg agattatgtt
721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatggtt tttcttagta
781 gattttaaaa gttattaata ttttaattta atcttccatg gattttggtg ggttttgaac
841 ataaagcctt ggatgtatat gtcatctcag tgctgtaaaa actgtgggat gctcctccct
901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtggcaa gatttgctt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021 atatgtaga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

```

```

//
LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION  X72308 S57464
NID        g313707
KEYWORDS   monocyte chemotactic protein 3.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE      Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of         the cDNA and comparison with other chemokines
JOURNAL    Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
MEDLINE    93213290
REFERENCE  2 (bases 1 to 1085)
AUTHORS    Opdenakker,G.M.
TITLE      Direct Submission
JOURNAL    Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE  3 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
            Speleman,F., Laureys,G. and Van Damme,J.
TITLE      The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
            assignment to the C-C chemokine gene cluster on chromosome
            17q11.2-q12
JOURNAL    Genomics 21 (2), 403-408 (1994)
MEDLINE    94375065
FEATURES   Location/Qualifiers
            source          1..1085
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            gene            299..810
                        /gene="MCP-3"
            CDS              299..628
                        /gene="MCP-3"
                        /codon_start=1
                        /product="monocyte chemotactic protein-3"
                        /db_xref="PID:g313708"
                        /db_xref="SWISS-PROT:P80098"

/translation="MWKPMSPSPNMKASALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWVQDFMKHLDK
            KTQTPKL"
            sig_peptide     299..397
                        /gene="MCP-3"
            mat_peptide      398..625

```



```

/ gene="MCP-3"
/ product="monocyte chemotactic protein-3"
polyA_signal 806..810
/ gene="MCP-3"
BASE COUNT 314 a 214 c 229 g 328 t
ORIGIN
1 gggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61 ctgggggttag tatagcttag ttaaactttc gtttattgct aaaggttaat cactgctggt
121 tcccgtgggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg ctgatgctt
181 gtcccttttg atcgtgggtg tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccagggt gcttgctcag ccagttggga ttaatacttc
421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481 cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661 cttgagaaac aaataatttg tataccctgt cctttctcag agtgggtctg agattatttt
721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatggtt tttcttagta
781 gattttaaaa gttattaata ttttaattta atcttccatg gattttgggt gggtttgaac
841 ataaagcctt ggatgtatat gtcattctcag tgctgtaaaa actgtgggat gctcctccct
901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcгаа gatttgcctt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

// LOCUS HSU46767 825 bp mRNA PRI 16-DEC-1996
DEFINITION Human monocyte chemoattractant protein-4 precursor (MCP-4)
mRNA, complete cds.
ACCESSION U46767
NID gl732122
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 825)
AUTHORS Garcia-Zepeda, E.A., Combadiere, C.C., Rothenberg, M.E.,
Sarafi, M.N., Lavigne, F., Hamid, Q., Murphy, P. and Luster, A.D.
TITLE Human monocyte chemoattractant Protein (MCP)-4: A novel CC
chemokine with activities on monocytes, eosinophils, and
basophils
induced in allergic and non-allergic inflammation that signals
through the CC chemokine receptors CCR-2 and 3
J. Immunol. 158 (1996) In press
REFERENCE 2 (bases 1 to 825)
AUTHORS Garcia-Zepeda, E.A. and Luster, A.D.
TITLE Direct Submission
JOURNAL Submitted (22-JAN-1996) Eduardo A. Garcia-Zepeda, Infectious
Disease Unit, Massachusetts General Hospital, 149 13th St.,
Charlestown, MA 02129, USA
FEATURES
Location/Qualifiers
source 1..825
/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="heart"
/clone_lib="EG3.16"
sig_peptide 34..102
/ gene="MCP-4"
CDS 34..330
/ gene="MCP-4"
/ note="small cytokine; intercrine/chemokine; C-C
signature; chemoattractant for monocytes, eosinophils"
/ codon_start=1
precursor" /product="monocyte chemoattractant protein-4
/db_xref="PID:gl732123"
/translation="MKVSAVLLCLLLMTAAFPQGLAQPDALNVPSTCCFTFSSKKIS

```

LQRLKSYVITTSRCPQKAVIFRTKLGKEICADPKEKWVQNYMKHLGRKAHTLKT"

gene 34..330
/gene="MCP-4"
mat_peptide 103..327
/gene="MCP-4"

BASE COUNT 221 a 175 c 185 g 244 t
ORIGIN

```

1 acattgtgaa atctccaact cttaaccttc aacatgaaag tctctgcagt gcttctgtgc
61 ctgctgctca tgacagcagc ttccaacccc cagggacttg ctcagccaga tgcactcaac
121 gtcccatcta cttgtgcttt cacatttagc agtaagaaga tctccttgca gaggctgaag
181 agctatgtga tcaccaccag caggtgtccc cagaaggctg tcactcttcag aaccaaactg
241 ggcaaggaga tctgtgctga cccaaaggag aagtgggtcc agaattatat gaaacacctg
301 ggccggaaag ctcacaccct gaagacttga actctgctac ccctactgaa atcaagctgg
361 agtacgtgaa atgacttttc cattctcctc tggcctcctc ttctatgctt tgggaatactt
421 ctaccataat tttcaaatag gatgcattcg gttttgtgat tcaaaatgta ctatgtgtta
481 agtaatatgt gctattatgt gacttgttgc tggtttggag tttatttgag tattgctgat
541 cttttctaaa gcaaggcctt gagcaagtag gttgctgtct ctaagccccc ttccttcca
601 ctatgagctg ctggcagtg gttgtattcg gttcccaggg gttgagagca tgcctgtggg
661 agtcatggac atgaagggat gctgcaatgt aggaaggaga gctctttgtg aatgtgaggt
721 tgttgctaaa ttattgttta ttgtggaaag atgaatgcaa tagtaggact gctgacattt
781 tgcagaaaat acattttatt taaaatctcc taaaaaaaaa aaaaaa

```

//LOCUS HSAMAC1 803 bp RNA PRI 10-AUG-1997
DEFINITION Homo sapiens mRNA for alternative activated macrophage specific
CC

chemokine 1.
ACCESSION Y13710
NID g2326515
KEYWORDS AMAC-1 gene; CC-chemokine 1.
SOURCE human. ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae;

Homo.

REFERENCE 1 (bases 1 to 803)

AUTHORS Politz,O.

TITLE Direct Submission

JOURNAL Submitted (10-JUN-1997) Politz O., Dermatology, Free University
Benjamin Franklin Medical Center, Hindenburgdamm 30; 12200

Berlin

GERMANY

REFERENCE 2 (bases 1 to 803)

AUTHORS Kodelja,V., Mueller,C., Politz,O., Hakiy,N., Orfanos,C.E. and
Goerdts,S.

TITLE Cloning of alternative activated macrophage associated CC
chemokine

1 (AMAC-1)

JOURNAL Unpublished

FEATURES Location/Qualifiers

source 1..803
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="macrophage"
sig_peptide 71..133
/gene="amac-1"
CDS 71..340
/gene="amac-1"
/note="macrophage specific"
/codon_start=1
/product="CC-chemokine 1"
/db_xref="PID:e321838"
/db_xref="PID:g2326516"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKLCLVYTSWQIPQKFI
VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"

gene 71..340
/gene="amac-1"
mat_peptide 134..337
/gene="amac-1"

BASE COUNT 214 a 213 c 160 g 216 t
ORIGIN

```

1  ccggcaccgag aggagttgtg agtttccaag cccagctca ctctgaccac ttctctgcct
61  gcccagcatc atgaagggcc ttgcagctgc cctccttgtc ctctgtctgca ccatggccct
121 ctgctcctgt gcacaagttg gtaccaacaa agagctctgc tgctctgtct atacctctg
181 gcagattcca caaaagttca tagttgacta ttctgaaacc agccccagc gcccgaagcc
241 aggtgtcatc ctcctaacca agagaggccg gcagatctgt gctgacccca ataagaagt
301 ggtccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg
361 gcccagtgaa cttggtgggc ccaggaggga acaggagcct gagccagggc aatggccctg
421 ccaccctgga ggccacctct tctaagagtc ccatctgcta tgcccagcca cattaactaa
481 ctttaatctt agtttatgca tcatatttca ttttgaaatt gatttctatt gttgagctgc
541 attatgaaat tagtattttc tctgacatct catgacattg tctttatcat cctttcccct
601 ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag
661 cagacattgt gccatatgta tcaaatgaca aatctttatt gaatggtttt gctcagcacc
721 accttttaat atattggcag tacttattat ataaaaggta aaccagcatt ctcactgtga
781 aaaaaaaaaa aaaaaaaaaa aaa

```

```

//
LOCUS      HUMLD78A      3176 bp      DNA                      PRI      17-JAN-1992
DEFINITION Human LD78 alpha gene.
ACCESSION  D90144
NID        g219905
KEYWORDS   LD78; LD78 alpha; cytokine; inducible gene family; secreted
           peptide.
SOURCE     Human blood lymphocyte DNA, clone Lm LD-3.
ORGANISM   Homo sapiens
           Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
           Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (bases 1 to 3176)
AUTHORS    Nakao,M., Nomiya,H. and Shimada,K.
TITLE      Structures of human genes coding for cytokine LD78 and their
           expression
JOURNAL    Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE    90287155
COMMENT    These data kindly submitted in computer readable form by:
Hisayuki

```

```

Nomiya
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.
FEATURES             Location/Qualifiers
     source            1..3176
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
     TATA_signal       1041..1045
     exon              1069..1227
                       /number=1
     prim_transcript   1069..2957
                       /note="LD78 alpha mRNA and introns"
     sig_peptide       1155..1220
                       /note="LD78 alpha signal peptide"
     CDS               join(1155..1227,1916..2030,2451..2541)
                       /codon_start=1
                       /product="LD78 alpha precursor"
                       /db_xref="PID:d1014875"
                       /db_xref="PID:g219906"
/translation="MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSYTSRQIPQ
NFIADYFETSSQCSKPGVIFLTRSRQVCADPSEEWQKYVSDLELSA"
     mat_peptide       join(1218..1227,1916..2030,2451..2538)
                       /partial
                       /note="LD78 alpha mature peptide"
     intron            1228..1915
     exon              1916..2030
                       /partial
                       /number=2
     intron            2031..2450
     exon              2451..2957
                       /number=3

```

```

BASE COUNT      833 a    741 c    752 g    850 t
ORIGIN
1  acccagggac ctatcacaca aatataagaa ctattcattc ttaaggcat gtatttccaa
61  gcctttgtat ttttttccat gcttaggggt ggcaaggaat atatataat ttgtacaaat
121 atatatgtgt atatgtacaa atacatgtat atatagtaca aatatatata tatatttgta
181 caattcttca gactttgtag aattttgtata atgtcgtatc ttgttttttt taaccactga
241 tgttataagc atatttatgc cacttcattc atttttagaga cttaataata aatgatctag
301 tggataatth atcattccct gatggagaaa aatttagctt tgtttattht agagttataa
361 acgatgctgg gtcagggtatc tttatgtttg aagatggctc catatttggg ttgtttccac
421 agaactcttt cctagaaatg ctttttctag gttaatggct acagatattt ctaggcacct
481 gacatattga caccacctc taaagtattt ttatgatcca caactagcgt ttaacacagc
541 gccctagtca ctacatgact aataaataga caaatgactg aaacatgacc tcatgttttc
601 tattctccca gctttcattc agttctttgc ctctgggagg aggaaggggt gtgcagccct
661 ccacagcatc agcccatcaa ccctatccct gtggttatag cagctgagga agcagaattg
721 cagctctgtg ggaaggaatg gggctggaga gttcatgcac agaccagttc ttatgagaag
781 ggactgacta agaatagcct tgggttgaca tataccctc ttcacactca caggagaaac
841 catttcccta tgaaactata acaagtcatt agttgagagc tgagagttag agaattagc
901 aaagatgcta ttcttgata tcttgagcag ctgtgggtac caggggacct gagttgtgca
961 acttagcatg acagcatcac tacgtttaa aatttccctc ctacccccca gattccattt
1021 ccccatccgc cagggtgccc tataaagagg agagctgggt tcagacttca gaaggacacg
1081 ggcagcagac agtggtcagt cctttcttgg ctctgctgac actcgagccc acattccgtc
1141 acctgctcag aatcatgcag gtctccactg ctgcccttgc tgccttcttc tgccacttgg
1201 ctctctgcaa ccagttctct gcatcacgtg agtctgagtt tcgttgtggg tatcaccact
1261 ctctggccat ggtagacca catcaatctt ttcttggggt ctaaaagccc ccaagagaaa
1321 agagaacttc ttaaagggtt gccaaacatc ttggtctttc tctttaagac ttttattttt
1381 atctctagaa ggggtcttag ccccttagtc tccaggtatg agaattctag caggggcagg
1441 ggagttacag tcccttttac agatagaaaa acagggttcg aaacgaatca gttagcaaga
1501 ggcagaatcc agggctgctt acttcccagt ggggtatggt gttcactctc cagctcactc
1561 taggtctccc aggagctctg tcccttggat gtcttatgag agatgtccaa ggcttctctt
1621 ggggtggggg atgacttctt gaaccagaca aaatttccctg aagagaactg agataagaga
1681 acagtcctgt caggtatctg gatcacacag agaaacagag aaccctactat gaagagtcaa
1741 ggagaaagaa ggatacagac agaaacaaag agacatttct cagcaaaaat gcccaaatgc
1801 cttccagtca cttggtctga gcaagcctgc ctctctcaac tgctcggggg tcagaagctg
1861 cctggccttt tcttctgagc tgtgactcgg ctgcttcagg tacacctccc ggcagattcc acagaatttc
1921 gctgacacgc cgaccgcctg ctgcttcagg ctgcttcagg tacacctccc ggcagattcc acagaatttc
1981 atagctgact actttgagac gagcagccag tgctccaagc ccggtgtcat gtaagtgcc
2041 gtcttctctg tcacctctat ggaggtaggg aggggtcaggg ttggggcaga gacaggccag
2101 aaggctatcc tggaaaggcc cagccttcag gacccatctg gggatcacag acgcagggtc
2161 ccgaggtgtg acctgacttg gagctggagt gaggcattgt ttacagagtc aggaagggtc
2221 gccccagccc agaggaaagg gacaggaaga agggagcagc gggacactct gagggccacc
2281 cctactgagt cactgagaga agctctctag acagagatag gcagggggcc cctgaaagag
2341 gagcaagccc tgagctgccc aggacagaga gcagaatggt ggggccatgg tgggccagg
2401 attcccctgc tggattcccc agtgcttaac tcttctctcc ttctccacag cttcctaacc
2461 aagcgaagcc ggcaggtctg tgctgacccc agtgaggagt ggggtccagaa atatgtcagc
2521 gacctggagc tgagtgcctg aggggtccag aagcttcagag gcccagcgac ctcggtgggc
2581 ccagtgggga ggagcaggag cctgagcctt gggaacatgc gtgtgacctc cacagctacc
2641 tcttctatgg actggttgtt gccaaacagc cacactgtgg gactcttctt aacttaaatt
2701 ttaatttatt tatactattt agtttttgta atttattttc gatttcacag tgtgtttgtg
2761 attgtttgct ctgagagttc cctgttcccc tcccccttcc ctacaccgc gtctggtgac
2821 aaccgagtggt ctgtcatcag cctgtgtagg cagtcatggc accaaagcca ccagctgac
2881 aaatgtgtat cggatgcttt tgttcagggc tgtgatcgcc ctggggaaat aataaagatg
2941 ctctttttaa aggtaaacca gtattgagtt tggttttgtt tttctggcaa atcaaaatca
3001 ctggttaaga ggaatcatag gcaaagatta ggaagagggt aaatggaggg aaattgggag
3061 agatggggag ggctaccaca gagttatcca ctttacaacg gagacacagt tctggaacat
3121 tgaactacg aatatgttat aactcaaatc ataactgca tgctctagga gaattc

```

```

//
LOCUS      AF043339      225 bp      mRNA      PRI      23-FEB-1998
DEFINITION Homo sapiens macrophage inflammatory protein 1 alpha (MIP1a)
mRNA,
partial cds.
ACCESSION  AF043339
NID        g2905627
KEYWORDS   .
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 225)
AUTHORS    Jang, J.S. and Kim, B.E.
TITLE      Direct Submission
JOURNAL    Submitted (15-JAN-1998) Protein Engineering, General Institute

```

of
Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
Sosa-gu, Bucheon 422-231, Korea

COMMENT forward primer (5'-tgcgcatcacttgctgctgaca-3')
reverse primer (5'-cttctggaccctcaggcact-3').

FEATURES
source Location/Qualifiers
1..225
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="PHA-treated peripheral blood leukocyte"
gene <1..225
/gene="MIPla"
primer_bind <1..19
/gene="MIPla"
/PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
cycles;
DeltaCycler II from Ericomp"
CDS <1..213
/gene="MIPla"
/function="CC chemokine"
/function="proinflammatory cytokine involved in
inflammation"
/note="8-10 kDa"
/codon_start=1
/product="macrophage inflammatory protein 1 alpha"
/db_xref="PID:g2905628"

/translation--ASLAADTPTACCFSTSRQIPQNFADYFETSSQCSKPGVIFLT
KRSRQVCADPSEEWVQKYVSDLELSA"
primer_bind complement(205..225)
/gene="MIPla"

BASE COUNT 50 a 68 c 62 g 45 t
ORIGIN
1 gcataccttg ctgctgacac gccgaccgcc tgctgcttca gctacacctc ccggcagatt
61 ccacagaatt tcatagctga ctactttgag acgagcagcc agtgctccaa gcccggtgct
121 atcttcctaa ccaagcgaag ccggcaggtc tgtgctgacc ccagtgagga gtgggtccag
181 aaatatgtca gcgacctgga gctgagtgcc tgaggggtcc agaag

//
LOCUS HUMLD78B 3112 bp DNA PRI 17-JAN-1992
DEFINITION Human LD78 beta gene.
ACCESSION D90145
NID g219907
KEYWORDS LD78; LD78 beta; cytokine; inducible gene family; secreted
peptide.
SOURCE Human placenta DNA, clone Lm LD-1.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
Homo.
REFERENCE 1 (bases 1 to 3112)
AUTHORS Nakao,M., Nomiyama,H. and Shimada,K.
TITLE Structures of human genes coding for cytokine LD78 and their
expression
JOURNAL Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE 90287155
COMMENT These data kindly submitted in computer readable form by:
Hisayuki
Nomiyama
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

FEATURES
source Location/Qualifiers
1..3112
/organism="Homo sapiens"
/db_xref="taxon:9606"
repeat_unit 498..797
/note="Alu repeat"

```

TATA_signal      1078..1082
prim_transcript  1106..2995
                  /note="LD78 beta mRNA and introns"
exon              1106..1267
                  /note="LD78 beta precursor, coding region of exon 1"
                  /number=1
CDS               join(1192..1267,1953..2067,2488..2578)
                  /partial
                  /codon_start=1
                  /product="LD78 beta precursor"
                  /db_xref="PID:d1014876"
                  /db_xref="PID:g219908"

/translation="MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSYTSRQIP
              QNFIADYFETSSQCSKPSVIFLTRGRQVCADPSEEWVQKYVSDLELSA"

sig_peptide      1192..1260
                  /partial
                  /note="LD78 beta signal peptide"
mat_peptide      join(1258..1267,1953..2067,2488..2575)
                  /partial
                  /note="LD78 beta mature peptide"
intron           1268..1952
exon              1953..2067
                  /number=2
intron           2068..2487
exon              2488..2955
                  /number=3

BASE COUNT      756 a    775 c    780 g    801 t
ORIGIN
1  ttagagactt aataataaag gatcttggtg ataatttata attccctgat agagaaaaat
61 ttagctttgc ttattttaga gttataaatg atgctgggtc aggtatcttt atgtttgaag
121 atggctccat atttgggttg tttccacaga actctttccc agaaatgctt tttctagggt
181 aatggctaca cataattcta ggcacctgac atactgacac ccacctctaa agtattttta
241 tgatccacaa ctagcgttta acacagcgcc ccagtcactc cgagactaat aaatagacaa
301 atgactgaaa cgtgacctca tgctttctat tcctccagct ttcattgagt tcctttcctc
361 tgggaggact gggggttggtc tagccctcca cagcatcagc ccattgacct tacccttggt
421 gttatagcag ctgaggaaagc agaattacag ctctgtggga aggaatgggg ctggagagtt
481 catgcataga ccaattcttt tttttttttt tttttgagat ggagtttcac tttgttggtc
541 caggctggag tgcaatggca tgatctcagc tcaccacagc cccacctcc tgggttcaag
601 cgattctcct gccctcagcc tcccagtag ctgggattac aggcattgtc caccacgctt
661 gactactttt gtatttttag tagagatgga gtttctcttt ctgtgtcagg ttggtctcaa
721 actcctgacc tcaggtgatc cgcagcctcg gcctccaaa gtgttgggat tacaggtgtg
781 agcgaccatg cctggctgca tagaccagtt cttatgagaa gggatcaact aagaatagcc
841 ttgggttgac acacaccctt cttcacactc acaggagaaa ccccatgaag ctagaaccag
901 tcatgagttg agagctgaga gttagagagt agctcagaga tgctattctt ggatattctg
961 agccccgtgt gtcaccaggg accctgagtt gtgcaacact cagcatgaca gcatcactac
1021 acttaaaaaa ttccctcctc acccccagat tccatttccc catccgccag ggctgcctat
1081 aaagaggaga gatggcttca gacatcagaa ggacgcaggc agcaaagagt agtcagtcct
1141 ttcttggttc tgetgacact cgagcccaca ttccatcacc tgctcccaat catgcaggtc
1201 tccactgctg cccttgccgt cctcctctgc accatggctc tctgcaacca ggtcctctct
1261 gcaccacgtg agtccatggt gttgttggtg gtatcaccac tctctggcca tggttagacc
1321 acatcagttt ttttttgctg cctgagagcc ccgaagagaa aagaaggaa tctttaagc
1381 gctgccaaac accttggtct tttctttcac aacttttatt tttatctcta gaagggtctt
1441 tagccctcct agtctccagg tatgagaatc taggcagggg caggggagtt acagtccctt
1501 gtacagatag aaaaacaggg ttcaaaacga atcagtttgc aagaggcaga atccagggtt
1561 gcttacttcc cagtgggggtc tgtgtttcac tctccagctc accctagggtc tcccaggagc
1621 cctgtccctt ggtgtcttta tgagagatgt ccagggtctc tcttgggctg gggatatgact
1681 tcttgaaccg aaaaaattcc atgaagagag ctaagagaac agtccattca ggatattgga
1741 tcacatagag aaacagagaa cccactatga agagtcaagg ggaagagga atatagacag
1801 aaacaaagag acatttctct gcaaaacccc ccaaatgcct tgcagtcact tgggtctgagc
1861 aagcctgccc tcctcaacca ctcagggatc agaagctgcc tggccttttc tctgagctg
1921 tgactcgggc ttattctctc ctttctccgc agttgctgct gacacgccga ccgctctgct
1981 cttcagctac acctcccagc agattccaca gaatttcata gctgactact ttgagacgag
2041 cagccagtgc tccaagccca gtgtcatgta agtgccagtc ttccgtctca cctctaggga
2101 ggtaggaggat gtcagggtgg gggcagaaac aggccagaa gccatcctgg aaaggcccag
2161 ccttcaggag cctatcgggg atacaggacg cagggcactg aggtgtgacc tgacttgggg
2221 ctggagtgag gtgggtgtta cagagtcagg aagggtctgc ccaggccaga ggaaaggaa
2281 aggaagaagg aggcagcagg acactctgag gggcccttg cctggagtca ctgagagaa
2341 ctctctagac ggagataggc agggggcccc tgagagagga gcaaggcctg agctgcccag
2401 gacagagagc aggatgtcag gccatggtgg gccaggatt ccccggtctg attccccagt
2461 gcttaactct tcctcccttc tccacagctt cctaaccaag agaggccggc aggtctgtgc

```

```

2521 tgacccagct gaggagtggg tccagaaata cgtcagtgac ctggagctga gtgcctgagg
2581 ggtccagaag cttcagggcc cagcgacctc agtgggcccc gtggggagga gcaggagcct
2641 gaggcttggg aacatgcgtg tgacctctac agctacctct tctatggact gggtattgcc
2701 aaacagccac actgtgggac tcttcttaac ttaaatttta atttatttat actatttagt
2761 ttttataatt tatttttgat ttcacagtgt gtttgtgatt gtttgcctcg agagttcccc
2821 ctgtcccttc cactttccct cacagtgtgt ctgggtgacga ccgagtggct gtcacgggcc
2881 tgtgtaggca gtcatggcac caaagccacc agactgacaa atgtgtatca gatgcttttg
2941 ttcagggctg tgatcgccct ggggaaataa taaagatggt cttttaaacg gtaaaccagt
3001 attgagtttg gttttgtttt tctggcaaat caaaatcact agttaagagg aatcataggc
3061 aaagattagg aagaggtgaa atggagggaa actgggagag atggggagcg ct

```

```

//
LOCUS      HUMACT2A      696 bp      mRNA      PRI      30-OCT-1994
DEFINITION Human activation (Act-2) mRNA, complete cds.
ACCESSION  J04130
NID        g178017
KEYWORDS   act2 gene; immune activation gene.
SOURCE     Human (Hut-102B2 library) activated T cells, cDNA to mRNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 696)
AUTHORS    Lipes,M.A., Napolitano,M., Jeang,K.T., Chang,N.T. and
Leonard,W.J.
TITLE      Identification, cloning, and characterization of an immune
            activation gene
JOURNAL    Proc. Natl. Acad. Sci. U.S.A. 85 (24), 9704-9708 (1988)
MEDLINE    89071764
COMMENT     Draft entry and computer-readable sequence [1] kindly submitted
            by
            W.Leonard, 09-JAN-1989.

```

```

FEATURES             Location/Qualifiers
     source            1..696
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /map="Unassigned"
     mRNA              <1..696
                        /note="act-2 mRNA"
     sig_peptide       109..177
                        /gene="LAG2"
                        /note="act-2 protein signal peptide"
     gene              109..387
                        /gene="LAG2"
     CDS               109..387
                        /gene="LAG2"
                        /note="act-2 protein precursor"
                        /codon_start=1
                        /db_xref="GDB:G00-127-452"
                        /db_xref="PID:g178018"

/translation="MKLCVTVLSLLMLVAAFCSPALSPMGSDPPTACCFSTARKLP
            RNFVVDYETSSLCSQPAVVFQTKRSKQVCADPSESQVQYVYDLELN"
     mat_peptide       178..384
                        /gene="LAG2"
                        /note="act-2 protein"

```

```

BASE COUNT      157 a      203 c      139 g      197 t
ORIGIN           Unreported.

```

```

1  ttcccccccc ccccccccc cccgccccga gcacaggaca cagctggggt ctgaagcttc
61  tgagttctgc agcctcacct ctgagaaaac ctcttttcca ccaataccat gaagctctgc
121 gtgactgtcc tgtctctcct catgctagta gctgccttct gctctccagc gctctcagca
181 ccaatgggct cagaccctcc caccgcctgc tgcttttctt acaccgcgag gaagcttccct
241 cgcaactttg tggtagatta ctatgagacc agcagcctct gctcccagcc agctgtggta
301 ttccaaacca aaagaagcaa gcaagtctgt gctgatccca gtgaatcctg ggtccaggag
361 tacgtgtatg acctggaact gaactgagct gctcagagac aggaagtctt caggaagagt
421 cacctgagcc cggatgcttc tccatgagac acatctcctc catactcagg actcctctcc
481 gcagttcctg tcccttctct taatttaatc ttttttatgt gccgtgttat tgtattaggt
541 gtcatttcca ttatttatat tagtttagcc aaaggataag tgtcctatgg ggatgggtcca
601 ctgtcactgt ttctctgctg ttgcataaac atggataaca catttgattc tgtgtgtttt
661 ccataataaaa actttaaaat aaaatgcaga cagtta

```

```

//
LOCUS      AF031587      481 bp      mRNA      PRI      02-JAN-1998
DEFINITION Homo sapiens MIP-1 delta mRNA, complete cds.

```

ACCESSION AF031587
 NID g2739163
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Molecular cloning and characterization of a new CC chemokine
 MIP-1
 delta
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Direct Submission
 JOURNAL Submitted (27-OCT-1997) Immunobiology, DNAX Research Institute,
 901

California Ave, Palo Alto, CA 94304, USA

FEATURES Location/Qualifiers
 source 1..481
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 CDS 1..342
 /note="CC or beta chemokine"
 /codon_start=1
 /product="MIP-1 delta"
 /db_xref="PID:g2739164"

/translation="MKVSVAALSCLMLVAVLGSQAQFINDAETELMMSKLPLENPVVL

NSFHFAADCCTSYISQSI PCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"

BASE COUNT 140 a 112 c 100 g 129 t
 ORIGIN

```

1 atgaaggtct ccgtggctgc cctctcctgc ctcagtcttg ttgctgtcct tggatcccag
61 gcccagttca taaatgatgc agagacagag ttaatgatgt caaagcttcc actggaaaat
121 ccagtagttc tgaacagctt tcactttgct gctgactgct gcacctcta catctcaca
181 agcatcccggt gttcactcat gaaaagttat ttgaaacga gcagcgagtg ctccaagcca
241 ggtgtcatat tcctcaccaa gaaggggagg caagtctgtg ccaaaccag tgggtccggga
301 gtccaggatt gcatgaaaaa gctgaagccc tactcaatat aataataaag agacaaaaga
361 gggcagccac ccacctcaa cacctcctgt gaggttcttg gtctgaaata cttaaaaaat
421 atatatattg ttgtgtctgg taatgaaagt aatgcatcta ataaagagta ttcaattttt
481 t

```

//
 LOCUS AF043340 234 bp mRNA PRI 23-FEB-1998
 DEFINITION Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a)
 mRNA,

partial cds.

ACCESSION AF043340
 NID g2905629
 KEYWORDS .
 SOURCE human.

ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 234)

AUTHORS Jang, J.S. and Kim, B.E.

TITLE Direct Submission

JOURNAL Submitted (15-JAN-1998) Protein Engineering, General Institute
 of

Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
 Sosa-gu, Bucheon 422-231, Korea

COMMENT forward primer (5'-tgcgacccctggccactgaactg-3')
 reverse primer (5'-ccttccttctggtcagttgga-3').

FEATURES Location/Qualifiers
 source 1..234
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PHA-treated peripheral blood leukocyte"


```

gene          <1..234
               /gene="MIP2a"
primer_bind   <1..21
               /gene="MIP2a"
               /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
cycles;
               DeltaCycler II from Ericomp"
CDS           <1..222
               /gene="MIP2a"
               /function="CXC chemokine"
               /function="proinflammatory cytokine involved in
inflammation"
               /note="8-10 kDa"
               /codon_start=1
               /product="macrophage inflammatory protein 2 alpha"
               /db_xref="PID:g2905630"

/translation="APLATELRQCQLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATL
               KNGQKACLNPA SPVMKKIIEKMLKNGKSN"
primer_bind   complement(214..234)
               /gene="MIP2a"
BASE COUNT    74 a      70 c      54 g      36 t
ORIGIN
1 gcacccctgg ccactgaact gcgctgccag tgcttgccaga ccctgcaggg aattcacctc
61 aagaacatcc aaagtgtgaa ggtgaagtc cccggacccc actgcgccc aaccgaagtc
121 atagccacac tcaagaatgg gcagaaagct tgtctcaacc ccgcacgcc catgggtaag
181 aaaatcatcg aaaagatgct gaaaaatggc aaatccaact gaccagaagg aagg
//
LOCUS          HSU77035      764 bp      mRNA      PRI      23-JAN-1997
DEFINITION     Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA,
               complete cds.
ACCESSION      U77035
NID            g1790924
KEYWORDS       .
SOURCE         human.
ORGANISM       Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 764)
AUTHORS        Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
               Zlotnik,A.
TITLE          Identification through bioinformatics of two new macrophage
               proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL        J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE        97166046
REFERENCE      2 (bases 1 to 764)
AUTHORS        Rossi,D.L. and Zlotnik,A.
TITLE          Direct Submission
JOURNAL        Submitted (31-OCT-1996) Immunology, DNAX Research Institute,
901            California Ave., Palo Alto, CA 94304, USA
FEATURES       Location/Qualifiers
               source          1..764
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
                               /cell_type="elutriated monocytes activated with
                               LPS/IFN-GAMMA"
               gene           1..291
                               /gene="MIP-3a"
               CDS            1..291
                               /gene="MIP-3a"
                               /note="chemokine"
                               /codon_start=1
                               /product="macrophage inflammatory protein 3 alpha"
                               /db_xref="PID:g1790925"

/translation="MCCTKSLLAALMSVLLLLHLCGESEAA SNFDCCLGYTDRI LHPK
               FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
BASE COUNT    235 a      121 c      146 g      260 t      2 others
ORIGIN
1 atgtgctgta ccaagagttt gctcctggct gctttgatgt cagtgtgct actccacctc

```

```

61 tgcggcgaat cagaagcagc aagcaacttt gactgctgtc ttggatacac agaccgtatt
121 cttcataccta aatttattgt gggcttcaca cggcagctgg ccaatgaagg ctgtgacatc
181 aatgctatca tctttcacac aaagaaaaag ttgtctgtgt gcgcaaattcc aaaacagact
241 tgggtgaaat atattgtgcg tctcctcagt aaaaaagtca agaacaatgta aaaactgttg
301 cttttctgga atggaattgg acatagccca agaacagaaa gaaccttgct ggggttgagg
361 gtttcacttg cacatcatgg aggggttagt gcttatctaa tttgtgcctc actggacttg
421 tccaattaat gaagttgatt catattgcat catagtttgc tttgtttaag catcacatta
481 aagttaaact gtattttatg ttattttatag ctgtaggttt tctgtgttta gctatttaat
541 actaattttc cataagctat tttggtttag tgcaaagtat aaaattatat ttggggggga
601 ataagattat atggactttt ttgcaagcaa caagctattt tttaaaamma actatttaac
661 attcttttgt ttatattgtt ttgtctccta aattgttgta attgcattat aaaataagaa
721 aatatattaat aagacaaata ttgaaataa agaaacaaaa agtt

```

```

//
LOCUS      HSU77180      545 bp      mRNA      PRI      23-JAN-1997
DEFINITION Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA,
complete cds.
ACCESSION  U77180
NID        g1791002
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 545)
AUTHORS    Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
            Zlotnik,A.
TITLE      Identification through bioinformatics of two new macrophage
            proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL    J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE    97166046
REFERENCE  2 (bases 1 to 545)
AUTHORS    Vicari,A. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (01-NOV-1996) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..545
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="macrophages activated with LPS or IFNg"
                        /chromosome="9"
            gene            1..297
                        /gene="MIP-3beta"
            CDS              1..297
                        /gene="MIP-3beta"
                        /function="chemokine"
                        /codon_start=1
                        /product="macrophage inflammatory protein 3 beta"
                        /db_xref="PID:g1791003"

```

/translation="MALLLALSLLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR

NFHYLLIKDGCRVPAVVFTTLRGRQLCAPDQPWVERIIQRLQRTSAKMKRRSS"

BASE COUNT 125 a 160 c 153 g 107 t

ORIGIN

```

1 atggccctgc tactggccct cagcctgctg gttctctgga cttccccagc cccaactctg
61 agtggcacca atgatgctga agactgctgc ctgtctgtga cccagaaacc catccctggg
121 tacatcgatga ggaacttcca ctaccttctc atcaaggatg gctgcagggt gcctgctgta
181 gtgttcacca cactgagggg cgcagctc tggtcacccc cagaccagcc ctgggtagaa
241 cgcacatcc agagactgca gaggacctca gccaaagatga agcgccgcag cagtaacct
301 atgaccgtgc agaggggagc cggagtccga gtcaagcatt gtgaattatt acctaacctg
361 gggaaaccgag gaccagaagg aaggaccagg cttccagctc ctctgcacca gacctgacca
421 gccaggacag ggcctggggg gtgtgtgagt gtgagtgtga gcgagagggt gagtgtgggtc
481 tagagtaaag ctgctccacc cccagattgc aatgctacca ataaagccgc ctggtgttta
541 caact

```

```

//
LOCUS      HUMTCSM      1160 bp      mRNA      PRI      15-JUN-1989
DEFINITION Human T cell-specific protein (RANTES) mRNA, complete cds.
ACCESSION  M21121
NID        g339420

```

KEYWORDS Alu repeat; T-cell-specific protein.
SOURCE Human peripheral blood (T lymphocyte) cell line AH2, cDNA to mRNA,
clone 228.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1160)
AUTHORS Schall,T.J., Jongstra,J., Dyer,B.J., Jorgensen,J.,
Clayberger,C.,
Davis,M.M. and Krensky,A.M.
TITLE A human T cell-specific molecule is a member of a new gene family
JOURNAL J. Immunol. 141, 1018-1025 (1988)
MEDLINE 88285659
COMMENT Draft entry and computer-readable sequence for [1] kindly provided
by A.M.Krensky, 24-OCT-1988.
FEATURES
source Location/Qualifiers
1..1160
/organism="Homo sapiens"
/db_xref="taxon:9606"
CDS 27..302
/note="T cell-specific protein precursor"
/codon_start=1
/db_xref="PID:g339421"
/translation="MKVSAARLAVILIATLALCAPASAPYSSDTPCCFAYIARPLPR
AHIKEYFYTSKGCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS"
sig_peptide 27..95
/note="T cell-specific protein signal peptide"
mat_peptide 96..299
/note="T cell-specific protein"
repeat_region 450..950
/note="Alu-related repeats"
BASE COUNT 298 a 332 c 295 g 235 t
ORIGIN 276 bp upstream of RsaI site.
1 cctccgacag cctctccaca ggtaccatga aggtctccgc ggcacgcctc gctgtcatcc
61 tcattgctac tgccctctgc gctcctgcat ctgcctcccc atattcctcg gacaccacac
121 cctgctgctt tgctacatt gcccgccac tgcccggtgc ccacatcaag gaggattttct
181 acaccagtgg caagtgtctc aaccagcagc tegtctttgt caccgaaag aaccgccaag
241 tgtgtgcaa cccagagaag aaatgggttc gggagtacat caactctttg gagatgagct
301 aggatggaga gtccttgaac ctgaacttac acaaatttgc ctgtttctgc ttgtctttgt
361 cctagcttgg gaggcttccc ctactatcc taccacccc gctccttgaa gggcccagat
421 tctgaccacg acgagcagca gttacaaaaa ccttccccag gctggacgtg gtggctcagc
481 cttgtaatcc cagcactttg ggaggccaag gtgggtggat cacttgaggt caggagttcg
541 agacagcctg gccaacatga tgaaacccca tgtgtactaa aaatacaaaa aattagccgg
601 gcgtggtagc gggcgctgt agtcccagct actcgggagg ctgaggcagg agaattggcgt
661 gaacccggga gcggagcttg cagtgcgagc agatcgcgcc actgcactcc agcctgggag
721 acagagcgag actccgtctc aaaaaaaaaa aaaaaaaaaa aaaaaataca aaaattagcc
781 gcgtggtagc ccacgcctgt aatcccagct actcgggagg ctaaggcagg aaaattgttt
841 gaacccagga ggtggaggct gcagtgcgct gagattgtgc cacttcactc cagcctgggt
901 gacaaagtga gactccgtca caacaacaac aacaaaaagc ttccccaact aaagcctaga
961 agagcttctg aggcgtgctc ttgtcaaaaag gaagtctcta ggttctgagc tctggctttg
1021 ccttggtctt gcaagggtc tgtgacaagg aagggaagtc gcatgcctct agaggcaagg
1081 aaggaggagg cactgcactc ttaagcttcc gccgtctcaa cccctcacag gagcttactg
1141 gcaaacatga aaaatcgggg
//
LOCUS HUMTLI309 520 bp mRNA PRI 14-JAN-1995
DEFINITION Human secreted protein (I-309) mRNA, complete cds.
ACCESSION M57502
NID g339728
KEYWORDS secreted protein.
SOURCE Human T-cell, cDNA to mRNA.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 520)
AUTHORS Miller,M.D., Hata,S., De Waal Malefyt,R. and Krangel,M.S.
TITLE A novel polypeptide secreted by activated human T lymphocytes
JOURNAL J. Immunol. 143 (9), 2907-2916 (1989)

MEDLINE 90038522
FEATURES

source Location/Qualifiers
1..520
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="T-cell"
/germline
/map="17"
mRNA <1..520
/gene="SCYA1"
/note="G00-118-872"
gene 1..520
/gene="SCYA1"
CDS 51..341
/gene="SCYA1"
/codon_start=1
/db_xref="GDB:G00-118-872"
/product="secreted protein I-309"
/db_xref="PID:g339729"

/translation="MQIITLALVCLLLAGMWPEDVDSKSMQVPFSRCCFSFAEQEIPL
RAILCYRNTSSICSNGLIFKLRGKEACALDTVGWVQRHRKMLRHCPSKRK"

BASE COUNT 140 a 137 c 122 g 121 t
ORIGIN

1 accaggctca tcaaagctgc tccaggaagg cccaagccag accagaagac atgcagatca
61 tcaccacagc cctgggtgtgc ttgctgctag ctgggatgtg gccggaagat gtggacagca
121 agagcatgca ggtacccttc tccagatgtt gcttctcatt tgcggagcaa gagattcccc
181 tgagggcaat cctgtgttac agaaatacca gctccatctg ctccaatgag ggcttaatat
241 tcaagctgaa gagaggcaaa gaggcctgcg ccttggaacac agttggatgg gttcagaggc
301 acagaaaaat gctgaggcac tgcccgtcaa aaagaaaatg agcagatttc tttccattgt
361 gggctctgga aaccacatgg cttcacctgt ccccgaaact accagcccta caccattcct
421 tctgccctgc ttttgctagg tcacagagga tctgcttggt cttgataagc tatgttgttg
481 cactttaaac atttaatta tacaatcatc aacccccaac

//
LOCUS AB000887 687 bp mRNA PRI 05-JUN-1997
DEFINITION Human mRNA for EB11-ligand chemokine, complete cds.
ACCESSION AB000887
NID g2189952
KEYWORDS EB11-ligand chemokine; ELC.
SOURCE Homo sapiens fetal tissue_lib:lung cDNA to mRNA.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
Homo.
REFERENCE 1 (bases 1 to 687)
AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
Kitaura,M., Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.
TITLE Direct Submission
JOURNAL Submitted (05-FEB-1997) to the DDBJ/EMBL/GenBank databases.
Hisayuki Nomiyama, Kumamoto University Medical School,
Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
(E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)
REFERENCE 2 (sites)
AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
Kitaura,M., Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.
TITLE Molecular cloning of a novel human CC chemokine EB11-ligand
chemokine that is a specific functional ligand for EB11, CCR7
J. Biol. Chem. 272 (21), 13803-13809 (1997)
MEDLINE 97298088
FEATURES Location/Qualifiers
source 1..687
/organism="Homo sapiens"
/db_xref="taxon:9606"
/dev_stage="fetal"
/tissue_lib="lung"
gene 139..435
/gene="ELC"

```

CDS                139..435
                   /gene="ELC"
                   /note="CC chemokine"
                   /codon_start=1
                   /product="EBI1-ligand chemokine"
                   /db_xref="PID:d1021215"
                   /db_xref="PID:g2189953"

/translation="MALLLALSLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR
NFHYLLIKDGCRVPAVVFVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMRRSS"
mat_peptide        202..432
                   /gene="ELC"
                   /product="EBI1-ligand chemokine"
polyA_signal        657..662
BASE COUNT         154 a    223 c    173 g    137 t
ORIGIN
    1 cattcccagc ctcacatcac tcacaccttg catttcaccc ctgcatccca gtcgccctgc
   61 agcctcacac agatcctgca cacacccaga cagctggcgc tcacacattc accgttggcc
  121 tgcctctgtt caccctccat ggccctgcta ctggccctca gctgtctggt tctctggact
  181 tccccagccc caactctgag tggcaccaat gatgctgaag actgctgcct gtctgtgacc
  241 cagaaaccca tcctgggta catcgtgagg aacttccact accttctcat caaggatggc
  301 tgcagggtgc ctgctgtagt gttaccaca ctgagggggc gccagctctg tgcaccccca
  361 gaccagccct gggtagaacg catcatccag agactgcaga ggacctcagc caagatgaag
  421 cgccgcagca gttaacctat gaccgtgcag agggagcccg gagtccgagt caagcattgt
  481 gaattattac ctaacctggg gaaccgagga ccagaaggaa ggaccaggct tccagctcct
  541 ctgcaccaga cctgaccagc caggacaggg cctgggggtg gtgtgagtg gtgtgtgagc
  601 gagaggggtg gtgtgggtcag agtaaagctg ctccaccccc agattgcaat gctaccaata
  661 aagccgcctg gtgtttacaa ctaattg

//
LOCUS               AB000221      760 bp    mRNA                PRI      31-JUL-1997
DEFINITION          Homo sapiens mRNA for CC chemokine, complete cds.
ACCESSION            AB000221
NID                  g2289718
KEYWORDS             CC chemokine; PARC; pulmonary and activation-regulated
                     chemokine.
SOURCE               Homo sapiens lung cDNA to mRNA.
ORGANISM              Homo sapiens
                     Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
                     Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
                     Homo.
REFERENCE            1 (bases 1 to 760)
AUTHORS              Nomiya, H.
TITLE                Direct Submission
JOURNAL              Submitted (04-JAN-1997) to the DDBJ/EMBL/GenBank databases.
                     Hisayuki Nomiya, Kumamoto University Medical School,
Department           of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
                     (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
                     Fax:81-96-372-6140)
REFERENCE            2 (sites)
AUTHORS              Hieshima, K., Imai, T., Baba, M., Shoudai, K., Ishizuka, K.,
                     Nakagawa, T., Tsuruta, J., Takeya, M., Sakaki, Y., Takatsuki, K.,
                     Miura, R., Opdenakker, G., Damme, J., Yoshie, O. and Nomiya, H.
TITLE                A novel human CC chemokine PARC that is most homologous to
                     macrophage-inflammatory protein-lalpha/LD78alpha and
chemotactic          for T lymphocytes, but not for monocytes
JOURNAL              J. Immunol. 159 (3), 1140-1149 (1997)
MEDLINE              97376836
FEATURES
    source            Location/Qualifiers
                     1..760
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /tissue_type="lung"
    gene              64..333
                     /gene="PARC"
    CDS               64..333
                     /gene="PARC"
                     /note="pulmonary and activation-regulated chemokine"

```

/codon_start=1
 /product="CC chemokine"
 /db_xref="PID:d1022520"
 /db_xref="PID:g2289719"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKLCLVYTSWQIPQKFI.
 VDYSETSPQCCKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"

BASE COUNT 186 a 208 c 155 g 211 t

ORIGIN
 1 gccaggagtt gtgagtttcc aagccccagc tcactctgac cacttctctg cctgccccagc
 61 atcatgaagg gccttgacgc tgccctcctt gtccctgtct gcaccatggc cctctgtcc
 121 tgtgcacaag ttggtaccaa caaagagctc tgctgcctcg tctataacct ctggcagatt
 181 ccacaaaagt tcatagttga ctattctgaa accagcccc agtgcccaa gccagggtgc
 241 atcctcctaa ccaagagagg ccggcagatc tgtgctgacc ccaataagaa gtgggtccag
 301 aaatacatca ggcacctgaa gctgaatgcc tgaggggcct ggaagctgag agggccagc
 361 gaacttggtg ggcacaggag ggaacaggag cctgagccag ggcaatggcc ctgccacct
 421 ggaggccacc tcttctaaga gtcccatctg ctatgccag ccacattaac taactttaat
 481 cttagtttat gcatcatatt tcattttgaa attgatttct attgttgagc tgcattatga
 541 aattagtatt ttctctgaca tctcatgaca ttgtctttat catcctttcc cctttccctt
 601 caactcttcg tacattcaat gcatggatca atcagtgtga tttagcttct cagcagacat
 661 tgtgccatat gtatcaaatg acaaatcttt attgaatggt tttgctcagc accacctttt
 721 aatatattgg cagtacttat tatataaaag gtaaaccagc

//
 LOCUS D86955 799 bp mRNA PRI 06-MAR-1997
 DEFINITION Human mRNA for CC chemokine LARC precursor, complete cds.
 ACCESSION D86955
 NID g1871138
 KEYWORDS CC chemokine LARC precursor.
 SOURCE Homo sapiens cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae;
 Homo.
 REFERENCE 1 (sites)
 AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
 Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
 Nomiyama,H.
 TITLE Molecular cloning of a novel human CC chemokine liver and
 activation-regulated chemokine (LARC) expressed in liver.
 Chemotactic activity for lymphocytes and gene localization on
 chromosome 2
 J. Biol. Chem. 272 (9), 5846-5853 (1997)
 JOURNAL MEDLINE 97190319
 REFERENCE 2 (bases 1 to 799)
 AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
 Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
 Nomiyama,H.
 JOURNAL Unpublished (1996)
 REFERENCE 3 (bases 1 to 799)
 AUTHORS Nomiyama,H.
 TITLE Direct Submission
 JOURNAL Submitted (08-AUG-1996) to the DDBJ/EMBL/GenBank databases.
 Hisayuki Nomiyama, Kumamoto University Medical School,
 Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
 (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)
 FEATURES Location/Qualifiers
 source 1..799
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="2"
 /map="q33-37"
 sig_peptide 59..136
 /gene="LARC"
 CDS 59..349
 /gene="LARC"
 /codon_start=1
 /product="CC chemokine LARC precursor"
 /db_xref="PID:d1013880"
 /db_xref="PID:g1871139"

```

/translation="MCCTKSLLLAALMSVLLHLGGESEAAASFDCCLGYTDRILHPK
              FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
gene          59..349
              /gene="LARC"
mat_peptide   137..346
              /gene="LARC"
              /product="CC chemokine LARC"
BASE COUNT    240 a    138 c    153 g    268 t
ORIGIN
    1 cactcccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaaccat
   61 gtgctgtacc aagagtttgc tcctggctgc tttgatgtca gtgctgtac tccacctctg
  121 cggcgaaatca gaagcagcaa gcaactttga ctgctgtctt ggatacacag accgtattct
  181 tcatacctaaa ttattgtgg gcttcacacg gcagctggcc aatgaaggct gtgacatcaa
  241 tgctatcatc ttccacacaa agaaaaagtt gtctgtgtgc gcaaatccaa aacagacttg
  301 ggtgaaatat attgtgcgtc tcctcagtaa aaaagtcaag aacatgtaaa aactgtggct
  361 tttctggaat ggaattggac atagcccaag aacagaaaga accttgctgg ggttggagggt
  421 ttcacttgca catcatggag ggtttagtgc ttatctaatt tgtgcctcac tggacttgct
  481 caattaatga agttgattca tattgcatca tagtttgctt tgtttaagca tcacattaaa
  541 gttaaactgt attttatgtt atttatagct gtaggttttc tgtgttttagc tatttaatac
  601 taattttcca taagctatct tggtttagtg caaagtataa aattatattt gggggggaaat
  661 aagattatat ggactttctt gcaagcaaca agctattttt taaaaaaact atttaacatt
  721 cttttgttta tattgttttg tctcctaaat tgttgtaatt gcattataaa ataagaaaaa
  781 cattaataag acaaatatt

//
LOCUS          HUMAR          538 bp    mRNA          PRI          11-SEP-1996
DEFINITION     Human mRNA for chemokine, complete cds.
ACCESSION      D43767
NID            g1536878
KEYWORDS       chemokine, thymus and activation-regulated; chemokine.
SOURCE         Homo sapiens male peripheral blood cDNA to mRNA, clone:D3A.
ORGANISM       Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
               Hominidae; Homo.
REFERENCE      1 (sites)
AUTHORS        Imai,T., Yoshida,T., Baba,M., Nishimura,M., Kakizaki,M. and
               Yoshie,O.
TITLE          Molecular cloning of a novel T cell-directed CC chemokine
               expressed
               in thymus by signal sequence trap using Epstein-Barr virus
               vector
JOURNAL        J. Biol. Chem. 271 (35), 21514-21521 (1996)
MEDLINE        96355526
REFERENCE      2 (bases 1 to 538)
AUTHORS        Imai,T.
JOURNAL        Unpublished (1996)
REFERENCE      3 (bases 1 to 538)
AUTHORS        Imai,T.
TITLE          Direct Submission
JOURNAL        Submitted (07-DEC-1994) to the DDBJ/EMBL/GenBank databases.
Toshio
               Imai, Shionogi Institute for Medical Science; 2-5-1 Mishima,
               Settsu, Osaka 566, Japan (Tel:06-382-2612, Fax:06-382-2598)
FEATURES
  source       1..538
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /clone="D3A"
               /sex="male"
               /tissue_type="peripheral blood"
  CDS          53..337
               /note="thymus and activation regulated"
               /codon_start=1
               /product="chemokine"
               /db_xref="PID:d1008410"
               /db_xref="PID:g1536879"

/translation="MAPLKMLALVTLLLGASLQHIHAARGTNVGRECCLEYFKGAIP
              RKLKTTYQTSSEDCSRDAIVFVTVQGRAICSDPNNKRVKNAVKYQLSLERS"

```

```

BASE COUNT      118 a      168 c      149 g      103 t
ORIGIN
    1 ccctgagcag agggacctgc acacagagac tccctcctgg gctcctggca ccatggcccc
   61 actgaagatg ctggccctgg tcaccctcct cctgggggct tctctgcagc acatccacgc
  121 agctcgaggg accaatgtgg gccgggagtg ctgcctggag tacttcaagg gagccattcc
  181 ccttagaaaag ctgaagacgt ggtaccagac atctgaggac tgctccaggg atgccatcgt
  241 ttttgtaact gtgcagggca gggccatctg ttcggacccc aacaacaaga gagtgaagaa
  301 tgcagttaaa tacctgcaaa gccttgagag gtcttgaagc ctccctaccc cagactcctg
  361 actgtctccc gggactacct gggacctcca ccgttggtgt tcaccgcccc caccctgagc
  421 gcctgggtcc aggggaggcc ttccagggac gaagaagagc cacagtgagg gagatcccat
  481 ccccttgtct gaactggagc catgggcaca aaggggccag attaaagtct ttatcctc

```

//

```

LOCUS      HUMEOTAXIN      807 bp      mRNA      PRI      25-SEP-1996
DEFINITION Human mRNA for eotaxin, complete cds.
ACCESSION  D49372
NID        g1552240
KEYWORDS   eotaxin; eosinophil-selective CC chemokine; chemoattractant.
SOURCE      Homo sapiens Small intestine, proximal cDNA to mRNA, clone:141.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE   1 (bases 1 to 807)
AUTHORS     Kitaura,M., Nakajima,T., Imai,T., Harada,S., Combadiere,C.,
            Tiffany,H.L., Murphy,P.M. and Yoshie,O.
TITLE       Molecular cloning of human eotaxin, an eosinophil-selective CC
            chemokine, and identification of a specific eosinophil eotaxin
            receptor, CC chemokine receptor 3
JOURNAL      J. Biol. Chem. 271 (13), 7725-7730 (1996)
MEDLINE      96205964
REFERENCE    2 (bases 1 to 807)
AUTHORS      Yoshie,O.
TITLE        Direct Submission
JOURNAL      Submitted (15-FEB-1995) to the DDBJ/EMBL/GenBank databases.
Osamu
            Yoshie, Shionogi Institute for Medical Science; 2-5-1 Mishima,
            Settsu, Osaka 566, Japan (E-mail:osamu.yoshie@shionogi.co.jp,
            Tel:06-382-2612, Fax:06-382-2598)
COMMENT      On Sep 20, 1996 this sequence version replaced gi:1313900.
FEATURES
    source          Location/Qualifiers
                    1..807
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="141"
                    /tissue_type="Small intestine, proximal"
    CDS              99..392
                    /codon_start=1
                    /product="eotaxin"
                    /db_xref="PID:d1008966"
                    /db_xref="PID:g1552241"
    /translation="MKVSAALLWLLLIAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
    RLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP"
    misc_signal      548..557
                    /note="mRNA destabilization signal"
    polyA_signal     775..780
    polyA_site       807

```

```

BASE COUNT      229 a      198 c      147 g      233 t
ORIGIN
    1 gcattttttc aagttttatg atttatttaa cttgtggaac aaaaataaac cagaaaccac
   61 cacctctcac gccaaagctc acaccttcag cctccaacat gaaggtctcc gcagcacttc
  121 tgtggctgct gctcatagca gctgccttca gccccaggg gctcgctggg ccagcttctg
  181 tcccaaccac ctgctgcttt aacctggcca ataggaagat accccttcag cgactagaga
  241 gctacaggag aatcaccagt ggcaaatgtc ccagaaaagc tgtgatcttc aagaccaaac
  301 tggccaagga tatctgtgcc gaccceaaga agaagtgggt gcaggattcc atgaagtatc
  361 tggaccaaaa atctccaact ccaaagccat aaataatcac catttttgaa accaaaccag
  421 agcctgagtg ttgcctaatt tgttttcctt tcttacaatg cattctgagg taacctcatt
  481 atcagtccaa agggcatggg ttttattata tatatatata tttttttttt aaaaaaaac
  541 gtattgcatt taatttattg aggctttaaa acttatcctc catgaatc atgtattttt

```



```

601 aaactgtaaa gctttgtgca gattctttac cccctgggag cccaattcg atccccgtc
661 acgtgtgggc aatgttcccc ctctcctctc ttctccctg gaatcttgta aaggctctgg
721 caaagatgat cagtatgaaa atgtcattgt tcttgtgaac ccaaagtgtg actcataaa
781 tggaagtaaa tgtgtttta ggaatac
//
LOCUS       HSCCCHM          232 bp    RNA                      PRI      10-SEP-1996
DEFINITION  H.sapiens mRNA for CC-chemokine.
ACCESSION   Z69291
NID         g1181148
KEYWORDS    CC-chemokine.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 232)
  AUTHORS   Bartels,J.H., Schlueter,C., Richter,E., Christophers,E. and
            Schroeder,J.M.
  TITLE     Cloning of a novel human chemokine homologous to human monocyte
            chemoattractant proteins and rodent eotaxins
  JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 232)
  AUTHORS   Bartels,J.H.
  TITLE     Direct Submission
  JOURNAL    Submitted (01-FEB-1996) Bartels J. H.,
            Christian-Albrechts-Universitaet                      zu      Kiel,
            Dermatology/Hautklinik,
            Mol.Biol.Lab.609, Schittenhelmstr. 7, Kiel, Schleswig-Holstein,
            Germany, D-24105
REFERENCE   3 (bases 1 to 232)
  AUTHORS   Bartels,J., Schluter,C., Richter,E., Noso,N., Kulke,R.,
            Christophers,E. and Schroder,J.M.
  TITLE     Human dermal fibroblasts express eotaxin: molecular cloning,
            expression, and identification of eotaxin sequence variants
  JOURNAL    Biochem. Biophys. Res. Commun. 225 (3), 1045-1051 (1996)
  MEDLINE    96374440
FEATURES    Location/Qualifiers
             source          1..232
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
                               /clone="clones 4(9512),
                               14(9512),15(9512),10(9601),11(9601)"
                               /tissue_type="foreskin"
                               /cell_type="fibroblast"
                               /sex="Male"
             mRNA            <1..>232
                               /citation=[1]
                               /product="CC-chemokine"
             sig_peptide     56..109
                               /citation=[1]
             CDS              56..>232
                               /function="putative chemoattractant protein"
                               /note="sequence homology to human MCP-1, MCP-2 and
            MCP-3           and to rodent eotaxins"
                               /citation=[1]
                               /codon_start=1
                               /product="CC-chemokine, preprotein"
                               /db_xref="PID:e221070"
                               /db_xref="PID:g1181149"
                               /db_xref="SWISS-PROT:P50877"
            /translation="MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
            mat_peptide      110..>232
                               /citation=[1]
                               /function="putative chemoattractant protein"
                               /product="CC-chemokine"
BASE COUNT   55 a      82 c      50 g      42 t      3 others
ORIGIN
1 accaaaccag aaaccwccam ytctcagcc aaagctcaca ccttcagcct ccaacatgaa

```

```

61 ggtctccgca gcgcttctgt ggctgtgct catagcggct gccttcagcc cccaggggct
121 cgctggggcca gcttctgtcc caaccacctg ctgctttaac ctggccaata ggaagatacc
181 ccttcagcga ctagagagct acaggagaat caccagtggc aaatgtcccc ag

//
LOCUS      HSHCC1GEN      4037 bp      DNA      PRI      01-OCT-1995
DEFINITION H.sapiens gene for chemokine HCC-1.
ACCESSION  Z49269
NID        g1004266
KEYWORDS   chemokine.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 4037)
AUTHORS    Pardigol,A., Maegert,H.J., Cieslak,A., Hill,O., Schulz-
            Knappe,P.
            and Forssmann,W.G.
TITLE      Nucleotide Sequence of the Gene for the Human Chemokine HCC-1
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 4037)
AUTHORS    Pardigol,A.
TITLE      Direct Submission
JOURNAL    Submitted (18-MAY-1995) Andreas Pardigol, Molecular Biology,
            Lower
            Saxony Institute for Peptide Research, Feodor-Lynen-Strasse 31,
            Hannover, Lower Saxon, 30625, Germany
FEATURES   Location/Qualifiers
            source          1..4037
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /clone="ph3b7"
                           /dev_stage="adult"
                           /tissue_type="placenta"
                           /clone_lib="lambda FIX II, Cat.Nr. 946203, Stratagene"
                           /sex="male"
            TATA_signal     727..733
                           /note="putative, determined by consensus rules."
            5'UTR           764..833
                           /note="first base determined by means of consensus
rules"
            exon            764..912
                           /note="first base determined by means of consensus
rules;
                           base 780 is the first base of cDNA (Z49270)"
                           /number=1
            CDS             join(834..912,3021..3135,3585..3672)
                           /codon_start=1
                           /product="chemokine HCC-1"
                           /db_xref="PID:g1004267"
            /translation="MKISVAAIPIFFLLITIALGKTESSSRGYPHPSECCFTYTTYKI
            PRQRIMDYETNSQCSKPGIVFITKRHGSVCTNPSPDKWVQDIKDMKEN"
            intron          913..3020
                           /number=1
            exon            3021..3135
                           /number=2
            intron          3136..3584
                           /number=2
            exon            3585..3817
                           /number=3
            3'UTR           3673..3817
BASE COUNT  1023 a   1048 c   1004 g   962 t
ORIGIN
1 gagctccggtt gggagtccca tgtttcttta tggcataatg ggtgagaaca cagacttgga
61 agccaaacca cctgaatttg aacccagtt ccatttacca actgtcaaaa gcttaggctt
121 tgattctaag cctgtttcct caactgctgt tctaaagatt aaataggcta atattcataa
181 ggcaactggg acagtggcct gtgtgtatag caaccattat ataagtgaat tatctactga
241 gcaccacagc acttcttcac tccatggtgt ggtgaccaga atggagatga gacagagaac
301 tgcaggttct gcttcgagtt taagtttagga tttcccttga ccaatgagac ctgacttgga
361 ggagtccctg cctcattcca ttaccccaaa caccctctag tctctagatg aacagatcct
421 gaatgtccag gccccacgtg gcctgttcta aggcctgaga tggaattgga tacaggacac

```

```

481 atccagcctt gagatctttt gctaagtgtg acacagtgcc cccagccctg tgctcatgtt
541 catgcctagg gaaaggett c tatcaaaaga gttgaacttc ttccactgg g gatggaaga
601 ccatttcttc ccttaaacct tggctctccc tgcttcttcc aggccacca caacacatgt
661 gcaggatatt aaattgctga ggcatactct ctttctact tcccttccaa gtctcagctc
721 ccttatttta aaaaatattt ggctcaatg atcatttctc aacaattcct caccgcagga
781 gcctctgaag ctcccaccag gccagctctc tctccacaac agcttcccac agcatgaaga
841 tctccgtggc tgccattccc ttcttctctc tcatcaccat cgccctagg accaagactg
901 aatcctcttc acgtgagtgc aatgccttgt ctctcttcca acctagagcc tgcagggaaa
961 taagcaggag tgaggttggg gctcagggga agaccaggag cagggactca gaaaggaggg
1021 ctggtatctt cttgaaattg tgtgtatagc aacattatat aaatgaatta tctactgagc
1081 accacagcac ttcaccccat ggtgtggtga gcaggatgga gatgagactt aggactgtag
1141 gttctgctta agagtttaag ttgggactct ccagccttga ccaatgagac ttgacttggg
1201 agactccagg cttcattcca ctaccccaaa tgccctctag tctccaaata aacagatcct
1261 gaatctccag gccctacatg gccttgatct cttatcattg cccccaggga ccagtcccc
1321 cttgcccctc aggacatgga gtgagaccag cctgcctctc tactcctcca atttctctct
1381 ctttgccgct aagcaaaaga gtggccacc ccatttgggg tatatttctc cagggagatt
1441 agggagcagt tcttgagccc ctcaagggca tttttctatt ggctctctga ggttggggcc
1501 cagcctgctt ccagcgtcac ctgtgccag tgagtgcagc attgcttggg tatgggctgg
1561 ggggaaacac gacagtgtgg ggtccatctt agggccctct tctcagctg atttcttaga
1621 ataagctgcc tttagagata accaaaacta tttatcactc ttccatttta cctactctcc
1681 ttttcagaaa ctggggggaa accgaaggtt gttaaaatac agctaaagtt ggtgggtatg
1741 tgcacagttt gacttgccct ctccgatgtc atttgtcagc tcagaggaa c aaggtgggag
1801 agtataggag ctctgactgg gtctcaggaa acagggggcc cttatgccgt tcttggatc
1861 gtgaggatgc tgcttgaat ggagctggaa aacaggatga gaccttcca cccagacatc
1921 tggccaccct cagtacctc tgaggccatt gtgatgcaca tccatgatcc tatgaagcag
1981 ggtcacataa catgcacaca cctgatttct ccactccata accacaacat gtgctgttt
2041 gtacagggct cttggcctac aatgtccttc ctgctactc tataattcaa gcttggggtg
2101 gctgctgtca ccttgcctct cctataaaag ccatgaaact tctcaatcag aaaaatagatg
2161 aaaaaatcac ccaatccagt gattttttaa actttttaga ccacaaaacc ttttcttcaa
2221 gcaatatctt ccacagaggc ccaatatgta aaacagaaaa aatgggttga gtagggatca
2281 agacaccact ctcaaatgca gcaaggcctc cacaaatagc cctgaggccc ccagagctca
2341 gtgtaaaaa cactgatgca gtccaaagggc ctcatttaca gaggagggaa cagggggaaa
2401 gtaaaatggc cacagtacac aggaagcaca ggcaagggtt ggttaggatt tgggtgccct
2461 gactctgtgg cctttgtcct tggggcttgc tgtgggcac cctgctctctc tgcaggttgt
2521 cgggttcaatg gggacatggg cagggtggag cactaggagg ggctggggtt gcatttccaa
2581 atggcatgtc tccaaatccc tattgggatt tcttccaaat attcctccta tttggagcac
2641 ctttcccga taaggcatga aggctgcatg atattggcca agtccctagc cttctctgcc
2701 agtcggcccc cagagatggt gtaagaagat ctgagtgtgc tgctcttcaa tcttgagtt
2761 gaaagtcac caccagtctt tccaagaggg gttgaagaaa agggagaaag gtgattgatg
2821 atgaggggag agaaaaagaa gagccaggga gtaccatgga gaaggagaag agaagatgag
2881 gaaagcctac tctcccctcc aagttctgag gggctgtctc ctcttctct cctctctcca
2941 tgcctcagc ttgcaggagc agccaatggt atggccttta acaaggggcc cctctcagc
3001 atctgatgct ctctcctcag ggggacctta ccacctctca gactgctgct tcacctacac
3061 tacctacaag atcccgcgtc agcggattat ggattactat gagaccaaca gccagtgtc
3121 caagcccga attgtgtagg tggtaacac acatcacact ggggggagag ggagccagca
3181 gggcctcctg gagggaaagc gggagtgggt gtggaatggg gacccccagc gtacctccca
3241 ggtgtgacta catggggaga ggcagctgag gggcaatctg agcgctttct ggctggagcc
3301 tgcaggagcc atggggaaac tgaccccatg gatggggaga tgacagagaa gggagaagaa
3361 ggcaagagg cacttctca gggggacaca gagactagat ggggtctagg gtcttaggaa
3421 ccgaagagta tgtctcagag aggagactgg ctctaagctg cctctgttga agaaaggaaa
3481 agcagtatag gtcaggtggg gaatttagga gggagggaag atgggctgtc tctccggcc
3541 actgggcccc tgggtttgtg atccttctcc ctcttgctcc acagcttcat caccaaaagg
3601 ggccattccg tctgtaccaa cccagtgac aagtgggtcc aggactatat caaggacatg
3661 aaggagaact gactgaccca gaaggggtgg cgaaggcaca gctcagagac ataaagagaa
3721 gatgccaaag cccctcctc caccaccgc taactctcag cccagtcac cctcttggag
3781 cttcctgtct ttgaattaaa gaccactcat gctcttccct ggctctatc ctttctacgg
3841 gatttactca ttggccatgc actgaggaca ccagggtgtg gcacctcgg catcaagcct
3901 cgctctgcag aagttttggt ggagcctggt acaaaaaata ggtcaggcct gcaatgcagg
3961 tagtgagaag cagaaagtga gaaagaaaag cagtgtaaag accgtctct cctcagcagc
4021 aacagtagca gaccccc

```

//

```

LOCUS       HSCC21      925 bp      mRNA                      PRI      30-JUN-1998
DEFINITION  H.sapiens mRNA for chemokine CC-2 and CC-1.
ACCESSION   Z70292
NID         g1296608
KEYWORDS    chemokine CC-1; chemokine CC-2.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 925)

```

AUTHORS Pardigol, A., Forssmann, U., Zucht, H.D., Loetscher, P.,
Schulz-Knappe, P., Baggiolini, M., Forssmann, W.G. and Magert, H.J.

TITLE HCC-2, a human chemokine: gene structure, expression pattern,
and biological activity

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)

MEDLINE 98263352

REFERENCE 2 (bases 1 to 925)

AUTHORS Pardigol, A.

TITLE Direct Submission

JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
Biology, Lower Saxony Institute for Peptide Research, Feodor-Lynen-
Strasse 31, Hannover, Lower Saxony, 30625, Germany

FEATURES Location/Qualifiers

source 1..925
/organism="Homo sapiens"
/db_xref="taxon:9606"
/dev_stage="adult"
/tissue_type="liver"
/clone_lib="PCR fragments"

5'UTR 1..55

CDS 56..397
/note="putative; first coding region of a bicistronic
mRNA"
/codon_start=1
/product="chemokine CC-2"
/db_xref="PID:e233855"
/db_xref="PID:g1296609"
/db_xref="SWISS-PROT:Q16663"

/translation="MKVSVAAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
NSFHFAADCCTSYISQSIPLMSKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
DCMKLKPYSI"

misc_feature 398..498
/note="spacing region between two coding regions of
the bicistronic mRNA"

CDS 499..780
/codon_start=1
/evidence="experimental"
/product="chemokine CC-1"
/db_xref="PID:e233856"
/db_xref="PID:g1296610"
/db_xref="SWISS-PROT:Q16627"

/translation="MKISVAAIPFFLLITIALGKTTESSSRGPYHPSECCFTYTTYKI
PRQRIMDYETNSQCSKPGIVFITKRHGSVCTNP SDKWVQDYIKDMKEN"

3'UTR 781..925

polyA_signal 902..908

BASE COUNT 240 a 296 c 199 g 190 t

ORIGIN

1 ccaggaagca gtgagcccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
61 ggtctccgtg gctgccctct cctgcctcat gcttggtgct gtccttgat ccaggccca
121 gttcacaaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgctcca agccagggtg
301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa cccagtgggc cgggagttca
361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc
481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcatc
541 accatcgccc tagggaccaa gactgaatcc tcctcacggg gaccttacca cccctcagag
601 tgctgcttca cctacactac ctacaagatc ccgcgtcagc ggattatgga ttactatgag
661 accaacagcc agtgctccaa gcccggaatt gtcttcatca ccaaaagggg ccattccgtc
721 tgtaccaacc ccagtgacaa gtgggtccag gactatatca aggacatgaa ggagaactga
781 gtgacccaga aggggtggcg aaggcacagc tcagagacat aaagagaaga tgccaaggcc
841 cctcctcca cccaccgcta actctcagcc ccagtcaccc tcttggaagt tcctgcttt
901 gaattaaaga ccactcatgc tcttc

//

LOCUS HSCC23 973 bp RNA PRI 03-MAY-1996
 DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-3.
 ACCESSION Z70293
 NID g1296611
 KEYWORDS Human chemokine CC-2; Human chemokine CC-3.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 973)
 AUTHORS Pardigol, A., Maegert, H.J., Zucht, HD., Forssmann, W.G. and
 Schulz-Knappe, P.
 TITLE Transcription of a Human Tandem Gene results in a Mature
 Bicistronic mRNA encoding two Novel CC-Chemokines
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 973)
 AUTHORS Pardigol, A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse
 31, Hannover, Lower Saxony, 30625, Germany
 FEATURES
 source Location/Qualifiers
 1..973
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233857"
 /db_xref="PID:g1296612"
 /translation="MKVSVAAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSIPLMSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the
 bicistronic mRNA"
 CDS 499..828
 /note="putative"
 /codon_start=1
 /product="chemokine CC-3"
 /db_xref="PID:e233858"
 /db_xref="PID:g1296613"
 /translation="MKISVAAIPFFLLITIALGKTESSQTGGKPKVVKIQLKLVG
 PYHPSECCFTYTTYKIPRQRIMDYETNSQCSKPGIVFITKRHVSCTNPSPDKWVQDY
 IKDMKEN"
 3'UTR 829..973
 polyA_signal 950..956
 BASE COUNT 257 a 301 c 215 g 200 t
 ORIGIN
 1 ccaggaagca gtgagccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gctgccctct cctgcctcat gcttggtgct gtccttgat cccaggccca
 121 gttcacaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
 181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
 241 ccggtgttca ctcataaaaa gttattttga aacgagcagc gagtgctcca agccagggtg
 301 catattcttc accaagaagg ggcggcaagt ctgtgccaaa cccagtggtc cgggagtcca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc

```

481 acaacagctt cccacagcat gaagatctcc gtggtgcca ttcccttctt cctcctcatc
541 accatcgccc tagggaccaa gactgaatcc tcctcacaaa ctggggggaa accgaaggtt
601 gttaaaatac agctaaagtt ggtgggggga ccttaccacc cctcagagtg ctgcttcacc
661 tacactacct acaagatccc gcgtcagcgg attatggatt actatgagac caacagccag
721 tgctccaagc ccggaattgt cttcatcacc aaaaggggccc attccgtctg taccaacccc
781 agtgacaagt ggggtccagga ctatatcaag gacatgaagg agaactgagt gacccagaag
841 ggggtggcgaa ggcacagctc agagacataa agagaagatg ccaaggcccc ctcctccacc
901 caccgctaac tctcagcccc agtcaccctc ttggagcttc cctgctttga attaaagacc
961 actcatgctc ttc

```

//

```

LOCUS      HSU91746      ,1430 bp      mRNA                      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL    Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..1430
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
                               /chromosome="17"
            gene            1..1430
                               /gene="HCC-4"
            CDS              1..363
                               /gene="HCC-4"
                               /note="CC or beta chemokine family member"
                               /codon_start=1
                               /product="IL-10-inducible chemokine"
                               /db_xref="PID:g2581781"

```

```

/translation="MKVSEAALSLVLILIITSASRSQPKVPEWVNTPTCCLKYYEK

```

```

VLPRRLVVGYRKALNCHLPAIIFVTKRNREVCTNPNDWVQYIKDPNLPPLPTRNLS
TVKIITAKNGQPQLLSQ"

```

```

BASE COUNT      401 a      351 c      293 g      385 t
ORIGIN

```

```

1 atgaaggtct ccgaggctgc cctgtctctc cttgtcctca tccttatcat tacttcggct
61 tctcgagccc agccaaaagt tcctgagtgg gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtgggtggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccctaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgctgcc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatggtaaac ccagctcct caactcccag
361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattagtc tgaaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatatct totcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagaggtag gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcaccg aggctggagt gcagtgggtg gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccacccca gcctcccag
721 tagctgggac tacaggcttg cgccaccaca cctggctaata ttttgattt ttggtagaga
781 cgggattcta ccatgttgcc caggctggtc tcaaactcgt gtgcccgaag aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgcac
901 tcttaataca cagaaaaata tatttcacat cttctcctg ctctctttca attcctcact
961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tctgttccat
1081 ctttatggat ttttctggat ctatattttc ttcaattatt ctttcatttt ataatgcaac

```

```

1141 tttttcatag gaagtcgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactccct tatttgacaa

```

//

LOCUS AB007454 1503 bp mRNA PRI 09-APR-1998
 DEFINITION Homo sapiens mRNA for chemokine LEC precursor, complete cds.
 ACCESSION AB007454
 NID g2723285
 KEYWORDS chemokine LEC precursor.
 SOURCE Homo sapiens liver cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (sites)
 AUTHORS Shoudai, K., Hieshima, K., Fukuda, S., Iio, M., Miura, R., Imai, T.,
 Yoshie, O. and Nomiyama, H.
 TITLE Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC
 JOURNAL Biochim. Biophys. Acta 1396 (3), 273-277 (1998)
 MEDLINE 98207719
 REFERENCE 2 (bases 1 to 1503)
 AUTHORS Nomiyama, H.
 TITLE Direct Submission
 JOURNAL Submitted (19-SEP-1997) to the DDBJ/EMBL/GenBank databases.
 Hisayuki Nomiyama, Kumamoto University Medical School,
 Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860-0811,
 Japan
 (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
 Fax:81-96-372-6140)

FEATURES
 source Location/Qualifiers
 1..1503
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /tissue_type="liver"
 sig_peptide 77..145
 CDS 77..439
 /codon_start=1
 /product="chemokine LEC precursor"
 /db_xref="PID:d1024963"
 /db_xref="PID:g2723286"
 /translation="MKVSEAALSLLVLILIITSASRSQPKVPEWVNTPTSCCLKYYEK"

VLPRRLVVG YRKALNCHLPAIIFVTKRNREVCTNPNDWVQ EYIKDPNLPLLPTRNLS
 TVKIIITAKNGQPQLNSQ"

mat_peptide 146..436
 polyA_signal 560..565
 polyA_signal 1485..1490
 BASE COUNT 417 a 374 c 312 g 400 t
 ORIGIN

```

1 gttggcaagc ggaccaccag caacagacaa catcttcatt cggctctccc tgaagctgta
61 ctgcctcgct gagaggatga aggtctccga ggctgccctg tctctccttg tctctatcct
121 tatcattact tcggcttctc gcagccagcc aaaagtctct gagggttgga acaccccatc
181 cacctgctgc ctgaagtatt atgagaaagt gttgccaaagg agactagtgg tgggatacag
241 aaaggccctc aactgtcacc tgccagcaat catcttcgtc accaagagga accgagaagt
301 ctgcaccaac cccaatgacg actgggtcca agagtacatc aaggatccca acctaccttt
361 gctgcctacc aggaacttgt ccacggttaa aattattaca gcaaagaatg gtcaacccca
421 gctctcaac tcccagtgat gaccaggctt tagtggaagc ccttgtttac agaagagagg
481 ggtaaaccta tgaaaacagg ggaagcctta ttaggctgaa actagccagt cacattgaga
541 gaagcagaac aatgatcaaa ataaaggaga agtattttcga atattttctc aatcttagga
601 ggaataacca aagttaaggg acgtgggcag aggtacgctc ttttattttt atatttatat
661 ttttattttt ttgagatagg gtcttactct gtcacccagg ctggagtgca gtggtgtgat
721 cttggctcac ttgatcttgg ctactgtaa cctccacctc ccaggctcaa gtgacccctc
781 caccacagcc tcccagtag ctgggactac aggttgctgc caccacacct ggctaatttt
841 tgtatttttg gtagagacgg gattctacca tgttgcccag gctggtctca aactcgtgtg
901 cccaagcaat ccacctgcct cagccttcca aaagtgtctg gattacagga gtgagccacc
961 acatccggcc agtgcactct taatacacag aaaaaatata ttcacatcct tctctgtctc
1021 tctttcaatt cctcacttca caccagtaca caagccattc taaatactta gccagtttcc

```

```

1081 agccttccag atgatctttg ccctctgggt cttgacccat taagagcccc atagaactct
1141 tgatttttcc tgtccatctt tatggatttt tctggatcta tttttcttc aattattctt
1201 tcattttata atgcaacttt ttcattaggaa gtccggatgg gaatattcac attaactatt
1261 tttgcagaga ctttgctaga tcctctcata tttgtcttc ctcagggtgg caggggtaca
1321 gagatgtcct gattggaaaa aaaaaaaaaa gagagagaga gagaagaaga agaagaagag
1381 acacaaatct ctacctccca tgtaagctt tgcaggacag ggaaagaaag ggtatgagac
1441 acggctaggg gtaaaactct agtccaaaac ccaagcatgc aataaataaa actcccttat
1501 ttg

```

//

```

LOCUS      AF001979      800 bp      mRNA      PRI      20-NOV-1997
DEFINITION Homo sapiens beta chemokine mRNA, complete cds.
ACCESSION  AF001979
NID        g2624924
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Identification and characterization of a novel beta chemokine
            containing six conserved cysteines
JOURNAL     J. Immunol. 159 (4), 1589-1593 (1997)
MEDLINE     97400322
REFERENCE  2 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Direct Submission
JOURNAL     Submitted (01-MAY-1997) Immunobiology, DNAX Research Institute,
901
            California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source      1..800
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS         1..405
                        /note="6Ckine; CC chemokine"
                        /codon_start=1
                        /product="beta chemokine"
                        /db_xref="PID:g2624925"

```

```

/translation="MAQSLALSLLILVLAFGIPRTQGS DGAQDCCLKYSQRKIPAKV

```

```

VRSYRKQEPSLGC SIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
CRKDRGASKTGKKGKSGKCKRTERSQTPKGP"

```

```

BASE COUNT      203 a      248 c      210 g      139 t

```

ORIGIN

```

1 atggctcagt cactggctct gagectcctt atcctgggtc tggcctttgg aatccccagg
61 acccaaggca gtgatggagg ggctcaggac tgttgctca agtacagcca aaggaagatt
121 cccgccagg ttgtccgcag ctaccggaag caggaaccaa gcttaggctg ctccatccca
181 gctatcctgt tcttgccccg caagcgctct caggcagagc tatgtgcaga ccaaaggag
241 ctctgggtgc agcagctgat gcagcatctg gacaagacac catccccaca gaaaccagcc
301 cagggctgca ggaaggacag gggggcctcc aagactggca agaaaggaaa gggctccaaa
361 ggctgcaaga ggactgagcg gtcacagacc cctaaagggc catagcccag tgagcagcct
421 ggagccctgg agacccacc agcttcacca gcgcttgaag cctgaaccca agatgcaaga
481 aggaggctat gctcaggggc cctggagcag ccaccccatg ctggccttgc cacactcttt
541 ctcttgcttt aaccacccca tctgcattcc cagctctacc ctgcatggct gagctgcccc
601 cagcaggcca ggtccagaga gaccgaggag ggagagtctc ccaggaggca tgagaggagg
661 cagcaggact gtcccttga aggagaatca tcaggacctt ggacctgata cggctcccca
721 gtacacccca cctcttctt gtaaatatga tttataccta actgaataaa aagctgttct
781 gtcttcccac ccaaaaaaaaa

```

//

```

LOCUS      HSU64197      821 bp      mRNA      PRI      25-JUN-1997
DEFINITION Homo sapiens chemokine exodus-1 mRNA, complete cds.
ACCESSION  U64197
NID        g1778716
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

```


Hominidae; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Homo.
 REFERENCE 1 (bases 1 to 821)
 AUTHORS Hromas, R., Gray, P.W., Chantry, D., Godiska, R., Krathwohl, M.,
 Fife, K., Bell, G.I., Takeda, J., Aronica, S., Gordon, M.,
 Cooper, S., Broxmeyer, H.E. and Klemsz, M.J.
 TITLE Cloning and characterization of exodus, a novel beta-chemokine
 JOURNAL Blood 89 (9), 3315-3322 (1997)
 MEDLINE 97275143
 REFERENCE 2 (bases 1 to 821)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (17-JUL-1996) Indiana University Medical Center,
 Medicine, 975 W. Walnut St., Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..821
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="Exodus-1"
 /cell_type="islet"
 /tissue_type="pancreas"
 /dev_stage="adult"
 CDS 43..330
 /function="inhibits proliferation of hematopoietic
 progenitors and HIV"
 /codon_start=1
 /product="chemokine exodus-1"
 /db_xref="PID:g1778717"
 /translation="MCCTKSLLLAALMSVLLHLGGESEASNFDCCLGYTDRILHPKF
 IVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
 variation 121^122
 /note="insertion of an extra codon GCA at nt 121,
 encoding for an alanine after the alanine at amino acid
 position 26, represents the allelic difference of the
 transcript isolated from macrophages"
 BASE COUNT 258 a 134 c 156 g 273 t
 ORIGIN
 1 ggtactcaac actgagcaga tctgttcttt gagctaaaaa ccatgtgctg taccaagagt
 61 ttgctcctgg ctgctttgat gtcagtgtctg ctactccacc tctgcggcga atcagaagca
 121 agcaactttg actgctgtct tggatacaca gaccgtattc ttcatcctaa atttattgtg
 181 ggcttcacac ggcagctggc caatgaaggc tgtgacatca atgctatcat ctttcacaca
 241 aagaaaaagt tgtctgtgtg cgcaaatcca aaacagactt gggtgaaata tattgtgcgt
 301 ctctcagta aaaaagtcaa gaacatgtaa aaactgtggc tttctggaa tgggaattgga
 361 catagcccaa gaacagaaag aacctgtctg gggttggagg tttcacttgc acatcatgga
 421 gggtttagtg cttatctaatt ttgtgcctca cctggacttg tccaattaat gaagttgatt
 481 catattgcat catagtttgc tttgtttaag catcacatta aagtgaaact gtattttatg
 541 ttatttatag ctgtaggttt tctgtgttta gctatttaatt actaattttc cataagctat
 601 tttgggttag tgcaaaagtat aaaattatat ttggggggga ataagattat atggactttc
 661 ttgcaagcaa caagctattt tttaaaaaaa actattttaac attcttttgt ttatattgtt
 721 ttgtctccta aattgttgta atgtcattat aaaataagaa aaatattaat aagacaaata
 781 ttgaaaataa agaaacaaaa agtgcttctg ttaaaaaaaa a
 //

LOCUS HSU88320 828 bp mRNA PRI 18-DEC-1997
 DEFINITION Human beta chemokine Exodus-2 mRNA, complete cds.
 ACCESSION U88320
 NID g2196919
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 828)
 AUTHORS Hromas, R., Kim, C.H., Klemsz, M., Krathwohl, M., Fife, K.,
 Cooper, S.,

Schnizlein-Bick, C. and Broxmeyer, H.E.
 TITLE Isolation and characterization of Exodus-2, a novel C-C
 chemokine with a unique 37-amino acid carboxyl-terminal extension
 JOURNAL J. Immunol. 159 (6), 2554-2558 (1997)
 MEDLINE 97444139
 REFERENCE 2 (bases 1 to 828)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..828
 /organism="Homo sapiens"
 /note="PCR amplified from activated THP-1 cells"
 /db_xref="taxon:9606"
 /clone_lib="Soares human placenta cDNA"
 /cell_line="THP-1"
 /cell_type="monoblast"
 CDS 15..419
 /codon_start=1
 /product="beta chemokine Exodus-2"
 /db_xref="PID:g2196920"

/translation="MAQSLALSLLILVLAFGIPRTQGSDDGAQDCLKYSQRKIPAKV

VRSYRKQEPSLGC SIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
 CRKDRGASKTGKKGKSGCKRTERSQTTPKGP"

BASE COUNT 218 a 255 c 216 g 139 t
 ORIGIN

```

1 ggcacgagggc agacatggct cagtcactgg ctctgagcct ccttatcctg gttctggcct
61 ttggcatccc caggacccaa ggcagtgatg gaggggctca ggactgttgc ctcaagtaca
121 gccaaaggaa gattcccgcc aagggtgtcc gcagctaccg gaagcaggaa ccaagcttag
181 gctgtcccat cccagctatc ctgttcttgc cccgcaagcg ctctcaggca gagctatgtg
241 cagacccaaa ggagctctgg gtgcagcagc tgatgcagca tctggacaag acaccatccc
301 cacagaaacc agcccagggc tgcaggaagg acaggggggc ctccaagact ggcaagaaag
361 gaaaggggctc caaaggctgc aagaggactg agcggtcaca gaccctctaa gggccatagc
421 ccagtggagca gcctggagcc ctggagaccc caccagcctc accagcgctt gaagcctgaa
481 cccaagatgc aagaaggagg ctatgtctag gggccctgga gcagccacc catgctggcc
541 ttgccacact ctttctcctg ctttaaccac cccatctgca ttcccagctc tcaccctgca
601 tggctgagtc tgcccacagc agggcaggtc cagagagacc gaggagggag agtctcccag
661 ggagcatgag aggaggcagc aggactgtcc ccttgaagga gaatcatcag gaccctggac
721 ctgatacggc tccccagtac accccacctc ttccttgtaa atatgattta tacctaactg
781 aataaaaaagc tgttctgtct tcccacccaa aaaaaaaaaa aaaaaaaaaa

```

//
 LOCUS HSU88321 502 bp mRNA PRI 22-JUN-1998
 DEFINITION Human beta chemokine Exodus-3 mRNA, complete cds.
 ACCESSION U88321
 NID g2196921
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 502)
 AUTHORS Hromas, R.A., Gray, P., Klemsz, M., Fife, K. and Broxmeyer, H.
 TITLE DCCL chemokines represent a novel beta chemokine subfamily
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REFERENCE 3 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (22-JUN-1998) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REMARK Amino acid sequence updated by submitter
 FEATURES Location/Qualifiers
 source 1..502

CDS

/organism="Homo sapiens"
 /note="PCR amplified from THP-1 cells"
 /db_xref="taxon:9606"
 /cell_line="THP-1"
 /cell_type="monoblast"
 /dev_stage="adult"
 120..416
 /note="Mip-3alpha/ELC/CKbeta11"
 /codon_start=1
 /product="beta chemokine Exodus-3"
 /db_xref="PID:g3243080"

/translation="MALLLALSLVLWLTSPAPTLSGTND AEDCLS VTQKPIPGYIVR

NFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"

BASE COUNT 113 a 170 c 121 g 98 t

ORIGIN

```

1  ctcacacctt gcatttcacc cctgcatccc atgcgccctg cagcctcaca cagatcctgc
61 acacacccag acagctggcg ctcacacatt caccgttggc ctgcctctgt tcaccctcca
121 tggccctgct actggccctc agcctgctgg ttctctggac ttccccagcc ccaactctga
181 gtggcaccaa tgatgctgaa gactgctgcc tgtctgtgac ccagaaaccc atccctgggt
241 acatcgtgag gaacttcacc taccttctca tcaaggatgg ctgcagggtg cctgctgtag
301 tgttcaccac actgaggggc cgccagctct gtgcaccccc agaccagccc tgggtagaac
361 gcatcatcca gagactgcag aggacctcag ccaagatgaa gcgccgcagc agttaaccta
421 tgaccgtgca gagggagccc cgagtcagag tcaagcattg tgaattatta ctaactggga
481 acgaggacag aaggaaggac ag

```

//

LOCUS HSU86358 879 bp mRNA PRI 11-SEP-1997
 DEFINITION Human chemokine (TECK) mRNA, complete cds.
 ACCESSION U86358
 NID g2388626
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 879)
 AUTHORS Vicari,A.P., Figueroa,D.J., Hedrick,J.A., Foster,J.S.,
 Singh,K.P., Menon,S., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., Bacon,K.B.
 and Zlotnik,A.
 TITLE TECK: a novel cc chemokine specifically expressed by thymic
 dendritic cells and potentially involved in T cell development
 JOURNAL Immunology 7, 291-301 (1997)
 REFERENCE 2 (bases 1 to 879)
 AUTHORS Vicari,A.P. and Zlotnik,A.
 TITLE Direct Submission
 JOURNAL Submitted (21-JAN-1997) Immunology, DNAX Research Institute,
 901

California Ave., Palo Alto, CA 94304, USA

FEATURES Location/Qualifiers
 source 1..879
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="4"
 /tissue_type="thymus"
 gene 1..879
 /gene="TECK"
 CDS 1..453
 /gene="TECK"
 /codon_start=1
 /product="chemokine"
 /db_xref="PID:g2388627"

/translation="MNLWLLACLVLGAWAPAVHTQGVFEDCLAYHYPIGWAVLR

RAWTYRIQEVSGSCNLPAAIFYLPKRHRKVCNPKSREVQRAMKLLDARNKVFAPLHH
 NMQTFQAGPHAVKLLSSGNSKLSSSKFSNPISSSKRNVSLLISANSGL"
 BASE COUNT 191 a 264 c 218 g 206 t

ORIGIN

```

1 atgaacctgt ggctcctggc ctgcctggtg gccggcttcc tgggagcctg ggcccccgct
61 gtccacaccc aaggtgtctt tgaggactgc tgcctggcct accactaccc cattgggtgg
121 gctgtgctcc ggcgcgctg gacttaccgg atccaggagg tgagcgggag ctgcaatctg
181 cctgctgcga tattctacct cccaagaga cacaggaagg tgtgtgggaa ccccaaaagc
241 agggaggtgc agagagccat gaagctcctg gatgctcgaa ataaggtttt tgcaaagctc
301 caccacaaca tgcagacctt ccaagcaggc cctcatgctg taaagaagtt gagttctgga
361 aactccaagt tatcatcatc caagtttagc aatcccatca gcagcagcaa gaggaatgtc
421 tccctcctga tatcagctaa ttcaggactg tgagccggct catttctggg ctccatcggc
481 acaggagggg ccggtatctt ctccgataaa accgtcgccc tacagaccca gctgtcccca
541 cgctctgtgc ttttgggtca agtcttaatc cctgcacctg agttggctct cctctgcac
601 ccccaccacc tccgtcccgt ctggcaactg gaaagaagga gttggcctga ttttaacctt
661 ttgccgctcc ggggaacagc acaatcctgg gcagccagt gctctttagt agaaaactta
721 ggataacctc ctcaactttt gtttcttgcc gtccaccccg ggccatgcca gtgtgtctc
781 tgggtccctt ccaaaaatct ggtcattcaa ggatccctc ccaaggctat gcttttctat
841 aacttttaaa taaaccttgg ggggtgaatg gaataaaaa

```

//

```

LOCUS      AB002409      852 bp      mRNA      PRI      15-AUG-1997
DEFINITION Homo sapiens mRNA for SLC, complete cds.
ACCESSION  AB002409
NID        g2335034
KEYWORDS   SLC; mature ELC.
SOURCE      Homo sapiens cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (bases 1 to 852)
AUTHORS    Nomiya, H.
TITLE       Direct Submission
JOURNAL     Submitted (28-MAR-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiya, Kumamoto University Medical School,
            Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE  2 (bases 1 to 852)
AUTHORS    Nagira, M., Imai, T., Hieshima, K., Kusuda, J., Ridanpaa, M.,
            Takagi, S., Nishimura, M., Kakizaki, M., Nomiya, H. and Yoshie, O.
TITLE       Molecular Cloning of a Novel Human CC Chemokine Secondary
            Lymphoid-Tissue Chemokine (SLC) That is an Efficient
            Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13
JOURNAL     Unpublished (1997)
FEATURES    Location/Qualifiers
            source      1..852
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS          59..463
                        /codon_start=1
                        /product="SLC"
                        /db_xref="PID:d1022673"
                        /db_xref="PID:g2335035"

/translation="MAQSLALSLLILVLAFGIPRTQGS DGAQDCCLKYSQRKIPAKV
VRSYRKQEPSLGC SIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
CRKDRGASKTGKKKGSKGCKRTSQT PKGP"
            mat_peptide  <107..460
                        /product="mature ELC"
            polyA_site    823..828
BASE COUNT  205 a      279 c      217 g      151 t
ORIGIN
1 cttgcagctg cccacctcac cctcagctct ggctcttac tcacctcta ccacagacat
61 ggctcagtc ctggctctga gcctccttat cctggttctg gcctttggca tccccaggac
121 ccaaggcagt gatggagggg ctccaggactg ttgcctcaag tacagccaaa ggaagattcc
181 cgccaagggt gtccgcagct accggaagca ggaaccaagc ttaggctgct ccatcccagc
241 tatcctgttc ttgccccgca agcgctctca ggcagagcta tgtgcagacc caaaggagct
301 ctgggtgcag cagctgatgc agcatctgga caagacacca tccccacaga aaccagccca

```

```

361 gggctgcagg aaggacaggg gggcctccaa gactggcaag aaaggaaagg gctccaaagg
421 ctgcaagagg actgagcggg cacagacccc taaagggcc tagccagtg agcagcctgg
481 agccctggag accccaccag cctcaccaac gcttgaagcc tgaacccaag atgcaagaag
541 gaggtatgc tcagggggccc tggagcagcc acccatgct ggccttgcca cactctttct
601 cctgctttta ccaccccatc tgcattccca gctctaccct gcatggctga gctgccaca
661 gcaggccagg tccagagaga ccgaggaggg agagtctccc agggagcatg agaggaggca
721 gcaggactgt ccccttgaag gagaatcatc aggaccctgg acctgatacg gctcccagct
781 acacccacc tcttcctgt aaatatgatt tatacctaac tgaataaaaa gctgttctgt
841 cttcccacc gc

```

//

```

LOCUS      AF055467      1481 bp      mRNA      PRI      06-AUG-1998
DEFINITION Homo sapiens monotactin-1 mRNA, complete cds.
ACCESSION  AF055467
NID        g3395775
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1481)
AUTHORS    Youn,B.S., Zhang,S., Broxmeyer,H.E., Antol,K., Fraser,M.J. Jr.,
            Hangoc,G. and Kwon,B.S.
TITLE      Isolation and characterization of LMC, a novel lymphocyte and
            monocyte chemoattractant human CC chemokine, with
myelosuppressive
            activity
JOURNAL     Biochem. Biophys. Res. Commun. 247 (2), 217-222 (1998)
MEDLINE     98308096
REFERENCE  2 (bases 1 to 1481)
AUTHORS     Youn,B.S. and Kwon,B.S.
TITLE      Direct Submission
JOURNAL     Submitted (24-MAR-1998) Microbiology and Immunology, Indiana
            University, School of Medicine, 605 Barnhill Dr. Medical
Science     Bldg., Indianapolis, IN 46202, USA
FEATURES    Location/Qualifiers
            source      1..1481
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
            5'UTR      1..34
            CDS        35..397
                        /note="Mtn-1; LMC; lymphocyte and monocyte
chemoattractant
                        CC chemokine"
                        /codon_start=1
                        /product="monotactin-1"
                        /db_xref="PID:g3395776"

```

/translation="MKVSEAALSLLVLIILITSASRSQPKVPEWVNTPTCCLKYEK

VLPRRLVVGGRKALNCHLPAIIFVTKRNREVCTNPNDWVQEIYKDPNLPPLPTRNLS
TVKIITAKNGQPQLNSQ"

3'UTR 398..1481
BASE COUNT 412 a 362 c 302 g 405 t
ORIGIN

```

1 gcacgagctg aagctgtact gcctcgctga gaggatgaag gtctccgagg ctgccctgtc
61 tctccttgct ctcctcctta tcattacttc ggcttctcgc agccagccaa aagttcctga
121 gtgggtgaac accccatcca cctgctgctt gaagtattat gagaaagtgt tgccaaggag
181 actagtggtg ggatacagaa aggcctccaa ctgtcacctg ccagcaatca tcttcgtcac
241 caagaggaac cgagaagtct gcaccaaccc caatgacgac tgggtccaa agtacatcaa
301 ggatcccaac ctaccttgc tgctaccag gaacttgctc acggttaaaa ttattacagc
361 aaagaatggt caacccagc tctcaactc ccagtgtatga ccaagcttta gtggaagccc
421 ttgtttacag aagagagggg taaactatga aaacagggga agccttatta ggctgaaact
481 agccagtcac attgagagaa gcagaacaat gatcaaaata aaggagaagt atttgaata
541 ttttctcaat cttaggagga aataccaaag ttaagggacg tgggcagagg tacgctcttt
601 tattttata tttatatatt tttttttt agatagggtc ttactctgtc acccaggctg
661 gagtgcagtg gtgtgatctt ggctcacttg atcttggtc actgtaacct ccacctccca
721 ggctcaagtg atcctccac cccacctcc cgagtagctg ggactacagg cttgcgccac
781 cacactggc taatttttgt atttttggt gagacgggat tctaccatgt tgccaggct

```

```

841 ggtctcaaac tcgtgtgccc aagcaatcca cctgcctcag ccttccaaaa gtgctgggct
901 tacaggcgtg agccaccaca tccggccagt ccactcttaa tacacagaaa aatataattc
961 acatccttct cctgctctct ttcaattcct cacttcacac cagtacacaa gccattctaa
1021 atacttagcc agtttccagc ctccagatg atctttgccc tctgggtctt gacccattaa
1081 gagccccata gaactcttga tttttcctgt ccacttttat gggatttttc tggatctata
1141 ttttcttcaa ttattctttc attttataat gcaacttttt cataggaagt ccggtaggga
1201 atattcacat taatcatttt tgcagagact ttgctagatc ctctcatatt ttgtcttctt
1261 cagggtggca ggggtacaga agtgcctgat tggttttttt tttttttgag agagagagag
1321 aagaagaaga agaagagaca caaatctcta cctcccatgt taagctttgc aggacaggga
1381 aagaaagggt atgagacacg gctagggtaa actcttagtc caaaacccaa gcatgcaata
1441 aataaaactc cttatttga caaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      HSRNAATAC      557 bp      RNA      PRI      06-JUL-1995
DEFINITION H.sapiens mRNA for ATAC protein.
ACCESSION  X86474
NID        g895846
KEYWORDS   ATAC gene.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 557)
AUTHORS    Muller, S., Dorner, B., Korthauer, U., Mages, H.W., D'Apuzzo, M.,
            Senger, G. and Krocze, R.A.
TITLE      Cloning of ATAC, an activation-induced, chemokine-related
molecule  exclusively expressed in CD8+ T lymphocytes
JOURNAL     Eur. J. Immunol. 25 (6), 1744-1748 (1995)
MEDLINE     95339892
REFERENCE  2 (bases 1 to 557)
AUTHORS     Krocze, R.A.
TITLE      Direct Submission
JOURNAL     Submitted (20-APR-1995) R.A. Krocze, Molecular Immunology,
            Robert-Koch-Institute, Nordufer 20, 13353 Berlin, FRG
FEATURES   Location/Qualifiers
            source      1..557
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /tissue_type="peripheral blood"
                        /cell_type="lymphocyte"
                        /chromosome="1"
                        /map="q23"
            gene        25..369
                        /gene="ATAC"
            CDS          25..369
                        /gene="ATAC"
                        /codon_start=1
                        /product="CD8+T cell specific protein"
                        /db_xref="PID:g895847"
                        /db_xref="SWISS-PROT:P47992"

```

/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR

IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMRKSNTNRNMIIQTKPTGT

```

polyA_signal 469..474
polyA_signal 534..539
BASE COUNT   157 a    139 c    112 g    149 t
ORIGIN

```

```

1 gcacagctca gcaggacctc agccatgaga cttctcatcc tggccctcct tggcatctgc
61 tctctcactg catacattgt ggaagggtga gggagtgaag tctcagataa gaggacctgt
121 gtgagcctca ctaccagcgc actgccggtt agcagaatca agacctacac catcacggaa
181 ggctccttga gagcagtaat ttttattacc aaacgtggcc taaaagtctg tgctgatcca
241 caagccacat ggggtgagaga cgtggctcagg agcatggaca ggaatccaa caccagaaat
301 aacatgatcc agaccaagcc aacaggaacc cagcaatcga ccaatacagc tgtgactctg
361 actggctagt agtctctggc accctgtccg tctccagcca gccagctcat ttacttttac
421 acgctcatgg actgagttta tactcgctt ttatgaaagc actgcatgaa taaaattatt
481 cctttgtatt tttactttta aatgtcttct gtattcactt atatgttcta attaataaat
541 tatttattat taagaat

```

//

LOCUS HSU85767 563 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA,
 complete
 cds.
 ACCESSION U85767
 NID g1916249
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 563)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T.,
 Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D.,
 Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-
 chemokines as inhibitors of two distinct classes of myeloid
 progenitors
 JOURNAL J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 563)
 AUTHORS Li,H. and Patel,V.P.
 TITLE Direct Submission
 JOURNAL: Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences,
 9410 Keywest Ave., Rockville, MD 20850, USA
 FEATURES Location/Qualifiers
 source 1..563
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 31..393
 /note="myeloid progenitor inhibitory factor-1"
 /codon_start=1
 /product="MPIF-1"
 /db_xref="PID:g1916250"

/translation="MKVSVAAALSCLMLVTALGSQARVTKDAETEFMMSKLPLENPVLL

DRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKGRRFCANPSDKQV
 QVCMRMLKLDTRIKTRKN"

BASE COUNT 164 a 143 c 117 g 139 t

ORIGIN
 1 ctcagccagc cctgcctgcc caccaggagg atgaaggtct ccgtggctgc cctctcctgc
 61 ctcagccttg ttactgccct tggatcccag gcccggttca caaaagatgc agagacagag
 121 ttcagtgatg caaagcttcc attggaaaat ccagtacttc tggacagatt ccatgctact
 181 agtgctgact gctgcatttc ctacacccca cgaagcatcc cgtgttccact cctggagagt
 241 tactttgaaa cgaacagcga gtgctccaag ccgggtgtca tcttcctcac caagaagggg
 301 cgacgtttct gtgccaaacc cagtataag caagttcagg ttgcatgag aatgctgaag
 361 ctggacacac ggatcaagac caggaagaat tgaactgtc aaggtgaagg gacacaagtt
 421 gccagccacc aactttcttg cctcaactac cttcctgaat tattttttta agaagcattt
 481 attcttgtgt tctggattta gagcaattca tctaataaac agtttctcac ttttaaaaaa
 541 aaaaaaaaaa aaaaaaaaaa aaa

//

LOCUS HSU85768 360 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA,
 complete
 cds.
 ACCESSION U85768
 NID g1916251
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 360)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T.,
 Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D.,
 Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-

C

chemokines as inhibitors of two distinct classes of myeloid progenitors

J. Exp. Med. (1997) In press

JOURNAL REFERENCE 2 (bases 1 to 360)

AUTHORS Li, H. and Patel, V.P.

TITLE Direct Submission

JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410

Keywest Ave., Rockville, MD 20850, USA

FEATURES Location/Qualifiers

source 1..360

/organism="Homo sapiens"

/db_xref="taxon:9606"

CDS 1..360

/note="myeloid progenitor inhibitory factor-2"

/codon_start=1

/product="MPIF-2"

/db_xref="PID:g1916252"

/translation="MAGLMTIVTSLFLGVCAHHIIPGSGVIVIPSPCCMFFVSKRIPE

NRVVSQYLSSRSTCLKGGVIFTTKKQQQFCGDPKQEWVQRYMKNLDAKQKKASPRARA

VAVKGPVQRYPGNQTTTC"

BASE COUNT 85 a 106 c 96 g 73 t

ORIGIN

1 atggcaggcc tgatgacat agtaaccagc cttctgttcc ttggtgtctg tgcccaccac

61 atcatcccta cgggctctgt ggatcatacc cttccctgct gcatgttctt tgtttccaag

121 agaattcctg agaaccgagt ggatcagctac cagctgtcca gcaggagcac atgcctcaag

181 ggaggagtga tcttcaccac caagaagggc cagcagttct gtggcgaccc caagcaggag

241 tgggtccaga ggtacatgaa gaacctggac gccaagcaga agaaggcttc ccctagggcc

301 agggcagtg ctgtcaagg ccctgtccag agatattcct gcaaccaaac cacctgctaa

//

LOCUS HUMSDF1A 1847 bp mRNA PRI 26-DEC-1996

DEFINITION Human pre-B cell stimulating factor homologue (SDF1a) mRNA, complete cds.

ACCESSION L36034

NID g1220363

KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating factor

homologue; alpha-chemokine.

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1847)

AUTHORS Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H., Shinohara, T. and Honjo, T.

TITLE Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene

JOURNAL Genomics 28 (3), 495-500 (1995)

MEDLINE 96039262

FEATURES Location/Qualifiers

source 1..1847

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="h5"

/cell_line="FLEB14-14"

sig_peptide 80..142

/gene="SDF1a"

CDS 80..349

/codon_start=1

/product="pre-B cell stimulating factor homologue"

/db_xref="PID:g1220364"

/translation="MNAKVVVVLVLVTALCLSDGKPVSLSYRCPCRFFESHVARANV

KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK"

gene 80..346

/gene="SDF1a"

mat_peptide 143..346

/gene="SDF1a"
 /product="pre-B cell stimulating factor homologue"

BASE COUNT	459 a	471 c	417 g	500 t
ORIGIN	1	61	121	181
	241	301	361	421
	481	541	601	661
	721	781	841	901
	961	1021	1081	1141
	1201	1261	1321	1381
	1441	1501	1561	1621
	1681	1741	1801	

//

LOCUS HUMSDF1B 3524 bp mRNA PRI 26-DEC-1996
 DEFINITION Human pre-B cell stimulating factor homologue (SDF1b) mRNA,
 complete cds.
 ACCESSION L36033
 NID gl220365
 KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating
 factor
 SOURCE homologue; alpha-chemokine.
 ORGANISM human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 3524)
 AUTHORS Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H.,
 Shinohara, T. and Honjo, T.
 TITLE Structure and chromosomal localization of the human stromal
 cell-derived factor 1 (SDF1) gene
 JOURNAL Genomics 28 (3), 495-500 (1995)
 MEDLINE 96039262
 FEATURES
 source Location/Qualifiers
 1..3524
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="h17"
 /cell_line="FLEB14-14"
 sig_peptide 80..142
 /gene="SDF1b"
 CDS 80..361
 /codon_start=1
 /product="pre-B cell stimulating factor homologue"
 /db_xref="PID:gl220366"
 /translation="MNAKVVVVLVLTLALCLSDGKPVLSYRCPFRFFESHVARANV
 KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIEYLEKALNKRFKM"

gene 80..358
 /gene="SDF1b"
 mat_peptide 143..358
 /gene="SDF1b"
 /product="pre-B cell stimulating factor homologue"

BASE COUNT	903 a	886 c	793 g	942 t			
ORIGIN	1	tctccgtcag	ccgcattgcc	cgctcggcgt	ccggcccccg	accctgtgtc	gtccgccccg
	61	ccgccccgcc	gccccgcgcca	tgaacgccaa	ggctcgtggtc	gtgctgggtcc	tcgtgctgac
	121	cgcgctctgc	ctcagcgacg	ggaagcccg	cagcctgagc	tacagatgcc	catgccgatt
	181	cttcgaaagc	catgttgcca	gagccaacgt	caagcatctc	aaaattctca	acactccaaa
	241	ctgtgccctt	cagattgtag	ccgggctgaa	gaacaacaac	agacaagtgt	gcattgaccc
	301	gaagctaaag	tggattcagg	agtacctgga	gaaagcttta	aacaagaggt	tcaagatgtg
	361	agaggggtcag	acgctgagg	aacctttaca	gtaggagccc	agctctgaaa	ccagtgttag
	421	ggaagggcct	gccacagcct	cccctgccag	ggcagggccc	caggcattgc	caagggtttt
	481	gttttgacaa	ctttgccata	ttttaccat	ttgattatgt	agcaaaatac	atgacattta
	541	tttttcattt	agtttgatta	ttcagtgatc	ctggcgacac	gtagcagctt	agactaaggc
	601	ctattattgta	cttgcccttat	tagagtgtct	ttccacggag	ccactcctct	gactcagggc
	661	tcctgggttt	tgtattctct	gagctgtgca	gggtggggaga	ctgggctgag	ggagcctggc
	721	cccatgggtca	gccctagggg	ggagagccac	caagagggac	gcctgggggt	gccaggacca
	781	gtcaacctgg	gcaaagccta	gtgaaggctt	ctctctgtgg	gatgggatgg	tggagggcca
	841	catggggagg	tcacccctt	ctccatccac	atgggagccg	ggtctgcctc	ttctggggagg
	901	gcagcagggc	taccctgagc	tgaggcagca	gtgtgaggcc	agggcagagt	gagaccagc
	961	cctcatcccg	agcacctcca	cactctccac	gttctgtcca	tcattctctg	tctcatccat
	1021	catcatgtgt	gtccacgact	gtctccatgg	ccccgcaaaa	ggactctcag	gaccaaagct
	1081	ttcatgtaaa	ctgtgcacca	agcaggaat	gaaaatgtct	tgtgttacct	gaaaacactg
	1141	tgcacatctg	tgtcttgtgt	ggaatattgt	ccattgtcca	atcctatggt	tttgttcaaa
	1201	gccagcgctc	tcctctgtga	ccaatgtctt	gatgcatgca	ctgttcccc	tgtgcagccg
	1261	ctgagcgagg	agatgtcct	tgggcccctt	gagtgacgtc	ctgatcagag	ccgtggctct
	1321	ttgggggtgaa	ctaccttggt	tccccactg	atcacaaaaa	catgggtggg	ccatgggcag
	1381	agcccaaggg	aattcgggtgt	gcaccaggg	tgaccccgaga	ggattgtctg	cccatcagt
	1441	ctccctcaca	tgtcagtacc	ttcaaactag	ggccaagccc	agcactgctt	gaggaaaaca
	1501	agcattcaca	actgtttttt	ggttttttaa	acccagtcca	caaaaataacc	aatcctggac
	1561	atgaagattc	tttcccaatt	cacatctaac	ctcatctctt	tcaccatttg	gcaatgccat
	1621	catctcctgc	cttctctctg	ggccctctct	gctctgcgtg	tcacctgtgc	ttcgggccc
	1681	tcacacagga	catttctcta	agagaacaat	gtgctatgtg	aagagtaagt	caacctgcct
	1741	gacatttgga	gtgttccct	cccactgagg	gcagtcgata	gagctgtatt	aagccactta
	1801	aaatgttcac	ttttgacaaa	ggcaagcact	tgtgggtttt	tgttttgttt	ttcattcagt
	1861	cttacgaata	cttttgcct	ttgattaaag	actccagtta	aaaaaaaaatt	taatgaagaa
	1921	agtggaaaac	aaggaaagtca	aagcaaggaa	actatgtaac	atgtagggaag	taggaagtaa
	1981	attatagtga	tgtaatcttg	aattgttaact	gttcgtgaat	ttataaatct	gtagggtaat
	2041	tagtaacatg	tgttaagtat	tttcataagt	atttcaaat	ggagcttcat	ggcagaaggc
	2101	aaacccatca	acaaaaattg	tcccttaaac	aaaaattaaa	atcctcaate	aaactcttca
	2161	atattgaaaa	aatagagcct	gagggatctt	tactagtatt	aaagatacac	aaactcttca
	2221	aaaccttttg	aaatthaact	ctcactatac	cagtataatt	gagttttcag	tggggcagtc
	2281	attatccagg	taatccaaga	tattttaaaa	tctgtcacgt	agaacttgga	tgtacctgcc
	2341	cccaatccat	gaaccaagac	cattgaattc	ttgggtgagg	aaacaaacat	gacctaaat
	2401	cttgactaca	gtcaggaaag	gaatcatttc	tatttctcct	ccatgggaga	aaatagataa
	2461	gagtagaaac	tgccaggaaa	attatttgca	taacaattcc	tctactaaca	atcagctcct
	2521	tcctggagac	tgcccagcta	aagcaatatg	catttaaata	cagtcttcca	tttgcaagg
	2581	aaaagtctct	tgtaatccga	atctcttttt	gctttcgaac	tgctagtcaa	gtgcgtccac
	2641	gagctgttta	ctagggatcc	ctcatctgtc	ctcccgggac	ctgggtgctg	ctctacctga
	2701	cactcccttg	ggctccctgt	aacctcttca	gaggccctcg	ctgccagctc	tgtatcagga
	2761	cccagaggaa	ggggccagag	gctcgttgac	tggctgtgtg	ttgggattga	gtctgtgcca
	2821	cgtgtatgtg	ctgtgggtgtg	tccccctctg	tccaggcact	gagataaccag	cgaggaggct
	2881	ccagagggca	ctctgcttgt	tattagagat	tacctcctga	gaaaaaagct	tccgcttggg
	2941	gcagaggggc	tgaatagcag	aaggttgac	ctcccccaac	cttagatggt	ctaagtcttt
	3001	ccattggatc	tcattggacc	cttccatggt	gtgatcgtct	gactgggtgt	atcaccgtgg
	3061	gtcccttgac	tgggagttga	tcgcctttcc	caggtgctac	acctttttcc	agctggatga
	3121	gaatttgagt	gctctgatcc	ctctacagag	cttccctgac	tcattctgaa	ggagccccat
	3181	tcctgggaaa	tattccctag	aaacttccaa	atccccaaag	cagaccactg	ataaaaccat
	3241	gtagaaaatt	tgttattttg	caacctcgct	ggactctcag	tctctgagca	gtgaatgatt
	3301	cagtgttaaa	tgtgatgaat	actgtatttt	gtattgtttc	aagtgcattc	cccagataat
	3361	gtgaaaatgg	tccaggagaa	ggccaattcc	tatacgacgc	gtgcttttaa	aaataaataa
	3421	gaaacaactc	tttgagaaac	aacaatttct	actttgaagt	cataccaatg	aaaaaatgta
	3481	tatgcactta	taattttcct	aataaagttc	tgtactcaaa	tgta	

//

LOCUS HSJ002211 663 bp mRNA
 DEFINITION Homo sapiens cDNA for a CXC chemokine.
 ACCESSION AJ002211

PRI 11-MAR-1998

NID g2832410
 KEYWORDS CXC chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 663)
 AUTHORS Legler,D.F., Loetscher,M., Roos,R.S., Clark-Lewis,I.,
 Baggiolini,M.
 and Moser,B.
 TITLE B cell-attracting chemokine 1, a human CXC chemokine expressed
 in lymphoid tissues, selectively attracts B lymphocytes via
 BLR1/CXCR5
 JOURNAL J. Exp. Med. 187 (4), 655-660 (1998)
 MEDLINE 98130629
 REFERENCE 2 (bases 1 to 663)
 AUTHORS Moser,B.
 TITLE Direct Submission
 JOURNAL Submitted (05-NOV-1997) Moser B., University of Bern, Theodor
 Kocher Institute, Freiestrasse 1, CH-3012 Bern, SWITZERLAND
 FEATURES
 source 1..663
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PBL"
 sig_peptide 35..100
 /gene="BCA-1"
 CDS 35..364
 /gene="BCA-1"
 /codon_start=1
 /product="CXC chemokine"
 /db_xref="PID:e1249325"
 /db_xref="PID:g2832411"
 /translation="MKFISTSLLLMLLVSSLSPVQGVLEVYYTSLRCRCVQESSVFIP
 RRFIDRIQILPRNGCPRKEIIVWKKNSIVCVDPAEWIQRMMEVLRKRSSSTLPVP
 VFKRKIP"
 gene 35..364
 /gene="BCA-1"
 mat_peptide 101..361
 /gene="BCA-1"
 BASE COUNT 176 a 136 c 145 g 198 t 8 others
 ORIGIN
 1 cagagctcaa gtctgaactc tacctccaga cagaatgaag ttcattctcga catctctgct
 61 tctcatgctg ctgggtcagca gcctctctcc agtccaaggt gttctggagg tctattacac
 121 aagcttgagg tgtagatgtg tccaagagag ctacgtcttt atccctagac gtttcattga
 181 tcgaattcaa atcttgcccc gtgggaatgg ttgtccaaga aaagaaatca tagtctggaa
 241 gaagaacaag tcaattgtgt gtgtggaccc tcaagctgaa tggatacaaa gaatgatgga
 301 agtattgaga aaaagaagtt cttcaactct accagttcca gtgtttaaga gaaagattcc
 361 ctgatgctga tatttccact aagaacacct gcattcttcc cttatccctg ctctgggatt
 421 ttagttttgt gcttagttaa atcttttcca gggagaaaga acttccccat acaaataagg
 481 catgaggact atgtaaaaat aaccttgtag gagctggatg gggggccaaa ctcaagcttc
 541 tttcactcca caggcaccct attntacact tgggggtttt gcnttctttn tttcntcagg
 601 ggggggggaaa gtttcttttg gaaantagtt nttccagttt ttaggtatta cagggttntt
 661 ttt
 //
 LOCUS HSHUMIG 2545 bp RNA PRI 16-NOV-1993
 DEFINITION H.sapiens Humig mRNA.
 ACCESSION X72755 S60728
 NID g311375
 KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2545)
 AUTHORS Farber,J.M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School

of
 USA
 REFERENCE 2 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE HuMig: a new human member of the chemokine family of cytokines
 JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
 MEDLINE 93236577
 FEATURES
 source Location/Qualifiers
 1..2545
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /germline
 /dev_stage="child"
 /tissue_type="leukaemia"
 /cell_type="monocyte"
 /cell_line="THP-1"
 /clone_lib="THP-1/IFN-gamma cDNA"
 /clone="H-1-3"
 misc_feature 13..19
 /note="cis-acting element; putative"
 gene 40..417
 /gene="Humig"
 CDS 40..417
 /gene="Humig"
 /codon_start=1
 /db_xref="PID:g311376"
 /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNGVQTCCLNPDSADVKEIKKWEKQVSQKKKQKNG
 KKHQKKKVLKVRKSQRSRQKKT"

BASE COUNT 755 a 581 c 457 g 752 t

ORIGIN

```

1 atccaataca ggagtgactt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttctctcttg gcatcatctt gctggttctg attggagtgc aaggaacccc agtagtgaga
121 aagggtcgct gttcctgcat cagcaccaac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 agaattggag ttcaaactatg tctaaaccca gattcagcag atgtgaagga actgattaaa
301 aagtgggaga aacaggtcag ccaaaaagaaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaagtgc tgaaagtctg aaaaatctca cgttctcgtc aaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaa gcttattaat ttgactagaa aatttaaaac
541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt ctttgttctt ctaccacca ccagttgaat ttcattcatg
661 ttaaggccat gatttttagca ataccatgt ctacacagat gttcacccaa ccacatccca
721 ctcaacaacag ctgcctggaa gagcagccct aggtctccac gtactgcagc ctccagagag
781 tatctgagga acatgtcagc aagtcctaag cctgttagca tgctgggtgag ccaagcagtt
841 tgaatttgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggtatcacc
961 actggagatc accagtggtg ggctttcaga gcttctttt tggctttgga agccatgtga
1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttccccct tgcttcattc
1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt ctctctcca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc tttctcatct tgtccccaac accccacaga
1201 agtgctttct tctcccaatt catctcact cagtccagct tagttcaagt cctgectctt
1261 aaataaacct ttttggacac acaaattatc ttaaaactcc tgtttcaact gggttcagta
1321 cacatgggtg aacactcaat ggttaactaa ttcttgggtg tttatcctat ctctccaacc
1381 agattgtcag ctccctgagg gcaagagcca cagtatatct ccctgtttct tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata attttttaat tgatgttgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctggctac tccatgttgg
1561 ctagcctctg gtaacctctt acttattatc ttcaggacac tcactacagg gaccagggat
1621 gatgcaacat ccttgtcttt tcatgacagg atgtttgtc agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
1741 aaaatcatat aatcttaca tgaaggagac tttatagatc agccagtgc caaccttttc
1801 ccaaccatcc aaaaattcct tttccggaag gaaaagggtt ttctcaataa gcctcagctt
1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg
1921 agttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
1981 tctcccatga agaaagggaa cgggtgaagta ctaagcgcta gaggaagcag ccaagtcggg
2041 tagtggaagc atgattggtg cccagttagc ctctgcagga tgtggaacc tcctccagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaattttaa cctatactca
```

```

2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgtgtt cgggtggaga
2221 tcccaccga acgtcttctc taatcatgaa actccctagt tcttctcatgt aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgacct acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca caggttataa
2401 tcattttatca tatatataca tacatgcata cactctcaaa gcaataaatt tttcacttca
2461 aaacagtatt gacttgtata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

LOCUS HSHUMIG 2545 bp RNA PRI 16-NOV-1993
 DEFINITION H.sapiens Humig mRNA.
 ACCESSION X72755 S60728
 NID g311375
 KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
 of Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
 USA
 REFERENCE 2 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE HuMig: a new human member of the chemokine family of cytokines
 JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
 MEDLINE 93236577
 FEATURES
 source Location/Qualifiers
 1..2545
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /germline
 /dev_stage="child"
 /tissue_type="leukaemia"
 /cell_type="monocyte"
 /cell_line="THP-1"
 /clone_lib="THP-1/IFN-gamma cDNA"
 /clone="H-1-3"
 misc_feature 13..19
 /note="cis-acting element; putative"
 gene 40..417
 /gene="Humig"
 CDS 40..417
 /gene="Humig"
 /codon_start=1
 /db_xref="PID:g311376"
 /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTTPVVRKGRCSISTNQGTIHLQ
 SLKDLKQFAPSPSCEKIEIIATLKNQVQTCLNPDADVKELIKKWEKQVSQKKKQKNG
 KKHQKKKVLKVRKSQRSRQKKTT"
 BASE COUNT 755 a 581 c 457 g 752 t
 ORIGIN

```

1 atccaatata ggagtgactt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttcctcttgg gcatcatctt gctggttctg attggagtgc aaggaacccc agtagtgaga
121 aagggtcgct gttcctgcat cagcaccacac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaacatg tctaaaccga gattcagcag atgtgaagga actgattaaa
301 aagtgggaga aacagggtcag ccaaaagaaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaaagttc tgaaagttcg aaaatctcaa cgttctcgtc aaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaaag gcttattaat ttgactagaa aatttataaac
541 attactctga aattgttaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt ctttgttctt ctaccaccca ccagttgaat ttcacatgc
661 ttaaggccat gatttttagca ataccatgt ctacacagat gttcaccaca ccacatccca
721 ctacacaacag ctgcctggaa gagcagccct aggcctccac gtactgcagc ctccagagag
781 tatctgaggc acatgtcagc aagtcctaag cctgttagca tgctgggtgag ccaagcagtt

```

```

841 tgaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggatcacc
961 actggagatc accagtggtg ggctttcaga gcttccttcc tggttttga agcatgtga
1021 ttccatcttg cccgctcagg ctgaccactt ttttctttt tgttccctt tgcttcattc
1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt cttctctcca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc tttctcatct tgtcccaac accccacaga
1201 agtgctttct tctcccaatt cactctcact cagtccagct tagttcaagt cctgcctctt
1261 aaataaacct ttttgacac acaaattatc ttaaaactcc tgtttcactt ggttcagtac
1321 cacatgggtg aacactcaat ggtaactaa ttcttgggtg tttatcctat ctctccaacc
1381 agattgtcag ctcttgagg gcaagagcca cagtatatct ccctgtttct tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata atttttaaat tgatgttgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctggctac tccatgttgg
1561 ctagcctctg gtaacctctt acttattatc ttcaggacac tcaactacag gaccagggat
1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgtct agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
1741 aaaatcatat aatcttaca tgaaaaggac tttatagatc agccagtgc caaccttttc
1801 ccaaccatac aaaaattcct tttccgaag gaaaagggtt ttctcaataa gcctcagctt
1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg
1921 agttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
1981 tctcccatga agaaaggaa cggtagagta ctaagcgcta gaggaagcag ccaagtcggt
2041 tagtggaagc atgattgtgt cccagtttagc ctctgcagga tgtggaaacc tccttccagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctatactca
2161 ctttcccaa ttgaatcact gctcacactg ctgatgattt agagtgtctg ccggtggaga
2221 tcccaccga acgtcttctc taatcatgaa actccctagt tccttcatgt aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgacct acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca caggtataa
2401 tcatattatca tatatatata tacatgcata cactctcaaa gcaataaatt tttcacttca
2461 aaacagtatt gacttgtata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      AF002985      995 bp      mRNA      PRI      01-NOV-1997
DEFINITION Homo sapiens putative alpha chemokine (H174) mRNA, complete
cds.
ACCESSION  AF002985
NID        g2580585
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D., Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
            A genetic selection for isolating cDNAs encoding secreted
            proteins
            JOURNAL      Gene 198 (1-2), 289-296 (1997)
            MEDLINE      98036061
            REFERENCE    2 (bases 1 to 995)
            AUTHORS      Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D., Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
            TITLE        Direct Submission
            JOURNAL      Submitted (07-MAY-1997) Genetics Institute, 87 Cambridge Park
            Drive, Cambridge, MA 02140, USA
FEATURES
            Location/Qualifiers
            source       1..995
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="PHA and PMA activated human peripheral
            blood       mononuclear cells"
            gene        1..995
                        /gene="H174"
            CDS         88..372
                        /gene="H174"
                        /codon_start=1
                        /product="putative alpha chemokine"

```

/db_xref="PID:g2580586"

/translation="MSVKGMALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"

BASE COUNT 382 a 170 c 194 g 249 t
ORIGIN
1 gaattcggcc aaagaggcct acttccaaga agagcagcaa agctgaagta gcagcaacag
61 caccagcagc aacagcaaaa aacaaacatg agtgtgaagg gcatggctat agccttggtt
121 gtgatattgt gtgtacagt tgttcaaggc ttcccatgt tcaaaagagg acgctgtctt
181 tgcataggcc ctggggtaaa agcagtgaag gtggcagata ttgagaaagc ctccataatg
241 tacccaagta acaactgtga caaaatagaa gtgattatta ccctgaaaga aaataaagga
301 caacgatgcc taaatcccaa atcgaagcaa gcaaggctta taatcaaaaa agttgaaaga
361 aagaattttt aaaaatatca aaacatatga agtcctggaa aagggcattt gaaaaacctt
421 gaacaagttt aactgtgact actgaaatga caagaattct acagtaggaa actgagactt
481 ttctatggtt ttgtgacttt caacttttgt acagtattgt gaaggatgaa aggtgggtga
541 aaggacaaa aacagaaata cagtcttcct gaatgaatga caatcagaat tccactgccc
601 aaaggagttc aacaattaaa tggatttcta ggaaaagcta ccttaagaaa ggctggttac
661 catcggagtt tacaaagtgc ttacacgttg ttacttgttg tattatacat tcatgcattt
721 ctaggctaga gaaccttcta gatttgatgc ttacaactat tctgttgta ctatgagaac
781 atttctgtct ctagaagtta tctgtctgta ttgatcttta tgctatatta ctatctgttg
841 ttacagtggg gacattgaca ttattactgg agtcaagccc ttataagtca aaagcaccta
901 tgtgtcgtaa agcattcctc aaacatttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
961 aaaaaaaaaa aaaaaaaaaa aaaaaaagcg gccgcg

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.
ACCESSION AF030514
NID g3219692
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1371)
AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T., Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E., Sahagan, B.G., and Neote, K.
TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3
JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE 98290735
REFERENCE 2 (bases 1 to 1371)
AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.
TITLE Direct Submission
JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc., Eastern Point Road, Groton, CT 06340, USA
FEATURES
source Location/Qualifiers
1..1371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/cell_type="astrocytes"
sig_peptide 70..132
CDS 70..354
/note="chemokine; I-TAC"
/codon_start=1
/product="interferon stimulated T-cell alpha chemoattractant precursor"
/db_xref="PID:g3219693"
/translation="MSVKGMALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental

/product="interferon stimulated T-cell alpha
chemoattractant"

BASE COUNT	487 a	228 c	244 g	411 t	1 others
------------	-------	-------	-------	-------	----------

ORIGIN

```

1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgtctaca
121 gttgttcaag gcttcccat gttcaaaaaga ggacgctgtc ttgcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccgaag taacaactgt
241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaaacatat gaagtccctg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aagggtgggt accatcggag ttacaaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcgaag ccttataagt caaaagcatt tatgtgtcgt aaagcattcc
901 tcaaacattt ttctatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccggtct taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatattgtg gtttactgta cttttgtttt tgatccgttt
1201 gtataaatga tagcaatc ttggacacat ttgaaataca aaatgttttt gtctacaaa
1261 gaaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaataca aaaaaaaaaa aaaaaaaaaa a

```

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998

DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.

ACCESSION AF030514

NID g3219692

KEYWORDS .

SOURCE human.

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1371)

AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T.,
Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E.,
Sahagan, B.G. and Neote, K.

TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel non-ELR CXC chemokine with potent activity on activated T cells
through selective high affinity binding to CXCR3

JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)

MEDLINE 98290735

REFERENCE 2 (bases 1 to 1371)

AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.

TITLE Direct Submission

JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern Point Road, Groton, CT 06340, USA

FEATURES

source Location/Qualifiers

1..1371

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="4"

/cell_type="astrocytes"

sig_peptide 70..132

CDS 70..354

/note="chemokine; I-TAC"

/codon_start=1

/product="interferon stimulated T-cell alpha
chemoattractant precursor"

/db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
 IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"
 mat_peptide 133..351
 /evidence=not_experimental
 /product="interferon stimulated T-cell alpha
 chemoattractant"

BASE COUNT 487 a 228 c 244 g 411 t 1 others
 ORIGIN
 1 ctcccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
 61 aaaacaaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
 121 gttgttcaag gcttccccat gttcaaaaaga ggacgctgtc ttgtcatagg ccctggggta
 181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
 241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
 301 aaatcgaaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
 361 caaaacatat gaagtcctgg aaaaggggcat ctgaaaaacc tagaacaagt ttaactgtga
 421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
 481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
 541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
 601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttacaaagt
 661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaacttc
 721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
 781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
 841 cattattact ggagtcgaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
 901 tcaaacatatt tttcatgcaa atacacaytt ctttcccaa atactcatgta gcacatcaat
 961 attgtaggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
 1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
 1081 atttcataac caaattagca gcaccggtct taatttgatg ttttcaact tttattcatt
 1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccggtt
 1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctacaaa
 1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
 1321 tgtctcttag aaaaatacat aatctaataca aaaaaaaaaa aaaaaaaaaa a

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
 DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
 precursor, mRNA, complete cds.
 ACCESSION AF030514
 NID g3219692
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1371)
 AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T.,
 Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E.,
 Sahagan, B.G.
 and Neote, K.
 TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a
 novel non-ELR CXC chemokine with potent activity on activated T cells
 through selective high affinity binding to CXCR3
 J. Exp. Med. 187 (12), 2009-2021 (1998)
 MEDLINE 98290735
 REFERENCE 2 (bases 1 to 1371)
 AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.
 TITLE Direct Submission
 JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
 Eastern Point Road, Groton, CT 06340, USA
 FEATURES Location/Qualifiers
 source 1..1371
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="4"
 /cell_type="astrocytes"
 sig_peptide 70..132
 CDS 70..354
 /note="chemokine; I-TAC"
 /codon_start=1

/product="interferon stimulated T-cell alpha
chemoattractant precursor"
/db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVGFPFMFKRGRLCIGPGVKAVKVAD
IEKASIMYPSNNCDKIEVITLKENKGQRCLNPKSKQARLIKKVERKNF"

mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"

BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN
1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttccccat gttcaaaaga ggacgctgtc tttgcatagg ccttggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccaag taacaactgt
241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg tttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttcaaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcacatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccggctc taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatatttgt gtttactgta cttttgtttt tgatccgttt
1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctaccaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaataca aaaaaaaaaa aaaaaaaaaa a

//

LOCUS HSMDNCF 1560 bp RNA PRI 31-MAR-1995
DEFINITION Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic factor).
ACCESSION Y00787
NID g34518
KEYWORDS cytokine.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1560)
AUTHORS Matsushima,K.
TITLE Direct Submission
JOURNAL Submitted (03-MAY-1988) Matsushima K., National Cancer Institute,, Bldg 560, Rm 31-19, Frederick, MD 21701
REFERENCE 2 (bases 1 to 1560)
AUTHORS Matsushima,K., Morishita,K., Yoshimura,T., Lavu,S., Kobayashi,Y., Lew,W., Appella,E., Kung,H.F., Leonard,E.J. and Oppenheim,J.J.
TITLE Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor
JOURNAL J. Exp. Med. 167 (6), 1883-1893 (1988)
MEDLINE 88258376
COMMENT for overlapping sequence see M17016 - M17017.
FEATURES
Location/Qualifiers
source 1..1560
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="monocyte"
/clone_lib="lambda gt10"
sig_peptide 102..182
/note="signal peptide (AA -27 to -1)"

```

CDS                102..401
                   /codon_start=1
                   /product="MDNCF precursor (AA -27 to 72)"
                   /db_xref="PID:g34519"
                   /db_xref="SWISS-PROT:P10145"

/translation="MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPF

HPKFIKELRVIESGPHCANTEIIVKLSGDGRELCLDPKENWVQRVVEKFLKRAENS"
mat_peptide        183..398
                   /note="mat. MDNCF (AA 1 - 72)"
BASE COUNT         526 a    247 c    281 g    506 t
ORIGIN
1   ctccataagg cacaaacttt cagagacagc agagcacaca agcttctagg acaagagcca
61  ggaagaaacc accggaagga accatctcac tgtgtgtaaa catgacttcc aagctggccg
121 tggctctctt gccagccttc ctgatttctg cagctctgtg tgaagggtgca gttttgcca
181 ggagtgtctaa agaacttaga tgctcagtgc taaagacata ctccaaacct ttccaccca
241 aatttatcaa agaactgaga gtgattgaga gtggaccaca ctgcgccaac acagaaatta
301 ttgtaaagct ttctgatgga agagagctct gtctggacct caaggaaaac tgggtgcaga
361 gggttgtgga gaagtttttg aagagggtcg agaattcata aaaaaattca ttctctgtgg
421 tatccaagaa tcagtgaaga tgccagtga aattcaagca aatctacttc aacacttcat
481 gtattgtgtg ggtctgtgtg agggttgcca gatgcaatac aagattcctg gttaaatttg
541 aatttcagta aacaatgaat agtttttcat tgtaccatga aatatccaga acatacttat
601 atgtaaagta ttattttatt gaatctacaa aaaacaacaa ataattttta aatataagga
661 ttttctaga tattgcacgg gagaatatac aaatagcaaa attgggccaa gggccaagag
721 aatatccgaa ctttaatttc aggaattgaa tgggtttgct agaattgtat atttgaagca
781 tcacataaaa atgatgggac aataaatttt gccataaagt caaatttagc tggaaatcct
841 ggattttttt ctgttaaatc tggcaaccct agtctgctag ccaggatcca caagtccttg
901 ttccactgtg ccttggtttc tcctttattt ctaagtggaa aaagtattag ccaccatctt
961 acctcacagt gatgtgtgga ggacatgtgg aagcacttta agttttttca tcataacata
1021 aattattttc aagtgttaact tattaacctt tttattattt atgtatttat ttaagcatca
1081 aatattttgt caagaatttg gaaaaataga agatgaatca ttgattgaat agttataaag
1141 atgttatagt aaatttattt tatttttagat attaaatgat gttttattag ataaatttca
1201 atcagggttt tttagattaa caaacaacaa attgggtacc cagttaaatt ttcatttcag
1261 atatacaaca aataattttt tagtataagt acattattgt ttatctgaaa ttttaattga
1321 actaacaatc ctagtttgat actcccagtc ttgtcattgc cagctgtgtt ggtagtgtctg
1381 tgttgaaata cggaaataat agttagaact attaaacag ccaaaactcc acagtcaata
1441 ttagtaattt cttgctggtt gaaacttggt tattatgtac aaatagattc ttataatatt
1501 atttaaatga ctgcattttt aaatacaagg ctttatattt ttaactttta aaaaaaccgg

```

```

//
LOCUS      HSINFGFR      1172 bp      RNA      PRI      21-MAR-1995
DEFINITION Human mRNA for gamma-interferon inducible early response gene
(with      homology to platelet proteins).
ACCESSION  X02530 M17752
NID        g33917
KEYWORDS   interferon response; signal peptide.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1172)
AUTHORS    Luster,A.D., Unkeless,J.C. and Ravetch,J.V.
TITLE      Gamma-interferon transcriptionally regulates an early-response
gene       containing homology to platelet proteins
JOURNAL    Nature 315 (6021), 672-676 (1985)
MEDLINE    85240552
REFERENCE  2 (bases 1 to 1172)
AUTHORS     Luster,A.D.
TITLE      Direct Submission
JOURNAL    Submitted (29-JUL-1986) to the EMBL/GenBank/DDBJ databases
COMMENT    Data kindly reviewed (29-JUL-1986) by Luster A.D.
FEATURES   Location/Qualifiers
            source          1..1172
                        /organism="Homo sapiens"
                        /strain="(U 937 histiocytic lymphoma cell line)"
                        /db_xref="taxon:9606"
            misc_RNA        1
                        /note="cap site"

```

sig_peptide 67..129
 /note="pot. signal peptide (aa-21 to -1)"
 CDS 67..363
 /note="early response precursor polypeptide (aa-21 to
 77)"
 /codon_start=1
 /db_xref="PID:g33918"
 /db_xref="SWISS-PROT:P02778"

/translation="MNQTAILICCLIFLTLSGIQVPLSRTVRCCTCISISNQPVNPRS

LEKLEIIPASQFCPRVEIIATMKKKGEKRCCLNPESKAIKNLLKAVSKEMSKRSP"

mat_peptide 130..360
 /note="mature early response polypeptide (aa 1-77)"
 old_sequence 1138..1141
 /note="ugaa was uga in [1]"
 /citation=[1]
 old_sequence 1146..1148
 /note="caa was ca in [1]"
 /citation=[1]
 misc_feature 1155..1160
 /note="pot. polyA signal"
 polyA_site 1172
 /note="polyA site"

BASE COUNT 384 a 231 c 208 g 349 t
 ORIGIN

```

1 gagacattcc tcaattgctt agacatattc tgagcctaca gcagaggaac ctccagtctc
61 agcaccatga atcaaaactgc gattctgatt tgctgcctta tcttctgac tctaagtggc
121 attcaaggag tacctctctc tagaaccgta cgctgtacct gcatcagcat tagtaatcaa
181 cctgtttaatc caagggtcttt agaaaaactt gaaattattc ctgcaagcca attttgtcca
241 cgtgttgaga tcattgctac aatgaaaaag aaggggtgaga agagatgtct gaatccagaa
301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctcct
361 taaaaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg
421 cctctcccat cacttcccta catggagtat atgtcaagcc ataattgttc ttagtttgca
481 gttacactaa aagtgaccca atgatggcca ccaaatcagc tgctactact cctgtaggaa
541 gggttaattgt catcatccta agctattcag taataactct accctggcac tataatgtaa
601 gctctactga ggtgctatgt tcttagtgga tgcttgacc ctgcttcaaa tatttcctc
661 acctttccca tcttccaagg gtactaagga atctttctgc tttggggttt atcagaattc
721 tcagaatctc aaataactaa aagggtatgca atcaaatctg ctttttaaaag aatgctcttt
781 acttcatgga cttccactgc cctctccca aggggcccaa attcttcag tggctacctc
841 catacaattc caaacacata cagggaaggta gaaatatctg aaaatgtatg tgtaagtatt
901 cttattttaat gaaagactgt acaaagtata agtcttagat gtatatattt cctatattgt
961 tttcagtgtg catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa
1021 ttttaaaaat acagatagat atatgctctg catgttacat aagataaatg tgctgaatgg
1081 ttttcaaata aaaatgaggt actctcctgg aaatattaag aaagactatc taaatgttga
1141 aagatcaaaa ggtaataaaa gtaattataa ct

```

//

LOCUS SYNRP4A 225 bp DNA SYN 15-JUN-1989
 DEFINITION Human recombinant platelet factor 4 (PF4) gene, complete cds.
 ACCESSION M20901
 NID g209285
 KEYWORDS platelet factor; platelet factor 4.
 SOURCE Synthetic oligonucleotide DNA, clone pIN-III-ompA-2.
 ORGANISM artificial sequence
 artificial sequence.
 REFERENCE 1 (bases 1 to 225)
 AUTHORS Barone,A.D., Ghayeb,J., Hammerling,U., Zucker,M.B. and
 Thorbecke,G.J.
 TITLE The expression in Escherichia coli of recombinant human
 platelet
 factor 4, a protein with immunoregulatory activity
 JOURNAL J. Biol. Chem. 263, 8710-8715 (1988)
 MEDLINE 88243725
 FEATURES Location/Qualifiers
 source 1..225
 /organism="artificial sequence"
 /db_xref="taxon:29278"
 CDS <1..>225
 /note="recombinant platelet factor 4"
 /codon_start=2

/transl_table=11
/db_xref="PID:g209286"

/translation="ASMEAEDGDLQCLCVKTTTSQVRPRHITSLEVIKAGPHCPTAQL
IATLKDGRKICLDLQAPLYKKIICKLLESQS"

BASE COUNT 59 a 59 c 51 g 56 t
ORIGIN HindIII site.
1 agcttctatg gaagctgaag aagacgggtga cctgcagtgc ctgtgcgtta aaactacttc
61 tcagggttcgt ccgcgtcata tcacttctct ggaagttatc aaagctggtc cgcattgccc
121 gactgctcag ctgatcgcta ctctcaaaga cggtcgtaaa atctgcctgg acctgcaggg
181 tccgctgtac aaaaaaatca tcaaaaaact gctggaatct ggatc

//

LOCUS HUMGRO 1050 bp mRNA PRI 11-JUN-1993
DEFINITION Human gro (growth regulated) gene.
ACCESSION J03561
NID g183622
KEYWORDS gro gene; tumor cell.
SOURCE Human bladder tumor cell (T24) cDNA to mRNA.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1050)
AUTHORS Anisowicz, A., Bardwell, L. and Sager, R.
TITLE Constitutive overexpression of a growth-regulated gene in
transformed Chinese hamster and human cells
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 84, 7188-7192 (1987)
MEDLINE 88041072
COMMENT Draft entry and computer-readable sequence kindly submitted by
R. Sager (20-NOV-1987).
FEATURES
source Location/Qualifiers
1..1050
/organism="Homo sapiens"
/db_xref="taxon:9606"
sig_peptide 54..140
/note="signal peptide (put.); putative"
CDS 54..377
/note="gro protein"
/codon_start=1
/db_xref="PID:g306806"

/translation="MARAALSAAPSNPRLLLRVALLLLLLVAAGRRAAGASVATELRQCQ

CLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNRKAACLNPA SPIVKKIIEKMLN

mat_peptide 141..374

/note="gro mature protein (put.); putative"

BASE COUNT 270 a 246 c 239 g 295 t
ORIGIN 52 bp upstream of NcoI site.
1 ctgcagcagct cttccgctcc tctcacagcc gccagaccgc cctgctgagc cccatggccc
61 gcgctgctct cttccgcgcc cccagcaatc cccggctcct gcgagtggca ctgctgctcc
121 tgctcctggg agccgctggc cggcgcgag caggagcgtc cgtggccact gaactgcgct
181 gccagtgtct gcagaccctg cagggaattc accccaagaa catccaaagt gtgaactgtga
241 agtcccccg gacccactgc gcccaaaccg aagtcatagc cacactcaag aatgggcgga
301 aagcttgctt caatcctgca tcccccatag ttaagaaaat catcgaaaag atgctgaaca
361 gtgacaaatc caactgacca gaagggagga ggaagctcac tgggtggctgt tcttgaagga
421 ggccctgccc ttataggaac agaagaggaa agagagacac agctgcagag gccacctgga
481 ttgtgcctaa tgtgtttgag catcgcttag gagaagtctt ctatttattt atttattcat
541 tagttttgaa gattctatgt taatatttta ggtgtaaaat aattaagggt atgattaaact
601 ctacctgcac actgtcctat tatattcatt ctttttgaaa tgtcaacccc aagttagttc
661 aatctggatt catatttaat ttgaaggtag aatgttttca aatgtttccc agtcattatg
721 ttaatatctc tgaggagcct gcaacatgcc agccactgtg atagaggctg gcggatccaa
781 gcaaatggcc aatgagatca ttgtgaaggc aggggaatgt atgtgcacat ctgttttgta
841 actgtttaga tgaatgtcag ttgttattta ttgaaatgat ttcacagtgt gtggtcaaca
901 tttctcatgt tgaaacttta agaactaaaa tgttctaaat atcccttgga cattttatgt
961 ctttcttgta aggcatactg cctgtgttaa tggtagtttt acagtgtttc tggcttagaa
1021 caaaggggct taattattga tgttttcgga

//

LOCUS HUMGROB5 1110 bp mRNA PRI 07-MAR-1995
DEFINITION Human cytokine (GRO-beta) mRNA, complete cds.

ACCESSION M36820
 NID g183628
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-beta.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1110)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,
 Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 TITLE Identification of three related human GRO genes encoding
 cytokine functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES Location/Qualifiers
 source 1..1110
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-beta"
 /tissue_type="monocyte and lymphocyte"
 gene 75..398
 /gene="GRO-beta"
 CDS 75..398
 /gene="GRO-beta"
 /codon_start=1
 /product="cytokine gro-beta"
 /db_xref="PID:g183629"

/translation="MARATLSAAPSNPRLLRVALLLLLVAASRRAGAPLATELRQC

CLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKACLNPA SP MVKKIIEKMLK
 NGKSN"

BASE COUNT 300 a 247 c 247 g 316 t
 ORIGIN

```

1 gacagagccc gggccacgga gtccttgcc agctctctc ctcgcacagc cgctcgaacc
61 gctgctgag ccccatggcc cgcgccacgc tctccgccgc cccagcaat ccccggtcc
121 tgcgggtggc gctgctgctc ctgctcctgg tggccgccag ccggcgcgca gcaggagcgc
181 cctggccac tgaactgccc tgccagtgtc tgcagaccct gcagggaatt cactcaaga
241 acatccaaag tgtgaagggt aagtcctccg gaccccaact cgcccaaac gaagtcatag
301 ccacactcaa gaatgggcag aaagcttgct tcaacccgc atcgcccatg gtaagaaaa
361 tcatcgaaaa gatctgaaa aatggcaaat ccaactgacc agaaggagg aggaagctta
421 ttggtggctg ttctgaagg aggcctgccc ttacaggaa acagaaggaa agagagacac
481 agctgcagag gccacctggc ttgcgcctaa tgtgtttgag catactagg agaagtctc
541 tttttattta tttatttatt ttttgtttg ttttagaaga ttctatgta atattttatg
601 tgtaaaataa gggtatgatt gaactactt gcacactctc ccattatatt tattgtttat
661 ttttagtcaa acccaagtta gttcaatcct gattcatatt taatttgaag atagaagggt
721 tgcagatatt ctctagtcatt ttgttaatat ttcttcgtga tgacatatca catgtcagcc
781 actgtgatag aggctgagga atccaagaaa atggccagta agatcaatgt gacggcaggg
841 aaatgtatgt gtgtctatgt tgtaactgta aagatgaatg tcagttgtta tttattgaaa
901 tgatttcaca gtgtgtgggc aacatttctc atgttgaagc tttagaact aaaatgttct
961 aaatatccct tggcatttta tgtctttctt gtaagatact gccttggtta atgttaatta
1021 tgcagtgttt cctctgtgt tagagcagag aggtttcgat atttattgat gttttcacia
1081 agaacaggaa aataaaatat ttaaaaatat
  
```

//

LOCUS HUMGROG5 1064 bp mRNA PRI 07-MAR-1995
 DEFINITION Human cytokine (GRO-gamma) mRNA, complete cds.
 ACCESSION M36821
 NID g183632
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-gamma.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1064)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,

TITLE cytokine Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 Identification of three related human GRO genes encoding functions

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)

MEDLINE 91017578

COMMENT Draft entry and computer-readable sequence for [Proc. Natl. Acad. Sci. U.S.A. (1990) In press] kindly submitted by S.Haskill, 20-JUL-1990.

FEATURES Location/Qualifiers

source 1..1064

gene 78..398

CDS 78..398

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="GRO-gamma"

/tissue_type="lymphocyte and monocyte"

/gene="GRO-gamma"

/codon_start=1

/product="cytokine GRO-gamma"

/db_xref="PID:g183633"

/translation="MAHATLSAAPSNPRLRLVALLLLLLLVGSRRRAAGASVVTELRCQC

LQTLOQIHLKNIQSVNVRSPGPHCAQTEVIATLKNKGKACLNPA SPMVQKIEKILNK

BASE COUNT 281 a 237 c 239 g 305 t 2 others

ORIGIN

1 cacagccggg tcgcaggcac ctcccngcc agctctcccg cattctgcac agcttcccg

61 cgcgtctgct gagccccatg gcccacgcca cgctctccgc cgccccagc aatccccggc

121 tccgtcgggg ggcgtgctg ctctgtctcc tgggtggcag ccggcgcgca gcaggagcgt

181 ccgtgggtcac tgaactgcgc tgccagtgtc tgcagacact gcagggaatt cacctcaaga

241 acatccaaag tgtgaatgta aggtccccc gacccactg cgcccaaacc gaagtcatag

301 ccacactcaa gaatgggaag aaagcttgct tcaacccgc atccccatg gtccagaaaa

361 tcatcgaaaa gatactgaac aaggggagca ccaactgaca ggagagaagt aagaagctta

421 tcagcgtatc attgacactt cctgcagggt ggtccctgcc ctaccagag ctgaaaatga

481 aaaagagaac agcagctttc tagggacagc tggaaaagga cttaattgtt ttgactatgt

541 cttacgaggg ttctacttat ttatgtatgt atttttgaaa gcttgtatgt taatatttta

601 catgctgtta tttaaagatg tgagtgtgtt tcatcaaaca tagctcagtc ctgattatgt

661 aattggaata tgatgggttt taaatgtgtc attaaactaa tatttagtgg gagaccataa

721 tgtgtcagcc accttgataa atgacagggt ggggaactgg agggtngggg gattgaaatg

781 caagcaatta gtggatcact gttagggttaa ggggaatgat gtacacatct atttttata

841 cttttttttt taaaaaagaa tgtcagttgt tatttattca aattatctca cattatgtgt

901 tcaacatttt tatgctgaag ttcccttag acattttatg tcttgcttgg agggcataat

961 gccttggtta atgtccattc tgcagcgttt ctctttccct tggaaaagag aatttatcat

1021 tactgttaca ttgtacaaa tgacatgata ataaaagttt tatg

//

LOCUS HUMCTAP3 673 bp mRNA PRI 06-MAR-1995

DEFINITION Human connective tissue activation peptide III mRNA, complete

cds.

ACCESSION M54995 M38441

NID g181175

KEYWORDS connective tissue activating peptide-III; platelet basic protein;

thromboglobulin.

SOURCE Human platelet, cDNA to mRNA, clone lambda-c[1,2].

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 673)

AUTHORS Wenger, R.H., Wicki, A.N., Walz, A., Kieffer, N. and Clemetson, K.J.

TITLE Cloning of cDNA coding for connective tissue activating peptide III

from a human platelet-derived lambda gt11 expression library

JOURNAL Blood 73 (6), 1498-1503 (1989)

MEDLINE 89229374

FEATURES Location/Qualifiers

source 1..673

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="platelet"
/clone="lambda-cl"
/cell_type="platelet"
/tissue_type="blood"
/tissue_lib="lambda-gt11"
/map="4p13-q21"
gene 67..453
      /gene="PPBP"
sig_peptide 67..168
             /gene="PPBP"
             /note="G00-127-391"
CDS 67..453
     /gene="PPBP"
     /codon_start=1
     /db_xref="GDB:G00-127-391"
     /product="connective tissue activating peptide III"
     /db_xref="PID:g181176"

/translation="MSLRDTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRN
LAGKKEESLDSLDYAE LRMCIKTTS GIHPKNIQSLEVIGKTHCNQVEVIATLKDGR
      KICLDPDAPRIKKIVQKLAGDESAD"
mat_peptide 196..450
             /gene="PPBP"
             /note="G00-127-391"
             /product="connective tissue activating peptide III"
mat_peptide 208..450
             /gene="PPBP"
             /note="G00-127-391"
             /product="beta-thromboglobulin"
polyA_site 673
            /gene="PPBP"
            /note="G00-127-391"
BASE COUNT      202 a      149 c      139 g      183 t
ORIGIN
1  gggcaactca ccctcactca gagggtcttct ggttctggaa acaactctag ctcagccttc
61  tccaccatga gcctcagact tgataccacc ccttctctga acagtgcgag accacttcat
121 gccttgagg tgctgctgct tctgtcattg ctgctgactg ctctggcttc ctccacaaa
181 ggacaaacta agagaaactt ggcgaaaggg aaagaggaaa gtctagacag tgacttgtat
241 gctgaactcc gctgcatgtg tataaagaca acctctggaa ttcattccaa aaacatccaa
301 agtttggaag tgatcgggaa aggaacccat tgcaaccaag tgaagtgtat agccacactg
361 aaggatggga ggaaaatctg cctggaccca gatgctccca gaatcaagaa aattgtacag
421 aaaaaattgg caggtgatga atctgctgat taattgttct tgtttctgcc aaacttcttt
481 aactcccagg aagggtagaa ttttgaaacc ttgattttct agagttctca tttattcagg
541 atacctattc ttactgtatt aaaatttggg tatgtgtttc attctgtctc aaaaatcaca
601 ttttattctg agaaggttgg ttaaaagatg gcagaaagaa gatgaaata aataagcctg
661 gtttcaaccc tct

//

LOCUS HUMENA78A 2177 bp DNA PRI 31-JAN-1996
DEFINITION Homo sapiens neutrophil-activating peptide 78 (ENA-78) gene,
complete cds.
ACCESSION L37036 Z46254
NID g607030
KEYWORDS ENA-78 gene; homologue; neutrophil-activating factor;
neutrophil-activating peptide 78.
SOURCE Homo sapiens DNA.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2177)
AUTHORS Walz,A., Burgener,R., Car,B., Baggiolini,M., Kunkel,S.L. and
Strieter,R.M.
TITLE Structure and neutrophil-activating properties of a novel
inflammatory peptide (ENA-78) with homology to interleukin 8
J. Exp. Med. 174 (6), 1355-1362 (1991)
JOURNAL MEDLINE 92078844
REFERENCE 2 (bases 1 to 2177)
AUTHORS Walz,A.

```


TITLE Direct Submission
 JOURNAL Submitted (14-OCT-1994) A. Walz, University of Bern, Theodor
 Kocher Institute, Freiestr. 1, Bern, Switzerland 3012
 REFERENCE 3 (bases 1 to 2177)
 AUTHORS Corbett, M.S., Schmitt, I., Riess, O. and Walz, A.
 TITLE Characterization of the gene for human neutrophil-activating
 peptide 78 (ENA-78)
 JOURNAL Biochem. Biophys. Res. Commun. 205 (1), 612-617 (1994)
 MEDLINE 95091791
 FEATURES
 source Location/Qualifiers
 1..2177
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="lymphoblastoid cells"
 /clone="4H2, 178C11, 106C1"
 /chromosome="4"
 /clone_lib="Chromosome 4 cosmid library of Riess et
 al."
 gene 539..1747
 /gene="ENA-78"
 CAAT_signal 539..547
 /gene="ENA-78"
 TATA_signal 675..681
 /gene="ENA-78"
 exon <803..911
 /gene="ENA-78"
 /number=1
 CDS join(803..911,1046..1178,1289..1372,1729..1747)
 /gene="ENA-78"
 /note="homologue to interleukin-8"
 /codon_start=1
 /product="neutrophil-activating peptide 78"
 /db_xref="PID:g607031"
 /translation="MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVL
 RELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNKEICLDPEAPFLKKV
 intron 912..1045
 /gene="ENA-78"
 /number=1
 exon 1046..1178
 /gene="ENA-78"
 /number=2
 intron 1179..1288
 /gene="ENA-78"
 /number=2
 exon 1289..1372
 /gene="ENA-78"
 /number=3
 intron 1373..1728
 /gene="ENA-78"
 /number=3
 exon 1729..>1747
 /gene="ENA-78"
 /number=4
 BASE COUNT 539 a 512 c 496 g 630 t
 ORIGIN
 1 gaattctcag taagcggact taccaaagta ggtgatctgt aggggagtta acaaaattca
 61 gtggtccttt caggccactg acttcaagtg gcaagagaca aggggtctctt gttatcatgt
 121 tatcttggtt tccaaagctg gttgaagtcc agagattcat aaagtcattc aagaaacctta
 181 gaatgacctg cctgcaagaa gacaggaagg actttcagtt tatagcaatt caaacatgaa
 241 taacatttcc tgattaatag taataataat tagaaaggat tgacttttcag aaatttttct
 301 caaatcaagg ctctgtttac ttggtttcca ctttttctct ctagaaggag agggaggagca
 361 tctcccagat gctgcgtgct ccagaaaagc cggcatccct agcccgtctt ggcacaggcc
 421 atgaggcgct gctgaatcct gctgaatagc tactcccttc tagctggagc cacagctccc
 481 tccaccgcgg aacagggtta caacgtccct ctcggtagag gtgcacgcag ctctctctgg
 541 ccaccctccc caccagttcc cattgtctgg cccccctccc ccaacctctt ctttccacac
 601 tgccccatga gttcagggaa tttccccagc atcccaaagc ttgagtttcc tgtcagtggt
 661 gagagatgag tgtagataaa aggagtgcag aaggaacgag gaagccacag tgctccggtat

```

721 cctccaatct tcgtctctcc aatctccgct cctccacca gttcaggaac ccgcgaccgc
781 tcgcagcgct ctcttgacca ctatgagcct cctgtccagc cgcgcgccc gtgtccccgg
841 tccttcgagc tccttggtgcg cgctgttggt gctgctgctg ctgctgacgc agccagggcc
901 catcgccagc ggtgagagcg catggcgcg gggacgcact cgactcggg cacagaggtg
961 catcccagcc tctgcggggt cgctgcgttc cagggaactc tcccagcaac ctgccctata
1021 aaggggtgtct ctctttcttc ccagctgggt cctgccgctg ctgtgttgag agagctgcgt
1081 tgcgtttgtt tacagaccac gcaaggagtt catcccaaaa tgatcagtaa tctgcaagtg
1141 ttcgccatag gccacagtg ctccaagggt gaagtgggtg aagtctgtg ctgctgtgtc
1201 cgctgtgacc ttggcaagag agaaatccc cagcctgggt cttcaacctt ggtatctcat
1261 gagtgtatct tcttttctt tccttcagag cctccctgaa gaacgggaag gaaatttgc
1321 ttgatccaga agccctttt ctaaagaaag tcatccagaa aattttggac ggggtactgt
1381 cactttgatc tttgtggtt ctaaatctga tctagggaga ccatagactt cacaaggtct
1441 ttattctctg tacgatttaa gtaacacttt tcatgtttag aattaaaagg ttgttgaatt
1501 gggaaagttt ttctggattg tcctgggaaa atataccaat cttacatgta attacttgag
1561 caattacaca cagcttgta ctaagttatg tttttgttt acccattgct tttattgatt
1621 tttgtattct ccttttttac caaacatcat aaacgctgag ttttgacaag ggtggagtag
1681 aaaggagttg gaaaaatggt taaactaata taacatttt ctcaacagtg gaaacaagga
1741 aaactgatta agagaaatga gcacgcatgg aaaagtttcc cagtcttcag cagagaagtt
1801 ttctggaggt ctctgaacc agggaagaca agaaggaaa attttgttg ttgttttta
1861 tttgttttct cagtagttag ctttcttct ggattcctca ctttgaagag tgtgaggaaa
1921 acctatgttt gccgcttaag ctttcagctc agctaataaa gtgttttagca tagtacctct
1981 gctatttgct gttattttat ctgctatgct attgaagttt tggcaattga ctatagtgtg
2041 agccaggaat cactggctgt taatctttca aagtgtctg aattgtaggt gactattata
2101 tttccaagaa atattcctta agatattaac tgagaaggct gtggatttaa tgtggaaatg
2161 atgtttcata agaattc

```

//

```

LOCUS      HSGCP2          254 bp      RNA          PRI          04-MAR-1997
DEFINITION H.sapiens mRNA for granulocyte chemotactic protein.
ACCESSION  Y08770
NID        gl769436
KEYWORDS   cell surface receptor; CXC chemokine; GCP-2 gene; granulocyte
           chemotactic protein.
SOURCE     human.
ORGANISM   Homo sapiens
           Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
           Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 254)
AUTHORS    Froyen,G., Proost,P., Ronsse,I., Mitera,T., Haelens,A.,
Wuyts,A., Opdenakker,G., Van Damme,J. and Billiau,A.
TITLE      Cloning, bacterial expression and biological characterization
of         recombinant human granulocyte chemotactic protein-2 and
           differential expression of granulocyte chemotactic protein-2
and        epithelial cell-derived neutrophil activating peptide-78 mRNAs
JOURNAL    Eur. J. Biochem. 243 (3), 762-769 (1997)
MEDLINE    97210779
REFERENCE  2 (bases 1 to 254)
AUTHORS    Froyen,G.F.V.
TITLE      Direct Submission
JOURNAL    Submitted (10-OCT-1996) G.F.V. Froyen, Rega Institute,
University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
FEATURES   Location/Qualifiers
           source      1..254
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
                       /haplotype="diploid"
                       /tissue_type="embryonic"
                       /rearranged
                       /cell_type="fibroblast"
                       /cell_line="E6SM (embryonic strain - skin and muscle)"
           gene        1..254
                       /gene="GCP-2"
           exon        <1..131
                       /gene="GCP-2"
                       /number=2
           CDS          <1..234
                       /gene="GCP-2"

```

```

/codon_start=1
/product="granulocyte chemotactic protein"
/db_xref="PID:e283124"
/db_xref="PID:g1769437"

/translation="GPVSAVLTELRC TCLRVTLRVNPKTIGKLQVFPAGPQCSKVEVV
              ASLKNGKQVCLDPEAPFLKKVIQKILDSGNKKN"
    exon      132..215
              /gene="GCP-2"
              /number=3
    exon      216..254
              /gene="GCP-2"
              /number=4
    3'UTR     235..254
              /gene="GCP-2"
BASE COUNT   66 a    64 c    70 g    54 t
ORIGIN
    1 ggtcctgtct ctgctgtgct cacggagctg cgttgcaactt gtttacgcgt tacgctgaga
   61 gtaaacccca aaacgattgg taaactgcag gtgttccccg caggcccgca gtgctccaag
  121 gtggaagtgg tagcctccct gaagaacggg aagcaagttt gtctggacct ggaagcccct
  181 tttctaaaga aagtcaccca gaaaattttg gacagtggaa acaagaaaaa ctgagtaaca
  241 gtcgacgcgg ccgc

//

LOCUS       D63789             5669 bp    DNA                PRI          27-DEC-1996
DEFINITION  Human DNA for SCM-1beta precursor, complete cds.
ACCESSION   D63789
NID         g1754608
KEYWORDS    SCM-1beta; SCM-1beta precursor.
SOURCE      Homo sapiens placenta DNA, clone:hg44.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1 (sites)
  AUTHORS   Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
  TITLE     Molecular cloning of a novel C or gamma type chemokine, SCM-1
  JOURNAL   FEBS Lett. 360 (2), 155-159 (1995)
  MEDLINE   95180438
REFERENCE   2 (sites)
  AUTHORS   Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
  Yaoui,T.  and Yoshie,O.
  TITLE     Structure and expression of two highly related genes encoding
            SCM-1/human lymphotactin
  JOURNAL   FEBS Lett. 395 (1), 82-88 (1996)
  MEDLINE   97002294
REFERENCE   3 (bases 1 to 5669)
  AUTHORS   Yoshida,T.
  JOURNAL   Unpublished (1995)
REFERENCE   4 (bases 1 to 5669)
  AUTHORS   Yoshida,T.
  TITLE     Direct Submission
  JOURNAL   Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya    Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima,   Settsu, Osaka 566, Japan (E-
mail:teyoshid@fl.lab.shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)
FEATURES
  source    Location/Qualifiers
            1..5669
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /chromosome="1"
            /clone="hg44"
            /map="1q23"
            /tissue_type="placenta"
  TATA_signal 2154..2158
  exon       2197..2278

```

/translation="MRLILALLGICSLTAYIVEGVGSEVSHRRTCIVSLTTQRLPVSR

IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMRKSNTNRNMIQTKPTGT
QQSTNTAVTLTG"

```

intron      2279..4074
            /gene="SCM-1beta"
            /number=1
exon        4075..4189
            /gene="SCM-1beta"
            /number=2
mat_peptide join(4077..4189,5062..5227)
            /gene="SCM-1beta"
intron      4190..5061
            /gene="SCM-1beta"
            /number=2
exon        5062..5349
            /number=3

```

	1702 a	1058 c	1248 g	1661 t
BASE COUNT				
ORIGIN				

N	1	61	121	181	241	301	361	421	481	541	601	661	721	781	841	901	961	1021	1081	1141	1201	1261	1321	1381	1441	1501	1561	1621	1681	1741	1801	1861	1921	1981	2041	2101	2161	2221	2281	2341	2401							
	ggatccagga	ggataacaag	ggaatctcct	actctcaaa	agtctgccat	ctagtgggag																																										
	acgcaaggaat	gtaattgagt	aggagaacac	aatgagattc	gttgacgaac	agccatgaga																																										
	acagaaacaaa	gttctaagag	agcataaaag	ggtggcacaa	cttaatttta	tcaaaaaaat																																										
	tcaggaaaac	ttatacacag	aggaggagtt	tacaagtaac	ctatgtagga	gctgtcattg																																										
	gtattccagt	taaaggaaac	atgtgaggag	ctaaaagag	gctggcccat	tgggttggct																																										
	gcacatgtat	gtgtttgtta	aggtttggga	gtgtgtgagt	gaatggtgga	aggtagtctt																																										
	gaaaggaaag	cagtactaga	tcttgagcat	tcttatatat	cacaatgaaa	gatttgaaat																																										
	acatcctgta	ggcattggaa	gttagcaaaa	gaggtttctca	gtagggaat	ggcatgatta																																										
	gatttgaggct	ttacagtgtat	taccctggca	aagctgcaga	gaacagactg	agcaggaggcc																																										
	ctggctctggg	taaccagtta	gtccactgta	atttgcctaa	catttgagca	gtgtggggag																																										
	aaaggaggac	acatctcaaa	ggactaccta	gaaggtatac	ttagtccagt	ttggttgaga																																										
	atgacatgta	ggtggatagc	aatgagttca	agatgatccc	tatatattcg	tatttgaaa																																										
	ttagatggaa	gagaaacacat	tgcctccatgc	taaggactaa	tataggaga	agcagttga																																										
	atagaagatg	tgctccagtg																																														

```

2461 gggagaattt gattagtatc tgggctccta cttttcctaa ttgggtaatt tcaggtaaatt
2521 tccttaacca ctcagggcct gtgcttattt atgtataaac tgaatagaat aagagacatg
2581 atcacctgag attaaagatta aataaaatatt atgggtttatt taataacatc agatttcctt
2641 acaagcagta atttttttagt taatgttagc tatggattag aggtgatgat tataaatgca
2701 tttgtagggtt ttgcccattt aatatatagt ttgataaatt atcaaaatct tagagagttc
2761 agttacaata tggggatgca ccagaggatg tatgttcttg agcaaatcaa tgttttcaat
2821 acaaaacctg tgtgaaggcg acagtagtgc ttgctgtgga ctggatgtcc cagtcttgcc
2881 ttccctcccc ttgataatgc aataagggac ccccatTTTA ggacgcagga caggcagaaa
2941 gataaccagc ttgatggggt ccacaccatg tgcaatcact accagctgag acttcttggt
3001 ttccagcaag gtgggtgatga tgttaacccc tgctcaaaga acaggtgatt tcctagtggg
3061 gacaaccctt ttgctagcag ctttcttctc agcctgggccc aacagtctct gcttcttctc
3121 ttgctttgtc tctgggtcagt acttggtgat cagcttaagt ggctgagt tagtttgggg
3181 gtctaaggct tgggtgaact ggtaaatggc agaaggcatt ttcagctgct tatagagat
3241 agctctttgc agctggaacc agatatagcg gggccatttc acaaagcagt ggaggtctct
3301 tttgggctgg atgtcctgtc caatgcctgc ctaagaaaac tcttaggcct tttctcacac
3361 agcgggtttca tcacttttct agcctctgac ttcttcacga cggcagggac tgggccaacct
3421 tctttctctt ggcccttctt cttttcagca tcttaggcag ctgacagaga gggaaatttg
3481 accatttaaa aagggggaaca cctttattta ctcagtcaaa agcatgcttc cttccctcac
3541 tgaatgttgc cttgcctaga gtactcttca cgcattactc tgtcatctca cttatggtag
3601 tgtaacatgt tgcactattt gaaatgatct tttctggttg cctgtctgct gcctggctcc
3661 ctcatgagaa gatatgctct atgaaaacag ggataatgtc tgtcttaata aaacatgttg
3721 gacacaacag gcaccattgt ataaatgaat gaatgcgtgt cactggggca tttgctagcc
3781 gtcccaaagc tctaagtga aatatacaca gagacgggat aacatcttgt tattttctct
3841 cagcatgaaa ttccctgaaac aattctgttg attgagttt taaattagca aaatatttac
3901 taagaatctg tgacgggcaa gagattcggg atgcctatca gtccctctct ccccaaaaaa
3961 gcaaatggcc ttatatcttc acaacattct cagagtaatt taacagacga ttgttctgt
4021 gatctgggta attgctttat ttttaattgt ctggtgtttt tttttctca tcaggtgtag
4081 ggagtgaagt ctcacatagg aggcctgtgt tgagcctcac taccagcga ctgccagtta
4141 gcagaatcaa gacctacacc atcacggaag gctccttgag agcagtaatt tgagtctgcc
4201 tcttcagaag ttgggctggg tgggtacctc gaggtataga aatacactct atagaaatgc
4261 tgccatcctc aggaaaagta ggtagcagca gaggaacacc tcaacttaac caaaaacctc
4321 tttagttttc cttatcaacc atgtctttct gcagcccaac cgaatagcga ttattgcaga
4381 aattgggctg ccaaagaaag aatagaagtc ctctctattt tgtcttagtg gaagagtctg
4441 ttgaatactg tgcacagctc tgagatctgg gtttagagat ggctggctca tgtcagggtt
4501 tccctgcaag cctcactgga gttgggggat cttagggttg agttaggcag agtcccatc
4561 tttatcagtt gccatatctt aagaaaatga gtcaatgcac aacctacatg gtccctttct
4621 tctaccagaa tctcattttt agaagtaata actcttccca atacatattg caagcttttg
4681 tctaaagaat gaaaatgtaa aaatcacctt tttaaaaaaa ataagatgag tattttcaaa
4741 ttgaaaagg aagaggttat ataataatgg aactagatgg cctcaaatgt ctttttgtaa
4801 caacatttgg tgacatggat gagaaaagga gcctgtgaat tatgggtgaac aaaggggctg
4861 gatactactt gcagatattt ctcttttatg ttaaaataga tggcagaaga aggggtgcta
4921 tttatgatct catggctctg aaagactatt tcttgcagta atttctgcac aagatctctt
4981 catgtctgcc ctgatcttaa ctctgaccc tgaggctttg agaacgtggc taacttcac
5041 tgtcttttcc ttgcgttaca gttttattac caaacgtggc ctaaaagtct gtgctgacc
5101 acaagccacg tgggtgagag acgtggtcag gagcatggac aggaaatcca acaccagaaa
5161 taacatgatc cagaccaagc caacaggaac ccagcaatcg accaatagc ctgtgacctt
5221 gactggctag tagtctctgg caccctgtcc gtctccagcc agccagctca tttcacttta
5281 caccctcatg gactgagatt atactacact tttatgaaag cactgcatga ataaaattat
5341 tcttttgat ttttactttt aaatgtcttc tgtattcact tatatgttct aattaataaa
5401 ttatttatta ttaagaatag ttccctagtc tattcattat atttagggaa aggtagtgt
5461 tcattgttgt ttgatttctg acctgtgacc tctctttgat ggtaaccata atggaagaga
5521 ttctggctag tgtctatcag aggtgaaagc tatatcgatc actcttagag tccagcttgt
5581 aatgggttctt tacacatcag tcacaagtta cagctgtgac aatggcaaca atttgagatc
5641 tatttcaact tgtctctata atagaattc

```

//

LOCUS D63790 5660 bp DNA PRI 27-DEC-1996
 DEFINITION Human DNA for SCM-lalpha precursor, complete cds.
 ACCESSION D63790
 NID g1754610
 KEYWORDS SCM-lalpha precursor; SCM-1 alpha.
 SOURCE Homo sapiens placenta DNA, clone:hg40.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae;
 Homo.
 REFERENCE 1 (sites)
 AUTHORS Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
 TITLE Molecular cloning of a novel C or gamma type chemokine, SCM-1
 JOURNAL FEBS Lett. 360 (2), 155-159 (1995)

MEDLINE 95180438
REFERENCE 2 (sites)
AUTHORS Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
Yaoi,T.
and Yoshie,O.
TITLE Structure and expression of two highly related genes encoding
SCM-1/human lymphotactin
JOURNAL FEBS Lett. 395 (1), 82-88 (1996)
MEDLINE 97002294
REFERENCE 3 (bases 1 to 5660)
AUTHORS Yoshida,T.
JOURNAL Unpublished (1995)
REFERENCE 4 (bases 1 to 5660)
AUTHORS Yoshida,T.
TITLE Direct Submission
JOURNAL Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima, Settsu, Osaka 566, Japan (E-
mail:teyoshid@fl.lab.shionogi.co.jp.
Tel:06-382-2612, Fax:06-382-2598)
FEATURES Location/Qualifiers
source 1..5660
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="1"
/clone="hg40"
/map="1q23"
/tissue_type="placenta"
TATA_signal 640..644
exon 683..764
/number=1
prim_transcript 683..5340
CDS join(704..764,4064..4178,5053..5221)
/codon_start=1
/product="SCM-1alpha precursor"
/db_xref="PID:d1010505"
/db_xref="PID:g1754611"

/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR
IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT
QQSTNTAVTLTG"
intron 765..4063
/number=1
exon 4064..4178
/number=2
mat_peptide join(4066..4178,5053..5218)
/note="SCM-1alpha mature peptide"
intron 4179..5052
/number=2
exon 5053..5340
/number=3
BASE COUNT 1623 a 1139 c 1175 g 1723 t
ORIGIN
1 aagcttctat aaatgtgtat gttatgttgt aataaagcaa acacatgcat gtagacatgc
61 ttaaacagtt atttaattgt ttcttgggta cctgggggaga tgggggtgaag aaaggggggt
121 gacttgaatg aaggtggagg agaaaaatga gaaccaagaa agcaaaggat cgagaagctc
181 agtgtggcag cagctctctt cccctcctga gagagtcaaa ggggtggcatc agggactcat
241 gatccatggt tgtggaagcc tcatgtcaca ctggatgtca catgagggtg gatggaacac
301 agtgaccacc ccacctcatt tcctttacag ctcccggtg gggccatggc agtgaacacc
361 ttcaggcatg tctacggcgg aatatctgaa ttcaggctgg tggcaggaga caacacaacc
421 acgttttctt ttatgcatgc atttggttta attgacacat taaccacaga caaaggggta
481 aaggccacaa ggcgttaggt tagtatgaac agggaaaagg gacttttttt ttttttttta
541 agaaaaataa aagcatcagt attgcaaaga ctctccatga tcctacaccc acctcgaaag
601 cccctctca ccacagggaag tgcactgacc actggaggga taaaagggt cctcaaagag
661 cccgatcctc actctccttg cacagctcag caggacctca gccatgagac ttctcctcct
721 ggcctcctt ggcactctgt ctctcactgc atacattgtg gaaggtaagt ggagaagctg
781 tctgtgagat aaagaacagg gaggcaaggc aggtgggcac acattttggg tttgactcag
841 gttatgactg gactaatctg ctttccccag gggagcctta aacttcccat gtgcaagaaa

901 ggaatgatga ttttgactgt agagggcttc gtaaaacttcc aaaacaggya gaatttgatt
 961 agtatctggg ctccctacttt tcctaattgg gtaatttcag gtaaatctct taaccactca
 1021 gggcctgtgc ttatttatgt ataactgaat agtataacag acttgatcac ctgagattaa
 1081 gattaaataa atattatggg ttatttaata acatcagatt tccttacaag cagtaatttt
 1141 ttgattaatg ttagctatgg attagaggtg atgattataa atgcatttgt aggttttgcc
 1201 catttaatat atagtttgat aaattatcaa aatccttagag agttcagtta cgtatggggg
 1261 atgcaccatt ggatgtatgt tctggagtaa atcaatgttt tcaatacaaa actaagcccc
 1321 aaatgactgg aagttcaaac ctctatgtcc agaaaatcaa tattaccttc aagtacgtgg
 1381 gggactctgt tagtaatgcc atgactatta ctatttatga gaaattttct gtttttgtaa
 1441 gagaacatac aataataact actaccaaact agatcagcac ctatacaca gttcaataaa
 1501 cctgcaagac acatccaggg aagattcaga tataccgagc ccttacctga gcattcagta
 1561 ggtattttctt aaggattgat ttttctatg actggagggtg aatctgtcga cttatttgtg
 1621 ttctagttgg taggcttatt acttagacta tgatattata acttaataat ggttcccaa
 1681 ggggttccat gaataaagggt ggctaagtct ggaagtcctt gaaattatgg ataaaaacaa
 1741 aaaatactga tgaacaaaaa gagtttgatt actacattag gccacatggt gctacctggc
 1801 tggcattttg ctgagacaat gggcatacca tttgagggtg actcagatct gagtagggga
 1861 aaggagctct ataagtccca ctgggtgctta gcttcttaca tacaataatg agggaaaacg
 1921 gtctctgctt tgactcaatt ttgcaacctg agtgaagggtg atattttaaa aaataacaca
 1981 gacactcaaa cattgctgac aataaggaaa aggtcttggg gtttcaagca taacaggatt
 2041 ccctgagctt taggagtcca ctccagatcc ttcacagaga gaaattatgt ttcttaataa
 2101 tgagagaaac agagaaaaaa cccagatttt tctcttttca ttggctacag aaacaattca
 2161 ccactaaaaa taaattggca aaggttagagg atagcaatgt gcagactggc attgagagtg
 2221 aagaaaatgat gaagaaaagc acacaatgaa cactctttgt tttagtccctt gctttaaaaa
 2281 atgccttctg atattagcaa cactacagac caatgttggc cattatcagt ggttacttta
 2341 gatgcttttt agctgcctat tccctggga agcaaagacc agtgtctaca gctaaggaga
 2401 aaatcagcac ttgaaaactt ggattagatt tcaccaaac ctttaacagta ttaattctcc
 2461 caagtatttt tctctcatgc aatgtttttt tgattctcta cacttaatag tttaattcct
 2521 ttggccattt actattgggg atgcataatt aagggctgac tctcttttat atatatctta
 2581 ccttttacca tttaattaatt ttttgagag tttttattat ttttatgtac agaaaactca
 2641 acagtgtaca tttaaccag tttagtggca agttcctctg cctttgctat ttccagcttg
 2701 gcatltgtag ccacagattt tggactcggg acattgcaga tctcatcata tccgtcattg
 2761 taatttgtcc tgatagcttc caccagctta gccaaagctc ctttgtcttc ctggttaact
 2821 ttgttgaagg ccacagtggg gcttctgtg gactggatgt cccagcttg ccttcttacc
 2881 ccttgataat gcattaaagg accccccatt ttaggacaca ggacagacag aaagttaacc
 2941 agcttgatgg ggtccacacc atgtgcaata ccagctgagc cttcttcttt tccagcaagg
 3001 tggatagat gttaaccctt gctcaaagaa cagggtgatt cctagtggg acaacccctt
 3061 tgcagcagc tttcttctca gctggggcca acagtctctg cttcttctct tgccttgtct
 3121 ctggctcagta cttgtggatc agcttaagtg gctgagtagc tgtttggggg tctaaggctt
 3181 ggggtgaactg gttaatggca gaaggcactt tcagctgctt atagaggata gctctttgca
 3241 gctggaacca gatatacggt ggccatttca caaagcagcg gaggtccctt ttgggctgga
 3301 tgcctgtccc aatgcctgcc taagaaaact cttaggcctt ttctcacaca gcggtttcat
 3361 cactttctta gctcctgct tctcacgac ggcagggtct ggggccactt tcttctctt
 3421 ggccatcttt cctttcagca tcttaggcag ctgacagaga gagacatttg accattttaa
 3481 aaggagaaca cctttattta gtctgtcaaa agcatgcttc cttccctcac tgaattgtgc
 3541 ctgtcctaga gtactcttca cgcattactc tgtcttctca ctatggtact gtaacatgtt
 3601 gcactatttg aaatgatctt ttctgtttgc ctgtctgctg cctggctcct tcatgagaga
 3661 gatattgctt atgaaaacag gagtaatgtc tgcttagtaa aacatgtggg acacaacagg
 3721 caccattgta taaatgaatg aatgcgtgtc actggggcat ttgctagccg tcccaaatgt
 3781 ctaagtgaat atatacacag agacgggata acatcttgtt attttctctc agcatgaaat
 3841 tcttgaaaca attctgttga ttgagttttt aaattagtca aatatttact aagaatctgt
 3901 gacgggcaag agattcggga tgcctatcag tctctcttcc ccccaaaaag caaatggcct
 3961 taaattctca caacattctc agagtaattt aacagatgat tgttctctgt atctggataa
 4021 ttgctttatt tttaattgtc tgttgttttt ttttctcac cagggtgtagt gtagtaagtc
 4081 tcagataaga ggacctgtgt gagctcactt acccagcgac tgccgggttag cagaatcaag
 4141 acctacacca tcacggaaagg ctcttgaga gcagtaatgt gagtctgcct cctcagaagt
 4201 tgtgctgggt ggttatctag aagtatagaa atacactctg tagaaatgct gccgtctca
 4261 ggaaaagtag gtcagcatag aggaacacct caacttaacc aaaaacctct ttagttttcc
 4321 ttatcaatca tgtctttctg cagcccaacc gaatagcgat tattgcagaa attgggctgc
 4381 caaagaaaga atagaagtcc tctctatttt agcttagtgg aagagtctgt tgaatactgt
 4441 gcacagctct gagacctggg tttagagatg actggcccat gtcagggttt cctgcaagc
 4501 ctactggag ttggggggtc tttaggggtga gtcaggcaga gtcccatact tttatcagtt
 4561 gccatatttc aagaaaatga gtcaatgcac aaactacatg gtccttctct ctaccagaat
 4621 ctcattttta gaagttaata actcttctca acatgtaatt gcaagcttta ctctaaaaaa
 4681 tgaatgtga aaaatcactt ttattttaaa aaataagatg aatattttta aatttgaaaa
 4741 ggaagagggt atgtaataat ggaactagtt ggctcaaag tctttttgtt acaacatttg
 4801 gtgacatgga tgagaaaagg accctgtgaa ttattgtgaa caaaggggct ggatactact
 4861 tgcagatatt actcctttat gttaaaatag atggcagaag aagggtactc atttatgatc
 4921 tcatggctct gaaagactat ttcttgcagt aatttctgca caagatctct tcatgtctgc
 4981 cctgacttta actcctgacc ctgaggcttt gagaatgtgg ctaacttctg ctgtcttttc
 5041 cttgcttac agttttatta ccaaactgtg cctaaaagtc tgtgctgac cacaagccac
 5101 atgggtgaga gacgtgggtc ggagcatgga caggaaatcc aacaccagaa ataactgat

```

5161 ccagaccaag ccaacaggaa cccagcaatc gaccaatata gctgtgactc tgactggcta
5221 gtagtctctg gcaccctgtc cgtctccagc cagccagctc atttcacttt acacgctcat
5281 ggactgagtt tatactcacc ttttatgaaa gcactgcatg aataaaatta ttcctttgta
5341 tttttacttt taaatgtctt ctgtattcac ttatatgttc taattaataa attatttatt
5401 attaagaata gtccctagt ctattcatta tatttaggga aaggtagtgt atcattgttg
5461 tttgatttct gaccttgtac ctctctttga tggttaaccat aatggaagag attctggcta
5521 gtgtctatca gaggtgaaag ctatatcaat ctctcttaga gtccagcttg taatggttct
5581 ttacacatca gtcacaagtt acagctgtga caatggcaac aatttgagat gtatttcaac
5641 ttgtctctat aatagaattc

```

//

```

LOCUS      HSU91835      1635 bp      mRNA      PRI      21-MAR-1997
DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
            complete cds.
ACCESSION  U91835
NID        g1899258
KEYWORDS   .
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      A new class of membrane-bound chemokine with a CX3C motif
JOURNAL    Nature 385 (6617), 640-644 (1997)
MEDLINE    97177111
REFERENCE  2 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      Direct Submission
JOURNAL    Submitted (03-MAR-1997) Molecular Biology, DNAX Research
Institute, 901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES   Location/Qualifiers
            source          1..1635
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
            CDS             80..1273
                           /note="membrane-tethered chemokine module"
                           /codon_start=1
                           /product="CX3C chemokine precursor"
                           /db_xref="PID:g1899259"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHGHVTKCNITCSKMTSKIP
VALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDQRQAALTRNGGT
FEKQIGEVKPRTPPAAGGMDESVVLEPEATGESSSLEPTSSQEAQRALGTSPELPTG
VTGSSGTRLPPTPKAQDGGPVGTGLFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA
PSTQDPSTQASTASSPAPEENAPSEGQRVWVGQGSPPRPNLSLREEMGPVPAHTDAFQ
DWGPGSMAHVSVPVSSEGTPSREPVASGSWTPKAEPIHATMDPQRLGVLITPVPDA
QAATRRQAVGLLAFLGLLFCLGVMFTYQSLQGCPRKMAGEMAEGRLRYIPRSCGSNSY
VLVPV"
            sig_peptide     80..151
            mat_peptide     152..1270
                           /product="CX3C chemokine"
            misc_feature     152..379
                           /note="encodes chemokine module"
            misc_feature     380..1102
                           /note="encodes glycosylation stalk"
            misc_feature     1103..1159
                           /note="encodes transmembrane helix"
            misc_feature     1160..1270
                           /note="encodes intracellular domain"
            3'UTR           1274..1635
                           /note="alternatively spliced; long transcript can be

```


found

BASE COUNT 338 a 544 c 464 g 289 t
 ORIGIN in GenBank Accession Number U84487*

```

1  ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgcctggcc cccgcgggga
61 ctcttgccca ccttcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
121 cttctgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
181 cacgtgcagc aagatgacat caaagatacc ttagctttg ctcatccact atcaacagaa
241 ccaggcatca tgcgggcaaac gcgcaatcat cttggagacg agacagcaca ggctgttctg
301 tgccgacccg aaggagcaat gggtaagga cgcgatgcag catctggacc gccaggctgc
361 tgccctaact cgaaatggcg gcaccttcca gaagcagatc ggcgaggtga agcccaggac
421 cacccttgcc gccgggggaa tggacgagtc tgggttcctg gagcccgaag ccacaggcga
481 aagcagtagc ctggagccga ctcttcttcc ccaggaagca cagagggcc tggggacctc
541 cccagagctg ccgacgggcg tgactggttc ctcagggacc aggtctcccc cgaccgaaa
601 ggctcaggat ggagggcctg tgggcacgga gcttttccga gtgcctcccc tctccactgc
661 cgccacgtgg cagagttctg ctccccacca acctggggcc agcctctggg ctgaggcaaa
721 gacctctgag gccccgtcca cccaggaccc ctccaccag gcctccactg cgtcctcccc
781 agccccagag gagaatgttc cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
841 caggccagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
901 cttccaggac tgggggcctg gcagcatggc ccacgtctct gtggtccctg tctcctcaga
961 agggaccccc agcagggagc cagtggcttc aggcagctgg accctaagg ctgaggaacc
1021 catccatgcc accatggacc cccagaggct gggcgtcctt atcactctg tccctgacgc
1081 ccaggctgcc acccgaggc aggcggtggg gctgtggccc ttcttggcc tctcttctg
1141 cctgggggtg gccatgttca ctaccagag cctccagggc tgccctcgaa agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
1261 ggtgcccgat tgaactcttc tggcctgtgt ctagtgttt gattcagaca gctgctggg
1321 atccctcatc ctcatacca cccccacca aggcctggc ctgagctgg atgattggag
1381 gggggaggtg ggatcctcca ggtgcacaag ctccaagtc ccaggcatt cccaggaggc
1441 cagccttgac cattctccac cttccaggga cagagggggg ggctcccaa ctcacccag
1501 ccccaaaact ctctctgct gctggctggt tagaggttcc ctttgacgcc atcccagccc
1561 caatgaacaa ttatttatta aatgccccagc cccttctgaa aaaaaaaaaa aaaaaaaaaa
1621 aaaaaaaaaa aaaaaa
  
```

//

LOCUS HSU84487 3310 bp mRNA PRI 15-MAR-1997
 DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
 complete cds.
 ACCESSION U84487
 NID g1888522
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 3310)
 AUTHORS Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Soo, K., Rossi, D.,
 Greaves, D.R., Zlotnik, A. and Schall, T.J.
 TITLE A new class of membrane-bound chemokine with a CX3C motif
 JOURNAL Nature 385 (6617), 640-644 (1997)
 MEDLINE 97177111
 REFERENCE 2 (bases 1 to 3310)
 AUTHORS Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Rossi, D.,
 Greaves, D.R., Zlotnik, A. and Schall, T.J.
 TITLE Direct Submission
 JOURNAL Submitted (07-JAN-1997) Molecular Biology, DNAX Research
 Institute,
 901 California Ave., Palo Alto, CA 94304-1104, USA
 FEATURES
 source Location/Qualifiers
 1..3310
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 80..1273
 /note="membrane-tethered chemokine module"
 /codon_start=1
 /product="CX3C chemokine precursor"
 /db_xref="PID:g1888523"
 /translation="MAPISLSWLLRLATFCHLTVLLAGQHGVTKCNITCSKMTSKIP
 VALLIHYQQNQASCGKRAIILETRQHLFCADPKEQWVKDAMQHLDRQAAALTRNGGT"

FEKQIGEVKPRTPPAAGGMDESIVLEPEATGESSSLEPTSSQEAQRALGTSPELPTG

VTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA

PSTQDPSTQASTASSAPEENAPSEGQRVWGQGSPPRPNLSLREEMGPVPAHTDAFQ

DWGP GSMHVSVVPVSSEGTSPREPASGSWTPKAEPIHATMDPQRLGVLITPVPDA

QAATRRQAVGLLAFLLFCLGVAMFTYQSLQGCPKRMAGEMAELRYIPRSCGSNSY

VLVPV"
 sig_peptide 80..151
 mat_peptide 152..1270
 /product="CX3C chemokine"
 misc_feature 152..379
 /note="encodes chemokine module"
 misc_feature 380..1102
 /note="encodes glycosylation stalk"
 misc_feature 1103..1159
 /note="encodes transmembrane helix"
 misc_feature 1160..1270
 /note="encodes intracellular domain"
 3'UTR 1274..3310
 /note="alternatively spliced; short transcript

deposited as GenBank Accession Number U91835"
 BASE COUNT 659 a 1051 c 916 g 682 t 2 others

ORIGIN
 1 ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgcctggcc cccgcggga
 61 ctcttgccca ccctcagcca tggtccgat atctctgtcg tggctgctcc gcttgccac
 121 ctcttgccat ctgactgtcc tggtggctgg acagcaccac ggtgtgacga aatgcaacat
 181 cacgtgcagc aagatgacat caaagatacc tgtagctttg ctcatccact atcaacagaa
 241 ccaggcatca tgcggcaaac gcgcaatcat cttggagacg agacagcaca ggctgttctg
 301 tgccgacccg aaggagcaat ggttcaagga cgcgatgcag catctggacc gccaggctgc
 361 tgccctaact cgaaatggcg gcaccttcga gaagcagatc ggcgaggatga agcccaggac
 421 cacccttgcc gccgggggaa tggacgagtc tgtggtcctg gagcccgaag ccacaggcga
 481 aagcagtagc ctggagccga ctctctcttc ccaggaagca cagaggggccc tggggacctc
 541 cccagagctg ccgacgggcg tgaactgttc ctcagggacc aggtctcccc cgacgcaaa
 601 ggctcaggat ggagggcctg tgggcacgga gcttttccga gtgectcccc tctccactgc
 661 cgcacagtg gtaggttctg ctccccacca acctggggccc agcctctggg ctgaggcaaa
 721 gacctctgag gccccgtcca cccaggaccc ctccaccag gcctccactg cgtctcccc
 781 agccccagag gagaatgtc cgtctgaagg ccagcgtgtg tggggctcag gacagagccc
 841 cagccagag aactctctg agcgggagga gatgggtccc gtgcccagc acacggatgc
 901 cttccaggac tgggggcctg gcagcatggc ccacgtctct gtggtccctg tctctcaga
 961 agggaccccc agcaggagc cagtggcttc aggcagctg acccctaagg ctgaggaacc
 1021 catccatgcc accatggacc cccagaggct gggcgctcct atcactcctg tccctgacgc
 1081 ccaggctgcc acccggaggg agggcggtgg gctgctggcc ttccttgccc tctcttctg
 1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgccctcgaa agatggcagg
 1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
 1261 ggtgcccgtg tgaactctc tggcctgtgt ctgattgttt gattcagaca gctgctggg
 1321 atccctcacc ctcataccga cccccacca agggcctgga ccaggcattc cccaggaggc
 1381 gggggaggtg ggatcctcca ggtgcacaag ctccaagctc ccaggcattc ctcaccccag
 1441 cagccttgac cattctccac cttccaggga cagaggggtt ggctctccaa atcccagccc
 1501 ccccaaaact ctctctgct gctggctggt tagaggttcc ctttgacgcc ccatgctgcc
 1561 caatgaacaa ttatttatta aatgcccagc cccttctgac ctctgcccac tccctgcaac
 1621 tacagtcctc ccattctcaca catgagcatc aggccaggcc ctctgcccac tccctgcaac
 1681 ctgatttgtt ctcttggtcc tgctgcagtt gccagtcacc ccggccacct gcggtgctat
 1741 ctccccagc cccatcctct gtacagagcc cagcggccca ctggtgacat gctcttctt
 1801 gcatgaggct agtgtgtgtt ttctgggga ctgcttccag tgaggctctg cccttggtta
 1861 ggsatttgtg gaaggggaga taagggtatc ttccaccatc aagccaccaaa catactccca
 1921 ctgagtctga aggttggtt ctgacccatg ttccaccatc ctgacaacac tcattgacct
 1981 tctgtgaaag gaaagaggga ggtaaggat acctgtcccc ctgacaacac tcattgacct
 2041 gaggcccttc tctccagccc ctggatgcag cctcacagtc ctacacagc ggcctgcarg
 2101 gacagtcctt gccaatggac taacttgtct gtgggcccc aaatggaaat gggcagagca
 2161 ggagttagtt gatagcacag accctgcccc tagtcaactga gacagcccg gctctgctc
 2221 gagaccatcc ctgaaggccc cgcccaggct tagtcaactga gacagcccg gctctgctc
 2281 ccatcaccgg ctaagaggga gggagggttc cagacacatg tccagagact cctgaggca
 2341 ctccaggagc agccacattc ctgatgcttc ccacacagc cagattcttt cctgaggctg
 2401 aagacccttg tggctccacc ccacacagc cagattcttt cctgaggctg ggtcccttc
 2461 ccacctctct cactccttga aaacactgtt ctctgcccct caagaccttc tcttccact
 2521 ttgtcccccac cgcagacagg accaggggat ttccatgatg ttttccatga gtcctctgt
 2581 tgtttctgaa agggacgcta cccgggaagg gggctgggac atgggaaagg ggaagtgtg

```

2641 ggcataaagt caggggttcc cttttttggc tgctgaaggc tcgagcatgc ctggatgggg
2701 ctgcaccggc tggcctggcc cctcagggtc cctgggtggca gctcacctct cccttggatt
2761 gtccccgacc cttgccgtct acctgagggg cctcttatgg gctgggttct acccaggtgc
2821 taggaacact ccttcacaga tgggtgcttg gaggaaggaa acccagctct ggtccataga
2881 gagcaaaacg ctgtgctgcc ctgcccaccc tggcctctgc actcccctgc tgggtgtggc
2941 gcagcatatt caggaagctc agggccctgg ctgaggtggg gtcactctgg cagctcagag
3001 aggggtgggag tgggtccaat gcactttgtt ctgggtcttc caggctggga gagcctttca
3061 ggggtgggac accctgtgat ggggcctgc ctccctttgt aggaagccgc tggggccagt
3121 tgggtccccc tccatggact ttgttagttt ctccaagcag gacatggaca aggatgatct
3181 aggaagactt tggaaagagt aggaagactt tggaaagact tttccaaccc tcataccaa
3241 cgtctgtgcc attttgtatt ttactaataa aattttaaag tcttgtgaaa aaaaaaaaaa
3301 aaaaaaaaaa

```

//

```

LOCUS      HSU91746      1430 bp      mRNA                      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL     Blood (1998) In press
REFERENCE   2 (bases 1 to 1430)
AUTHORS     Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE       Direct Submission
JOURNAL     Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901         California Ave, Palo Alto, CA 94304, USA
FEATURES
            Location/Qualifiers
            source          1..1430
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
                               /chromosome="17"
            gene            1..1430
                               /gene="HCC-4"
            CDS              1..363
                               /gene="HCC-4"
                               /note="CC or beta chemokine family member"
                               /codon_start=1
                               /product="IL-10-inducible chemokine"
                               /db_xref="PID:g2581781"
            /translation="MKVSEALSLLVLILIITSASRSQPKVPEWVNTPTCCLKYIEK
VLPRLVVG YRKALNCHLPAIIFVTKRNRVCTNPNDWVQEIYKDPNLPPLPTRNLS
TVKIITAKNGQPQLLSQ"
BASE COUNT 401 a 351 c 293 g 385 t
ORIGIN
1 atgaaggctc ccgaggctgc cctgtctctc cttgtcctca tccttatcat tacttcggct
61 tctcgcagcc agccaaaagt tcctgagtgg gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtgggtgggac acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgcctgc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatgggtcaac cccagctcct caactccag
361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattaggg tgaaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatattt tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagagggtac gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcacc caggtggagt gcagtggtgt gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccccccca gcctcccgag
721 tagctgggac tacaggcttg cgccaccaca cctggctaata tttgtattt ttggtagaga
781 cgggattcta ccatgttgcc caggctgggt tcaaactcgt gtgcccacgc aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgcac
901 tcttaataca cagaaaaata tatttcacat ccttctcctg ctctctttca attcctcact

```

961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tcctgtccat
1081 ctttatggat tttctggat ctatattttc ttcaattatt ctttcatttt ataatgcaac
1141 tttttcatag gaagtccgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aacccaagca tgcaataaat aaaactccct tatttgacaa

//

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,141, 867 A (IVANOFF et al.) 25 August 1992, see entire document.	22-32, 45-55
A	ENG et al. The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo. J. Exp. Med. May 1995, Vol.181, pages 1893-1898, see entire document.	1-21, 33-44
A	ORANGE et al. Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids. J. Exp. Med. March 1995, Vol.181, pages 901-914, see entire document.	1-21, 33-44

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 MARCH 1999

Date of mailing of the international search report

15 APR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WU et al. Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System. The Journal of Biological Chemistry. 05 April 1987, Vol.252, No. 10, pages 4429-4432, see entire document.	22-32, 45-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07K 14/47, 14/52; C12N 15/12, 15/19, 15/63; A61K 38/16, 38/19, 48/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAN ONLINE, MEDLINE, CAPLUS

search terms: chemokine, vaccination, immunogenic, antigen, HIV, efficacy, macrophage-derived chemokine, stromal cell-derived factor, monocyte chemotactic protein, composition, administration

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-21, 33-44, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto.

Group II, claims 22-32, 45-55, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering nucleic acid sequences encoding one or more antigens and nucleic acid sequences encoding one or more chemokines.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product and method, a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.